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Abstract 
The discovery of cisplatin revolutionised the treatment of cancer and opened the door to 
investigations into the discovery and use of other metallodrugs as chemotherapeutic agents. 
Both goldI and goldIII complexes have demonstrated promising anticancer properties both in 
vitro and in vivo. 
The following work will focus on the synthesis and anticancer activity of cyclometalated goldIII 
complexes with both tridentate (C^Npz^C) pincer ligands and bidentate (C^N) cyclometalated 
ligands to improve their physiological stability. Biologically relevant ligands were then 
incorporated into the complexes via the free coordination sites. These were selected to 
enhance the cytotoxicity of the complexes towards human cancer cell lines as well as 
improving the selectivity towards cancer cell lines over healthy cells.  
Chapter 1 explores the use of goldIII compounds as anticancer agents and their typical cellular 
and molecular targets. Chapter 2 introduces the synthesis and anticancer activity of the first 
(C^Npz^C)AuIII complexes of acyclic carbene ligands, decorated with amine and amino ester 
functional groups. Chapter 3 introduces the synthesis and anticancer properties of 
cyclometalated goldIII complexes with acridine-decorated functional groups, chosen to 
promote DNA binding. Chapter 4 discusses the synthesis and biological activity of 
cyclometalated goldIII complexes with dithiocarbamate ligands. 
The complexes were all tested for their anticancer activity in vitro towards a panel of human 
cancer cell lines, including some cell lines that typically show a reduced sensitivity towards 
cisplatin. Investigations into the possible mechanism of action of these complexes were also 
undertaken, including DNA binding assays, GSH reactivity and the production of ROS.  
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Chapter 1 
 
GoldIII compounds as anticancer agents and their cellular and molecular 
targets. 
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1.1 Part 1 – goldIII complexes for chemotherapeutic purposes 
1.11 Introduction 
The discovery of the anticancer drug cis-diamminedichloroplatinumII or cisplatin in the 1960s 
marked the start of a new era in the discovery and use of metallodrugs.1 Cisplatin and its 
clinically approved derivatives, carboplatin and oxaliplatin (Figure 1), are highly effective 
chemotherapeutic agents and they are widely used for the treatment of various types of 
cancer, in particular head and neck, testicular and ovarian cancers.2 However, despite the 
clinical success of these drugs, platinum based metallodrugs do not specifically target the 
cancer cells but also affect other rapidly dividing cells such as those found in the bone marrow 
and in the gastrointestinal tract and this causes severe side effects which can limit the 
administrable dose to patients.3 Other drawbacks include acquired or intrinsic drug 
resistance as well as a limited spectrum of action.4 All of these factors have increased the 
interest into the development of other metallodrugs. Both goldI and goldIII complexes have 
demonstrated promising anticancer properties.5-8 
 
Figure 1 – structures of the three clinically available platinum based chemotherapeutics; 
cisplatin, carboplatin and oxaliplatin.2  
The application of gold in medicine dates far back into history, perhaps as early as 2500 BC.9 
However, perhaps the most notable find was the discovery that goldI thiolates could be used 
to reduce joint pain which led to initial investigations into the use of gold complexes for the 
treatment of rheumatoid arthritis.10 In the 1970s Sutton et al. developed an orally active 
thioglucose goldI phosphine complex, auranofin (Figure 2), which was approved for clinical 
use for the treatment of rheumatoid arthritis in the 1980s.11 During this time, auranofin was 
also shown to possess anticancer properties both in vitro and in vivo and this was the start of 
the development of other goldI complexes for anticancer applications.12 
 
Figure 2 – structure of auranofin.11 
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GoldIII complexes were initially investigated as potential anticancer agents because, being 
isoelectronic and isostructural to platinumII, they were thought to be able to mimic the 
activity of cisplatin in a biological system. However, goldIII complexes are frequently unstable 
under physiological conditions as they are easily reduced to goldI and elemental gold. Their 
physiological stability can be improved by finetuning the ligand environment around the 
goldIII centre and a diverse range of different complexes have been shown to have both in 
vitro and in vivo anticancer activity.5-8 
1.12 GoldIII complexes with N-donor ligands 
There are numerous examples of multidentate N-donor ligand complexes showing in vitro 
anticancer activity.13-15 Isab et al. synthesised tetracoordinate goldIII complexes of 
ethylenediamine and N-substituted ethylenediamine, [Au(en)2]Cl3, 1 (Figure 3) and tested 
their cytotoxicity in vitro on human gastric carcinoma (SGC-7901) and prostate cancer (PC-3) 
cell lines. The complexes exhibited a concentration dependent cytotoxic effect on both cell 
lines and were thought to act by interrupting the mitotic cycle and inducing both apoptosis 
and necrosis.13 
Examples of cytotoxic bipyridyl goldIII complexes are also known. [Au(bipy)(OH)2]PF6, 2 
(Figure 3) synthesised by Marcon et al. displayed high cytotoxicity towards both cisplatin 
sensitive and cisplatin resistant human ovarian carcinoma cells (A2780 S/R) with IC50 values, 
(the concentration of a drug that causes a 50% reduction in cell viability), falling in the low 
micromolar range.14 
 
Figure 3 – cytotoxic goldIII complexes of ethylenediamine and bipyridyl.13, 14 
Similar bipyridyl derivatives, synthesised by Amani et al. with 4,4’-dimethyl-2,2’-bipyridine 
ligands, 3 (Figure 4) were tested on three human cancer cell lines; skin carcinoma (A431), 
cervical carcinoma (HeLa) and colon carcinoma (HT-29) in comparison to both cisplatin and 
its derivative carboplatin. All the gold derivatives were more cytotoxic than carboplatin 
against all three cell lines and also showed higher cytotoxicity than cisplatin against the HeLa 
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cells.15 Although the mechanism of action of these goldIII bipyridyl derivatives was not 
determined, the complexes showed weak and reversible interactions with calf thymus DNA, 
which suggests that DNA is not the primary target of these complexes.14 
 
Figure 4 – structure of the bipyridyl goldIII derivative, 3 and its anticancer activity towards 
three human cancer cell lines in comparison to platinum based chemotherapeutic agents; a 
Skin carcinoma, b Cervical carcinoma, d Colon carcinoma. Data taken from ref 15. 
GoldIII complexes of 1,4,7-triazacyclononane, 4 (Figure 5) synthesised by Shi et al. showed 
greater cytotoxicity than cisplatin against both human lung carcinoma (A549) and human 
colon carcinoma (HCT-116) cancer cells, possibly acting by inducing conformational changes 
to DNA by non-covalent interactions.16 DNA binding was also a mechanism of action for 
tridentate terpyridine derivatives, 5 (Figure 5) synthesised by the same group and these 
complexes were shown to target intracellular DNA in vitro. Once again, promising 
cytotoxicities were observed although it should be noted that they were comparable to those 
of the free terpyridine ligands.17 Other tridentate (N^N^N) aminoquinoline derivatives, 6 
synthesised by Yang et al. showed significant cytotoxicities against a panel of human cancer 
cell lines including A549, with three times the activity of cisplatin against this cell line. The 
complexes could replace ethidium bromide from an EB-DNA system. Ethidium bromide is a 
DNA intercalating agent, commonly used as a nucleic acid stain or fluorescent tag. This 
suggested that the complexes were acting as DNA intercalating agents.18 
 
Figure 5 – Cytotoxic triazacyclononane, terpyridine and aminoquinoline goldIII complexes.16-18 
 IC50 ± SD (µM) 
Complex A431a HeLab HT-29c 
3 0.63 ± 0.007 0.09 ± 0.002 19.48 ± 1.99 
Cisplatin 6.83 ± 1.31 5.86 ± 0.17 10.50 ± 0.48 
Carboplatin 79.38 ± 3.72 >200 >200 
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The cytotoxic activities of the dinuclear, goldIII oxo-bridged complex, 7 (Figure 6) synthesised 
by Gabbiani et al. was initially assayed against both cisplatin sensitive and cisplatin resistant 
ovarian cancer (A2780 S/R) and displayed promising results with IC50 values of 1.8 and 4.8 
µM for A2780 S/R respectively. The complex was further tested on a panel of 36 cancer cell 
lines and again showed promising results although it was also noted that the cytotoxicity 
profile of the complex differed from that of cisplatin, implying that their respective modes of 
action were different and that DNA was not the primary target. Further work determined 
that the mechanism of action was likely to involve a variety of protein targets including the 
enzyme Thioredoxin reductase (TrxR).19 
 
Figure 6 – structure of the dinuclear goldIII oxo-bridged complex, 7 and its anticancer activity 
towards A2780 cells in comparison to cisplatin; a Ovarian cancer. Data taken from ref 19. 
1.13 Cyclometalated goldIII complexes  
The physiological stability of a goldIII centre can be improved by introducing either a 
bidentate, (C^N) or tridentate, (C^N^C), (C^N^N) or (N^C^N) cyclometalating ligand. Both 
neutral and cationic (C^N)AuL2 complexes have shown promising anticancer activity.20, 21 
Derivatives of Au(damp)Cl2, 8 (Figure 7), (damp = 2-((dimethylamino)methyl)phenyl), were 
originally synthesised by Parish et al. and were assessed for their ability to inhibit tumour cell 
growth. Au(damp)Cl2 had a similar toxicity profile to cisplatin against a panel of human cancer 
cell lines in vitro, as well as showing promising in vivo activity against solid breast cancer 
xenografts (ZR-75-1) in a nude mice model.20 These complexes have since been shown to act 
as potent TrxR inhibitors.22 
 
Figure 7 – Au(damp)Cl2.20 
 IC50 ± SD (µM) 
Complex A2780/Sa A2780/Ra 
7 1.79 ± 0.17 4.8 ± 0.5 
Cisplatin 2.1 ± 0.1 24.4 ± 0.1 
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There are also numerous examples of cytotoxic goldIII complexes with 2-phenylpyridine 
cyclometalating ligands, and a general formula of Au(C^N)X2; 9-11.21, 23-25 Derivatives 
synthesised by Fan et al. (Figure 8) bearing either carboxylate, 9a or isothiocyanate, 9b 
ligands were tested for their cytotoxicity in vitro against human leukaemia (MOLT-4) and 
mouse tumour (C2C12) cell lines and showed high cytotoxicity towards both cell lines with 
IC50 values in the low micromolar range.21, 23 
 
Figure 8 – structures of 9a and 9b and their anticancer activity towards human and mouse 
cancer cell lines in comparison to cisplatin; a Human leukaemia, b Mouse tumour. Data taken 
from ref 21, 23. 
A cationic water soluble goldIII complex, [Au(butyl-C^N)biguanidine]Cl, 10 (Figure 9) 
synthesised by Zhang et al. combined the lipophilic, cyclometalated (C^N) ligand and the 
hydrophilic, H-bonding NH2 groups of the biguanidine ligand. The complex was tested on a 
panel of human cancer cell lines and also on normal lung fibroblast cells (CCD-19-Lu) for 
comparison and showed high cytotoxicities towards the cancer cell lines, with IC50 values in 
the low micromolar ranges and, more importantly, a lower cytotoxicity towards the healthy 
CCD-19-Lu cells. The complex was also found to induce stress to the endoplasmic reticulum 
in HeLa cells, possibly by upregulating certain ER-stress markers such as CHOP and HSP70 and 
causing partial S-phase cell cycle arrest and subsequently cell death.24 
 
Figure 9 – structure of complex 10 and its anticancer activity towards human cell lines in 
comparison to cisplatin; a Cervical epithelial carcinoma, b Hepatocellular carcinoma, c Breast 
carcinoma, d Nasopharyngeal carcinoma, e Normal lung fibroblasts. Data taken from ref 24. 
  IC50 (µM) 
Complex MOLT-4a C2C12b 
9a 3.3 9.0 
9b 2.6 11.0 
Cisplatin 6.8  14.7  
 IC50 ± SD (µM) 
Complex HeLaa PLCb MDA-
MB-231c 
SUNE1d CCD-19-
Lue 
10 7.7 ± 0.1 8.8 ± 0.3 8.7 ± 0.2 2.1 ± 0.1 32.8 ± 2.6 
Cisplatin 5.2 ± 0.1  46.4 ± 1.8 66.7 ± 1.3 12.0 ± 2.6 36.2 ± 0.4 
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Rubbiani et al. synthesised a series of both neutral and cationic 2-phenylpyridine goldIII 2,4,6-
tris(trifluoromethyl)phenyl complexes, 11 (Figure 10) as prospective anticancer agents. The 
complexes were assessed for their cytotoxicity against cervical cancer (HeLa) cells and 
noncancerous, human lung fibroblast cells (MRC-5) for comparison. For complex 11, a low 
EC50, (the concentration of a drug that gives the half-maximal response), of 0.42 µM was 
observed for the HeLa as well as an interesting selectivity profile for the cancer cells over the 
noncancerous MRC-5 cells; (EC50MRC-5/EC50HeLa = 6.43).25 
A series of neutral cyclometalated (C^N)Au(N^N) chelated complexes, 12 (Figure 10) were 
synthesised by Kilpin et al. and their cytotoxicities against mouse leukaemia cells (P388) were 
tested. Derivatives bearing electron withdrawing toluene sulfonyl groups appeared to show 
the highest activities; for example complex 12 had an IC50 of 0.30 µM (in comparison to 
cisplatin with an IC50 of 8.15 µM).26 
 
Figure 10 – structures of complexes 11 and 12.25, 26 
There are also examples of goldIII complexes with tridentate cyclometalating ligands that 
show anticancer activity.27-29 The cyclometalated (N^N^C) complex, [Au(bipydmb)(OH)]PF6, 13 
(Figure 11), (bipydmb = 6-(1,1-dimethyl-benzyl)-2,2’-bipyridine), was synthesised by 
Coronnello et al. and tested for its cytotoxic activity against ovarian cancer (A2780 S/R). 
Results indicated that although the complex showed comparable cytotoxicity to cisplatin, 
with results for both cell lines falling between 1-7 µM, it also showed poor DNA binding 
abilities, suggesting that the cell death is not a consequence of direct nuclear DNA damage, 
as with platinum based compounds.27 Further research established that 13 was a potent and 
highly selective inhibitor of the enzyme TrxR.30 
A dinuclear oxo-bridged goldIII complex, 14 (Figure 11) synthesised by Gabbiani et al. used 
the same (N^N^C) skeleton, (bipydmb). In comparison to its mononuclear precursor, the oxo-
bridged derivative showed only moderate cytotoxicity towards a panel of twelve human 
cancer cell lines with mean IC50 values rising to around 20 µM.28 
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Figure 11 – the mononuclear (N^N^C) complex, 13 and its dinuclear oxo-bridged variant, 14.27, 
28 
The cationic [(C^N^C)AuIIIpy]CF3SO3 derivative, 15 (Figure 12) was synthesised by Zhang et al. 
and combined the hydrophilic, H-bonding biguanidine motif, seen with complex 10 and the 
(C^N^C) pincer scaffold. The complex was found to self-assemble into supramolecular 
polymers in acetonitrile. These polymers were found to be stable towards glutathione, (GSH) 
a common drug deactivating peptide found inside cells, and displayed sustained cytotoxicity 
towards melanoma cells (B16) as well as selective cytotoxicity towards this cell line over 
noncancerous lung fibroblast cells (CCD-19-Lu).29 
 
Figure 12 – structure of 15.29 
Li et al. also used the 2,6-diphenylpyridine (C^N^C) skeleton to synthesise a series of 
complexes with highly cytotoxic phosphine ligands, 16a as well as a series of dinuclear 
derivatives where the goldIII centres were joined by bridging (1,2-
bis(diphenylphosphino)(CH2)n) ligands with the hydrocarbon linker of varying size, 16b (n = 
1-6) (Figure 13). The cytotoxicity of the complexes was tested towards several human cancer 
cell lines including nasopharyngeal carcinoma (SUNE1 and CNE1), hepatocellular carcinoma, 
(HEPG2) and cervical epithelial carcinoma (HeLa). While complex 16a displayed only 
moderate cytotoxicity in comparison to cisplatin, the dinuclear derivatives, 16b showed 
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significantly increased activities with IC50 values falling to nM concentrations. However, it 
must be noted that these cytotoxic values also correlate to those of the metal-free phosphine 
ligands which were equally cytotoxic. Interestingly, a slight trend towards increasing 
cytotoxicity with the increasing length of the hydrocarbon linker was also observed, with IC50 
values falling as low as 0.043 µM for the propane derivative. This could be due to the increase 
in lipophilicity of the complex and therefore an easier transition through the cell membrane. 
This trend ceased once the linker became longer than propane and the cytotoxicities of the 
butane, pentane and hexane derivatives were all significantly lower, possibly because the 
complex became too big to easily cross the cell membrane. The phosphine derivatives 
showed no significant DNA binding nor any ability to induce cell cycle arrest.31 
The same group also showed that a derivative of 16b (n=3) also showed significant in vivo 
anticancer activity when assessed on human liver hepatoma xenographs (PLC) in a nude mice 
model with a tumour reduction of 77%, (in comparison to cisplatin with a tumour reduction 
of 28%), and no obvious side effects. The complex was also shown to be a potent inhibitor of 
TrxR with an IC50 of 2.7 nM and was thought to induce apoptosis by the induction of ER 
stress.32 
 
Figure 13 – cyclometalated goldIII phosphine pincer complex, 16a and its dinuclear derivatve, 
16b and their anticancer activity towards human cell lines in comparison to cisplatin; a 
Nasopharyngeal carcinoma (cisplatin sensitive), b Nasopharyngeal carcinoma (cisplatin 
resistant). Data taken from ref 31. 
  
 
 
 
 
 
 
 IC50 ± SD (µM) 
Complex SUNE1a CNE1b 
16a 17 ± 2 11 ± 2 
16b (n=3) 0.055 ± 0.007 0.091 ± 0.012 
16b (n=6) 4.3 ± 0.9 3.2 ± 0.5 
Cisplatin 1.0 ± 0.1 3.3 ± 0.5 
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1.14 GoldIII N-heterocyclic carbene complexes 
There are many examples of both cationic and neutral cytotoxic goldI complexes bearing N-
heterocyclic carbene (NHC) ligands.33-36 Several examples of goldIII(NHC) complexes with 
biological activity also exist.37, 38 Yan et al. synthesised a cyclometalated 
[Au(C^N^C)(NHC)]OTf complex, 17 (Figure 14) which displayed significant in vitro cytotoxicity 
across a panel of human cancer cell lines with IC50 values between 0.17 and 1.2 µM as well 
as reduced cytotoxicity for normal lung fibroblast cells (CCD-19-Lu) (IC50 of 25 µM). The in 
vivo cytotoxicity was also examined in a nude mice model where it reduced tumour growth 
by up to 47% in comparison to the control with no apparent toxicity induced side effects 
including death or weight loss.37 
 
Figure 14 – goldIII NHC derivative, 17 and its anticancer activity towards human cell lines in 
comparison to cisplatin; a Hepatocellular carcinoma, b Non-small cell lung carcinoma, c 
Nasopharyngeal carcinoma, d Normal lung fibroblasts. Data taken from ref 37. 
Fung et al. also used the same [Au(C^N^C)(NHC)]OTf scaffold to synthesise a series of 
complexes by increasing the length of the N-hydrocarbon chain; methyl, ethyl, propyl and 
butyl, 18 (Figure 15). The increased length of the alkyl chain and therefore the increase in the 
lipophilicity of the complex resulted in enhanced cytotoxicity towards HeLa, HCT-116 and 
NCI-H460 cell lines, with a gradual decrease in the IC50 from 2.04 µM to 0.36 µM (and thus a 
gradual increase in cytotoxicity) from the N-methyl to the N-butyl derivatives towards the 
HeLa cells. The butyl derivative also showed potent selectivity for cancer cells over healthy 
human hepatocyte cells (MIHA) with more than 30-fold lower cytotoxicity towards the 
healthy cells. An in vivo nude mice model against HeLa xenografts demonstrated a 71% 
reduction in tumour size after treatment with 3 mg kg-1 of the complex as well as a 53% 
reduction when NCI-H460 xenografts were treated with the same dosage. Derivatives 
bearing photoaffinity probes were also synthesised and used to identify a number of 
intracellular proteins as the molecular targets of these compounds, including HSP60, 
vimentin, nucleophosmin and YB-1.38 
 IC50 ± SD (µM) 
Complex HepG2a SUNE1b NCI-H460c CCD-19-
Lud 
17 0.37 ± 0.03 0.25 ± 0.02 0.17 ± 0.05 25 ± 3.8 
Cisplatin 10.5 ± 0.5  4.9 ± 0.8 3.5 ± 1.0 51 ± 7 
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Figure 15 – derivatives of 18 and their anticancer activity towards human cell lines in 
comparison to cisplatin; a Cervical carcinoma, b Colon cancer, c Lung cancer, d Normal 
hepatocyte. Data taken from ref 38. 
A similar pyrazine-based (C^Npz^C) pincer ligand was used by Bertrand et al. along with a 
benzimidazole-based NHC ligand, 19 (Figure 16). This derivative showed excellent in vitro 
cytotoxicity with IC50 values in the micromolar and sub-micromolar range against MCF-7 and 
HL60 and A549 cells, although it showed poor selectivity for cancer cells over healthy MRC-5 
cells.39 
 
Figure 16 – structure of benzimidazole-based goldIII NHC complex, 19.39 
Another example of a cytotoxic goldIIINHC complex, synthesised by Zou et al. used a 
tridentate (N^N^N) pincer ligand to stabilise the goldIII centre, making a series of 
[Au(N^N^N)(NHC)]OTf complexes, 20 (Figure 17) (n = 3,7,9 and 15). The complex bearing the 
longest hydrocarbon chain, n = 15, displayed the most promising cytotoxicity against HeLa 
cells, (IC50 of 1.4 µM) and also significantly increased cellular uptake. An in vivo study in nude 
mice, bearing HeLa xenografts showed tumour inhibition of up to 70% after eleven days with 
no observable toxicity induced side effects. The complexes were also shown to act as TrxR 
inhibitors.40 
  IC50 ± SD (µM) 
Complex HeLaa HCT-116b NC1-H460c MIHAd 
18 (R=Me) 2.0 ± 0.2 4.4 ± 1.5 2.4 ± 0.3 42.8 ± 12.3 
18 (R=Bu) 0.4 ± 0.1 0.2 ± 0.1 0.2 ± 0.1 11.8 ± 3.2 
Cisplatin 15.3 ± 1.1 11.8 ± 2.8 54.9 ± 3.6 95.2 ± 2.2 
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Figure 17 – derivatives of 20 and their anticancer activity towards human cervical cancer cells; 
a Cervical carcinoma. Data taken from ref 40. 
Rana et al. synthesised a novel [Au(NHC)2Cl2]PF6 complex, 21 (Figure 18) and tested its 
cytotoxicity against HCT-116, HepG2, A549 and MCF-7 human cancer cell lines where it 
displayed a higher cytotoxicity than cisplatin across all four cell lines.41 Another goldIII hetero 
bis-carbene dichloro complex, published by Sivaram et al., 22 (Figure 18) also displayed 
prominent cytotoxicity against non-small cell lung cancer cells (NCI-H1666) with a low IC50 
value of 0.2 µM, (IC50 of cisplatin = 2.5 µM).42 
 
Figure 18 – examples of [AuIII(NHC)2Cl2]+ complexes with biological activity.41, 42 
1.15 GoldIII dithiocarbamate  
GoldIII dithiocarbamate derivatives, with the general structure AuX2(DTC) have also shown 
cytotoxic activity.43, 44 Two of the most widely studied are AuX2(DMDT), 23a and AuX2(ESDT), 
23b (Figure 19) (DTC = dithiocarbamate, DMDT = N,N-dimethyldithiocarbamate and ESDT = 
ethylsarcosinedithiocarbamate). Both the dichloro and dibromo derivatives have been 
studied. These complexes have shown both in vitro and in vivo cytotoxicity towards cancer 
cells, as well as significant inhibition of TrxR and the induction of reactive oxygen species 
(ROS).43, 44 
  
 IC50 ± SD 
(µM) 
Complex HeLaa 
20 (n=3) 16.5 ± 1.4 
20 (n=15) 1.4 ± 0.2 
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Figure 19 – structures of goldIII dithiocarbamate derivatives 23a and 23b.43, 44 
Another goldIII dithiocarbamate derivative with cytotoxic potential is complex 24, 
[Au(Et2DTC)2]Cl (Figure 20) synthesised by Altaf et al. The complex displayed in vitro 
cytotoxicity towards A2780 S/R and MCF-7 cells, (EC50 of 6.3, 29.8 and 3.9 µM respectively), 
as well as showing some selectivity towards cancer cells over healthy MRC-5 cells, (EC50 of 
19.7 µM).45 
 
Figure 20 – goldIII DTC derivative, 24 and its anticancer activity towards human cell lines in 
comparison to cisplatin; a Ovarian cancer, b Breast carcinoma, c Normal lung fibroblasts. Data 
taken from ref 45. 
There are few examples of cyclometalated goldIII dithiocarbamate complexes. Zhang et al. 
synthesised a series of [(C^N)AuIII(R2NCS2)]PF6 complexes, 25 (Figure 21) and demonstrated 
that they could act as potent deubiquitinase inhibitors. The in vitro cytotoxicities of the 
[(C^N)AuIII(DTC)]PF6 complexes were also tested on several cancer cell lines and also a non-
tumorigenic immortalized liver cell line (MIHA) for comparison. The complexes all showed 
significantly higher cytotoxicities than cisplatin with IC50 values ranging from 0.07 to 6.30 µM, 
(in comparison to cisplatin; IC50 values of 11.6 to 59.0 µM). Complexes containing a 
diethyldithiocarbamate ligand also displayed specificity towards the MCF-7 breast cancer 
cells with more than 80-fold higher activity towards this cell line in comparison to the MIHA 
cells.46 
  EC50 ± SD (µM) 
Complex A2780/Sa A2780/Ra MCF-7b MRC-5c 
24 6.3 ± 2.1 29.8 ± 5.8 3.9 ± 2.3 19.7 ± 6.4 
Cisplatin 10.0 ± 1.6 21.0 ± 2.1 >50 >50 
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Figure 21 – cyclometalated goldIII dithiocarbamate derivative, 25 and its anticancer properties 
in comparison to cisplatin; a/b Breast carcinoma, c Cervical carcinoma, d Melanoma, e Lung 
carcinoma, f Non-tumorigenic immortalised liver cells. Data taken from ref 46. 
1.16 GoldIII dithiocarbamate oligopeptide complexes 
Dithiocarbamate ligands can also be used to functionalise goldIII centres with cancer targeting 
oligopeptides that act as carrier mediated delivery systems and exploit the peptide 
transporters that are upregulated in certain cancer cell lines. Nardon et al. synthesised one 
derivative, complex 26 (Figure 22), and demonstrated both its in vitro and in vivo anticancer 
activity on MDA-MB-231 breast cancer cells.47 
 
Figure 22 – goldIII dithiocarbamate oligopeptide complex. 
1.17 Other goldIII sulfur complexes 
There are also examples of other goldIII sulfur complexes that show cytotoxic activity towards 
cancer cell lines.23, 48 Fan et al. synthesised a series of cyclometalated 2-phenylpyridine goldIII 
complexes and attached both monodentate (SCN-), 27a and bidentate (thiolactic acid), 27b 
ligands (Figure 23). In vitro cytotoxicity studies against MOLT-4 and C2C12 showed 
comparable results to cisplatin with IC50 values of under 4.0 µM for the leukaemic cell line, 
(in comparison to cisplatin with an IC50 of 6.8 µM).23 
 IC50 ± SD (µM) 
Complex MCF-7a MDA-MB-
231b 
HeLac B16d NC1-H460e MIHAf 
25 0.09 ± 0.05 0.20 ± 0.03 0.50 ± 0.14 0.37 ± 0.01 1.3 ± 0.4 1.2 ± 0.4 
Cisplatin 30 ± 6  60 ± 2 12 ± 2 33 ± 3 59 ± 11 55 ± 0.6 
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Figure 23 – structures of 27a and 27b and their anticancer activity towards human and mouse 
cancer cell lines in comparison to cisplatin; a Human leukaemia, b Mouse tumour. Data taken 
from ref 23. 
The same group also synthesised a cyclometalated goldIII thiosalicylate complex, 28 (Figure 
24) which demonstrated high cytotoxicity against P388 leukaemia cells with an IC50 of 2.5 
µM.48 
 
Figure 24 – structure of the goldIII thiosalicylate derivative, 28.48 
Bertrand et al. synthesised neutral derivatives with thiophenol, 29a and thioguanine, 29b 
ligands based on the cyclometalated (C^Npz^C) pyrazine pincer system (Figure 25). Whereas 
the thiophenol derivative showed no in vitro cytotoxicity, the thioguanine complex was toxic 
at sub-micromolar levels towards leukaemia (HL60) and breast cancer (MCF-7) cells, (IC50 of 
0.9 and 0.4 µM respectively) whereas the cytotoxicity towards human lung cancer (A549) 
cells was considerably lower (IC50 of 29.0 µM). In this particular case, the cytotoxic properties 
of 29b were attributed to the thioguanine ligand, a clinically used anticancer drug, rather to 
the (C^Npz^C)AuIIIS scaffold.39 
  IC50 (µM) 
Complex MOLT-4a C2C12b 
27a 2.6 11.0 
27b 3.8 18.0 
Cisplatin 6.8  14.7  
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Figure 25 – structures of 29a and 29b and the cytotoxicity of 29b towards human cancer cell 
lines in comparison to cisplatin; a Leukaemia, b Breast carcinoma, c Lung carcinoma. Data 
taken from ref 39. 
 
1.18 GoldIII porphyrin complexes 
Experiments conducted by Che et al. showed that goldIII tetraarylporphyrins, like complex 30 
(Figure 26) showed high activity across a panel of human cancer cell lines including some 
drug resistant variants; the multi-drug resistant human oral carcinoma (KB-V1) and also 
cisplatin-resistant human nasopharyngeal carcinoma (CNE1). IC50 values were between 0.11-
0.73 µM across the board, indicating that no cross resistance was occurring and suggesting 
that the complex was inducing cytotoxicity via different mechanisms to cisplatin.49 
  
  IC50 ± SD (µM) 
Complex HL60a MCF-7b A549c 
29b 0.90 ± 0.22 0.78 ± 0.11 29.0 ± 1.8 
Cisplatin 3.7 ± 0.3 21.2 ± 3.9 33.7 ± 3.7 
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Figure 26 – goldIII porphyrin complex, 30 and its cytotoxicity towards human cancer cell lines; 
a Oral epidermoid carcinoma, b Oral epidermoid carcinoma (multi drug resistant), c 
Nasopharyngeal carcinoma, d Nasopharyngeal carcinoma (cisplatin resistant). Data taken 
from ref 49. 
1.19 GoldIII amino acid and peptide conjugates 
One example of a goldIII oligopeptide complex has already been discussed, (26)47 but other 
goldIII amino acid and peptide conjugated complexes have also been investigated for their 
chemotherapeutic potential.50-52 Two such derivatives are the complexes with L-Histidine 
containing peptides synthesised by Glisic et al.; a tridentate Gly-L-His dipeptide derivative, 
[Au(Gly-L-His)Cl]NO3, 31a and a tetradentate Gly-Gly-L-His tripeptide derivative, [Au(Gly-Gly-
L-His]Cl, 31b (Figure 27). The cytotoxic activity of both complexes was strongly cell line 
dependent. For example, while 31b was highly cytotoxic towards cervical cancer (HeLa) and 
promyelocytic leukaemia (HL60); (IC50 values of 0.005 and 2.98 µM respectively), 31a showed 
only moderate activity; (IC50 values of 15.9 and 11.9 µM). However, against breast cancer 
(MCF-7) and colon cancer (HT-29) it was 31a which showed the better activity; (19.7 and 14.7 
µM) while 31b was nontoxic, (>100 µM). Remarkably, both derivatives also showed 
significantly reduced activity towards healthy lung fibroblast cells (MRC-5) with IC50 values of 
more than 100 µM.50 
  IC50 ± SD (µM) 
Complex KB-3-1a KB-V1b SUNE1c CNE1d 
30 0.20 ± 0.03 0.11 ± 0.02 0.11 ± 0.02 0.17 ± 0.02 
Cisplatin 13.2 ± 1.24 12.6 ± 0.78 12.6 ± 0.92 40.8 ± 2.17 
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Figure 27 – goldIII complexes with L-Histidine containing peptide, 31a and 31b and their 
cytotoxic activity towards human cancer cell lines in comparison to cisplatin; a Cervical 
carcinoma, b Promyelocytic leukaemia, c Breast carcinoma, d Colon carcinoma, e Normal lung 
fibroblasts. Data taken from ref 50. 
Lemke et al. synthesised a phenylalanine-NHC goldIII conjugate, 32 (see Figure 28) although 
the complex showed relatively poor activity towards both HeLa and HT-29 cells with IC50 
values of between 40 and 100 µM.51 Other trihalide derivatives 33, reported by Ortego et al. 
conjugated amino ester derivatives, (L-AlaOMe, L-ValOMe and L-PheOMe), to a goldIII centre 
via a pyridine nitrogen. These also showed reduced cytotoxicity towards a panel of human 
cancer cell lines with IC50 values of above 50 µM.52 
 
Figure 28 – examples of other goldIII amino acid conjugates.51, 52 
  
 IC50 ± SD (µM) 
Complex HeLaa HL60b MCF-7c HT-29d MRC-5e 
31a 15.90 ± 1.69 11.93 ± 1.02 19.68 ± 0.23 14.70 ± 1.36 >100 
31b 0.0045 ± 0.0002 2.98 ± 0.12 >100 >100 >100 
Cisplatin 2.02 ± 0.12  10.31 ± 2.54 1.56 ± 0.26 18.6 ± 2.32 0.48 ± 0.02 
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1.2 Part 2 – cellular and molecular targets of goldIII complexes  
1.21 DNA binding 
Due to the high levels of structural and electronic similarity between goldIII and platinumII 
complexes, (d8, square planar), initial mechanistic studies focused on DNA and RNA as the 
primary molecular target for goldIII complexes as these are the major targets for platinum 
based chemotherapeutic agents like cisplatin.53 However, mechanistically, platinumII and 
goldIII appear to be rather different and although there are examples of goldIII complexes 
targeting both double-stranded DNA and higher order DNA structures like G-quadruplexes, 
these structures are clearly not the primary molecular target.39, 49 
The cytotoxic effects of cisplatin mainly result from its interaction with DNA. Cisplatin forms 
covalent adducts between purine DNA base pairs, usually between two guanines or one 
guanine and one adenine, and this causes the formation of adducts and the distortion of the 
DNA helix which inhibits DNA replication and transcription processes (Figure 29).53 
 
Figure 29 – mechanism of cisplatin. Image taken from Bioinorganic Chemistry and 
Applications, 2012, ref 54. 
Porphyrin goldIII complexes like derivative 30 (Figure 26) are also able to interact strongly 
with DNA, causing DNA fragmentation, although these interactions are different from those 
of cisplatin and are non-covalent and reversible.49, 55 The mechanism of this complex is clearly 
non-specific as numerous other molecular targets have also been confirmed for porphyrin 
goldIII complexes.56-58 
Similarly triazacyclononane goldIII derivatives like derivative 4 (Figure 5) can induce non-
covalent conformational changes to DNA.16 Further studies on dithiocarbamate complexes, 
23a/b (Figure 19) by Ronconi et al. showed that the complexes are able to produce complex-
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DNA adducts, resulting in the inhibition of DNA synthesis and consequently cell death. More 
importantly, it was also shown there was no cross resistance with cisplatin, suggesting that 
the DNA lesions induced by the dithiocarbamate derivatives are repaired less effectively than 
those induced by cisplatin. However, in spite of the complexes showing affinity towards DNA, 
the adducts formed were less stable than those induced by the reference drug cisplatin, once 
again suggesting that the interaction with the DNA double helix was weak and reversible in 
nature.59 
DNA intercalation is another reversible mode of DNA-ligand binding which consists of the 
direct insertion of planar aromatic moieties in between the base pairs of DNA which causes 
unwinding to the double helix. Terpyridine goldIII, 5 and aminoquinoline goldIII, 6 derivatives 
(Figure 5) can bind to intracellular DNA by intercalation of the planar goldIII coordination 
plane between the DNA base pairs although it has not been determined whether or not this 
interaction is responsible for the cytotoxicities of the complexes.17, 18 Cyclometalated goldIII 
NHC complexes, 18 (Figure 15) can also bind to double stranded DNA by intercalation, 
causing inhibition of the enzyme topoisomerase (TopoI) and the induction of apoptosis.37 
TopoI is an enzyme that unwinds chromosomal DNA and is an important target for anti-
cancer agents.60  
1.22 G-quadruplex and i-motif stabilisation 
G-quadruplexes are emerging as promising targets for the development of novel anticancer 
agents. These are four-stranded DNA structures that form in guanine-rich DNA sequences 
and are found both in the telomers and in the over-expressed gene promoter regions of 
cancer genes (Figure 30).61, 62 I-motifs are higher-order DNA structures that are formed in 
sequences rich in cytosine via hydrogen bonding between the hemiprotonated pairs of 
cytosines (Figure 30).63 Stabilisation of i-motif structures has been shown to have an effect 
on telomerase activity and oncogene expression and therefore compounds that stabilise 
these structures have potential as anticancer drugs.64 
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Figure 30 – structure of G-quadruplex (left) and i-Motif (right) structures. Image adapted from 
Chemistry Society Reviews, 2014, ref 65.  
There are several recent examples of goldIII complexes that target these structures. For 
example, Gratteri et al. showed that dioxobridged goldIII complexes like derivative 7 (Figure 
6) and cyclometalated oxo compounds like 13 and 14 (Figure 11) all showed high levels of 
binding to human G-quadruplexes whereas double stranded DNA was not affected at all.66 
Recently Bertrand et al. also showed that a goldIII benzimidazole-based NHC complex, 19 
(Figure 16) could selectively stabilise both G-quadruplex and i-motif structures over double 
stranded DNA.39 
1.23 Inhibition of the proteasome 
Another emerging target for gold complexes is the ubiquitin proteasome. The proteasome is 
an important regulator of cellular growth and apoptosis and specific proteasome inhibitors 
can act as novel anticancer agents.67 Milacic et al. showed that the dithiocarbamate 
derivative 23a, (Figure 19) was able to suppress tumour growth by the direct inhibition of the 
chemotrypsin-like activity both in purified rabbit 20S proteasome and also in the 26S 
proteasome of intact MDA-MB-231 breast cancer cells.68 Tomasello et al. showed similar 
results for 23b in intact MCF-7 cells.69 The proteasome has also been identified as a major 
target of goldIII dithiocarbamate peptide conjugates, 26 (Figure 22) both in purified human 
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20S proteasome and also in intact MDA-MB-231 cell extracts as well as in an in vivo nude 
mice model.47 
Other cyclometalated goldIII dithiocarbamate derivatives, like derivative 25 (Figure 21), have 
shown potent deubiquitinase inhibition properties.46 These are protease enzymes that 
regulate the ubiquitin system by specifically hydrolysing peptide bonds between ubiquitin 
and its conjugated proteins. The regulation of the ubiquitin cycle is important for many 
cellular processes in cancer cells including DNA repair, the cell cycle and some signalling 
pathways and therefore deubiquitinase inhibitors are emerging as promising targets for new 
anticancer agents.70 
1.24 Inhibition of thioredoxin reductase (TrxR) 
Thioredoxin reductase, (TrxR) catalyses the NADPH-dependent reduction of thioredoxin 
disulphide and other oxidised cell constituents. TrxR contributes to the redox homeostasis in 
cells thus helping to prevent oxidative stress which can result in DNA damage. Reduced 
thioredoxin acts as a growth factor in cancer tumours and consequently the overexpression 
of this enzyme has been observed in many cancer cell lines and high intracellular levels have 
also been associated with cellular resistance to platinum-based drugs.71 
The enzyme has a high degree of sequence homology to the antioxidant enzyme glutathione 
reductase, (GR) but contains an essential selenocysteine, (SeCys) residue in the active site, 
(Figure 31), which is not present in GR. This SeCys residue is a major target of gold-containing 
complexes; for example, the anti-rheumatic drug auranofin (Figure 2) is a potent and specific 
TrxR inhibitor.71, 72 Due to the high selectivity of gold compounds for selenocysteines, the 
inhibition of TrxR tends to be highly selective and the inhibition of GR requires significantly 
higher drug concentrations.73 
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Figure 31 – catalytic site of TrxR. Image adapted from Dalton Transactions, 2011, ref 74.  
There are numerous examples of both goldI and goldIII complexes that show high levels of 
TrxR inhibition.44, 75, 76 For example, enzyme inhibition studies on cyclometalated goldIII 2,4,6-
tris(trifluoromethyl)phenyl complexes, 11a-11d (Figure 32) showed that the complexes were 
acting as TrxR inhibitors with up to 49-fold selectivity towards this enzyme over glutathione 
reductase (GR).25 As both of these enzymes are two of the main components of the cellular 
antioxidant mechanism, the inhibition of these enzymes can cause a strong cellular response 
in the form of reactive oxygen species (ROS).71, 77, 78 The complexes were also shown to induce 
a strong increase in intracellular ROS levels in a concentration-dependent manner, further 
confirming their ability to inhibit TrxR.25  
 
Figure 32 – the inhibition of TrxR and GR by goldIII derivatives 11a-11d in comparison to 
auranofin. Data taken from ref 25.  
  IC50 (µM) 
Complex TrxRa GRb Selectivity 
(IC50TrxR/IC50GR) 
11a 2.0 12.3 6.2 
11b 1.0 >50 >49.0 
11c 6.3 >50 >7.9 
11d 1.1 36.4 32.8 
Auranofin 0.009 15 1666 
24 
 
1.25 Induction of apoptosis  
The induction of apoptosis, (the process of programmed cell death), is a highly complex 
process which involves an energy-dependent cascade of molecular events which includes the 
permeabilization of the outer membrane of the mitochondria and the initiation of both 
caspase-dependent and caspase-independent cell death.79 
Park et al. demonstrated that treatment of HL60 leukaemia cells with auranofin induced 
apoptosis in both a concentration and time dependent manner, causing the generation of 
ROS. This, in turn, caused the subsequent activation of p38 mitogen-activated protein kinase, 
(p38 MAPK) leading to the activation of initiator caspases to stimulate further apoptotic 
events including the activation of caspase-3, PARP degradation, DNA fragmentation and 
finally cell death.80 
Further work on goldIII porphyrin complexes, 30 (Figure 26) also showed the induction of 
apoptosis related to the production of ROS in human nasopharyngeal carcinoma cell lines. 
Treatment with the goldIII complex caused a depletion of the mitochondrial transmembrane 
potential, (∆ψm) which led to cytochrome c release, nucleus translocation of apoptosis 
inducing factor and the generation of ROS. Similarly to the studies on auranofin, conducted 
by Park et al., treatment with the goldIII porphyrin complex also led to the subsequent 
activation of p38 MAPK and led to further apoptotic events.56 
1.26 Glutathione and other protein targets  
Glutathione (GSH) is a tripeptide formed by glutamic acid, cysteine and glycine (Figure 33) 
that reaches millimolar concentration inside cells. It plays an important role in many cellular 
processes including the maintenance of the intracellular redox homeostasis by the 
scavenging of ROS. An increased intracellular concentration of GSH in cancer cells contributes 
towards the extravascular growth of metastatic cells as well as being a major contributing 
factor towards drug resistance by deactivation.81, 82 
 
Figure 33 – structure of the GSH tripeptide.82 
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There are many examples of GSH deactivating goldIII complexes. Further work by Gabbiani et 
al. on the dinuclear, goldIII oxo-bridged complex, 7 (Figure 6) showed a rapid reduction by 
GSH, which suggested that within the cellular environment the complex is reduced to a goldI 
active species.19, 28 The gold dithiocarbamate complex, derivative 24 (Figure 20) also reacted 
with reduced glutathione and L-cysteine in a time dependent manner by the substitution of 
one diethyldithiocarbamate ligand for one cysteine molecule.45 
Stability in the presence of reduced glutathione can improve the cytotoxic potential of goldIII 
complexes. In comparison to the dinuclear (N^N) chelate complex, 7 (Figure 6), discussed 
earlier, the cyclometalated (N^N^C) complex, 14 (Figure 11) showed significantly increased 
stability under physiological conditions and was not reduced in the presence of GSH. Upon 
reaction with two model proteins; hen egg white lysozyme, (HEWL) and horse heart 
cytochrome c, (cyt c) the complex formed a monometallic adduct with the gold centre 
remaining in the +3 oxidation state and maintaining the (N^N^C) ligand, thus implying that 
the reaction of the complex with proteins facilitates the cleavage of the oxygen bridge and 
the conversion of the bimetallic species to the monometallic equivalent.19, 28 
Complex 19 (Figure 16) was also stable in the presence of GSH, showing no reduction to gold0 
or goldI. Results also suggested that the complex inhibited MDM2-p53 protein-protein 
interactions, another emerging target for anticancer agents (Figure 34).39 MDM2 inhibits the 
p53 tumour suppressor and overexpression of this enzyme is associated with many different 
cancers thus making the disruption of MDM2-p53 protein-protein interactions a promising 
target for selective anticancer cytotoxicity.83 
 
Figure 34 – representation of the cyclometalated goldIII benzimidazole-based derivative, 
complex 19 docked in MDM2. Image taken from Inorganic Chemistry, 2017, ref 39. 
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GoldIII tetraarylporphyrins, like complex 30 (Figure 26) are also highly stable under 
physiological conditions and are not reduced in the presence of glutathione, making them 
promising as potential chemotherapeutic agents. Biochemical and cellular experiments also 
identified heat-shock protein 60, Hsp60, to be an important molecular target of the 
complex.84 Hsp60 is an essential chaperone for mitochondrial protein transport and folding 
and plays an important role in the regulation of apoptosis as well as in the regulation of 
tumours. It is also upregulated in some human cancers.85 
1.3 Conclusion 
GoldIII complexes are undeniably an emerging class of potential chemotherapeutic agents. In 
recent years, numerous and structurally diverse goldIII complexes have been synthesised and 
characterised as prospective anticancer agents and have shown potent cytotoxicity both in 
vitro and in vivo towards human cancer cells. Certainly, the majority of the complexes 
discussed here appear to show comparable or higher cytotoxicity than the clinically available 
drug cisplatin, which again highlights their chemotherapeutic potential. However, although 
biochemical experiments have successfully identified a large variety of molecular targets for 
these complexes, more extensive studies are required to fully determine the mechanism of 
action of cytotoxic goldIII complexes in vivo. Until the full picture is determined, it will be 
impossible to know the full potential of goldIII complexes as prospective anticancer drugs. 
The following work will focus on the synthesis and anticancer activity of cyclometalated goldIII 
complexes with both tridentate (C^Npz^C) pincer ligands and bidentate (C^N) cyclometalated 
ligands to improve their physiological stability. Biologically relevant ligands, selected to 
enhance the cytotoxicity of the complexes towards cancer cell lines, were then incorporated 
into the complexes via the free coordination sites.  
Chapter 2 introduces the synthesis and anticancer activity of the first (C^Npz^C)AuIII 
complexes of acyclic carbene ligands, decorated with amine and amino ester functional 
groups. The synthesis started with the formation of the cationic gold-isocyanide complex and 
the subsequent nucleophilic attack by an amine, as depicted in Scheme 1. 
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Scheme 1 – the synthetic pathway to the acyclic carbene complexes introduced in Chapter 2. 
Chapter 3 introduces the synthesis and anticancer properties of cyclometalated goldIII 
complexes with acridine-decorated functional groups, chosen to promote DNA binding and 
thus increase the cytotoxicity of the complexes. These complexes included a series of neutral 
mono-cyclometalated (C^N)-(N^X)AuIII complexes with both simple and acridine-decorated 
(N^O) and (N^N) chelating ligands, and two cationic bis-cyclometalated (C^Npz^C)AuIII 
complexes where the acridine moiety was connected to an acyclic diamino carbene ligand or 
to an N-heterocyclic carbene ligand, (Figure 35).  
 
Figure 35 – mono-cyclometalated (C^N)-(N^X)AuIII complexes and cationic bis-cyclometalated 
(C^Npz^C)AuIII complexes with acridine decorated ACC and NHC ligands discussed in Chapter 
3. 
Chapter 4 discusses the synthesis and biological activity of cyclometalated goldIII complexes 
with dithiocarbamate ligands, synthesised by the reaction of the cyclometalated goldIII 
dichloride precursor with the respective dithiocarbamate ligand, followed by an anion 
exchange reaction to give the cationic cyclometalated goldIII dithiocarbamate complex, 
(Scheme 2). 
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Scheme 2 – the synthesis of the cyclometalated goldIII dithiocarbamate complexes, discussed 
in Chapter 4. 
The complexes were all tested for their anticancer activity in vitro towards a panel of human 
cancer cell lines in comparison to the clinically available drug cisplatin. Investigations into the 
possible mechanism of action of these complexes were also undertaken, including cell uptake 
studies, DNA binding assays, GSH reactivity, reactivity towards other representative 
biomolecules and the production of ROS.  
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Chapter 2 
 
The synthesis and anticancer activity of (C^Npz^C)AuIII complexes of 
acyclic carbene ligands decorated with amino esters. 
 
Based on: (C^Npz^C)AuIII complexes of acyclic carbene ligands: synthesis and anticancer 
properties. Dalton Trans., 2017, 46, 13397-13408.86 
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2.1 Abstract 
A series of novel cationic goldIII pincer complexes containing a cyclometalated pyrazine based 
(C^Npz^C) pincer ligand and acyclic diamino carbene ancillary ligands were synthesised and 
characterised as prospective anticancer agents. The two-step synthesis included the 
formation of a cationic (C^Npz^C)AuIII isocyanide complex, (41) followed by a nucleophilic 
attack onto the highly electrophilic isocyanide carbon by a broad range of nucleophiles 
including water, (42) amines (43a and 43b) and amino ester derivatives (43c-43g). This 
allowed the synthesis of a library of [(C^Npz^C)Au(ACC)]SbF6 complexes with aniline, (43a) 
adamantyl amine, (43b) as well as five amino ester derivatives, (43c-43g). The complexes 
were tested with a preliminary cytotoxicity assay against human adenoma-type lung cancer 
cells (A549) and the four most promising, (43b-43d and 43g) were then further tested on a 
panel of human cancer cell lines and also healthy lung fibroblast cells (MRC-5) for 
comparison. The four selected complexes showed promising cytotoxicity results in 
comparison to cisplatin as well as an improved selectivity for MCF-7 breast adenocarcinoma 
cells over healthy lung fibroblast cells. 
2.2 Introduction 
As discussed previously (Section 1.13) cyclometalating ligands are frequently used to stabilise 
a goldIII centre towards reduction under physiological conditions and thus enhance the 
cytotoxic potential of prospective anticancer agents. Both bidentate (C^N) and tridentate 
(C^N^N) or (C^N^C) ligands can be used for this purpose.25, 27, 31, 39 These complexes tolerate 
a broad range of ancillary ligands such as N-heterocyclic carbene (NHC); 17,37 N-donor; 15,29 
phosphine; 11,25 and sulfur-based ligands; 29a,39 which enables the optimization of the 
biological properties of these complexes (Figure 36).  
Figure 36 – examples of cyclometalated goldIII complexes with cytotoxic properties.25, 29, 37, 39 
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In the 1970s, Parks et al. and Minghetti et al. reported the synthesis of the first goldIII acyclic 
carbene complexes, prepared by the reaction of isocyanides and amines with AuCl4. These 
were shown to behave as oxidising agents.87, 88 Further early work on goldIII open-carbene 
systems by Usón et al. also described the synthesis of mononuclear, mono-carbene goldIII 
complexes, synthesised by the reaction of primary or secondary amines with goldIII 
isocyanide complexes to produce the corresponding acyclic carbene complex.89 More 
recently Crespo et al. synthesised acyclic carbene complexes, 34 by the insertion of an 
isocyanide into a gold-nitrogen bond, (Scheme 3).90  
 
Scheme 3 – the insertion of an isocyanide into a gold-nitrogen bond to produce an acyclic 
carbene.90 
The same group demonstrated the biological activity of several acyclic carbene complexes 
towards three human cancer cell lines; T-cell leukaemia (Jurkat), pancreatic cancer 
(MiaPaca2) and lung cancer (A549), (Figure 37). Derivatives 35a and 35b displayed a higher 
cytotoxicity than cisplatin towards all three cell lines (IC50 values of between 0.8 – 25 µM in 
comparison to cisplatin 11 – >100 µM). The derivatives also appeared to show some 
selectivity towards certain cell lines. While derivative 35a was highly cytotoxic towards the 
MiaPaca2 cell line (IC50 value of 1.7 µM), it was poorly cytotoxic towards the A549 cells (IC50 
of 17.5 µM). In comparison, derivative 35b showed an increased cytotoxicity towards A549 
over MiaPaca2 cells, (IC50 values of 1.5 vs 25 µM respectively).91 
 
Figure 37 – biologically active acyclic carbene derivatives 35a and 35b and their cytotoxicity 
towards human cancer cell lines in comparison to cisplatin; a T-cell leukaemia, b Pancreatic 
cancer, c Lung cancer. Data taken from ref 91. 
 IC50 ± SD (µM) 
Complex Jurkata MiaPaca2b A549c 
35a 0.8 ± 0.7 1.7 ± 0.8 17.5 ± 1.7 
35b 1.26 ± 0.6 25 1.52 ± 0.8 
Cisplatin 10.8 ± 1.2 114.2 ± 9.1 76.5 ± 7.4 
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The nucleophilic attack of an amine onto a gold-isocyanide complex is another method that 
can be used for the synthesis of acyclic carbene complexes (Scheme 4). David et al. used this 
method to synthesise the (C^C) cyclometalated goldIII N-acyclic carbene complex, 
AuCl(tBu2Bip)-[C(NEt2)(NHXy)], 36.92 
 
Scheme 4 – the nucleophilic attack of an amine onto a gold- isocyanide complex to produce 
an acyclic carbene, 36.92 
GoldIII acyclic carbene complexes were therefore chosen as the proposed synthetic target as 
they presented a simple way to functionalise goldIII complexes with bio-active functional 
groups. These functional groups could be fine-tuned to enhance the anticancer activity and 
improve the selectivity of the complex towards cancer cells over healthy cells. 
As described in Section 1.14, the pyrazine-based goldIII pincer complex with a benzimidazole-
based ligand, [(C^Npz^C)Au(NHC)]+, 19 (Figure 38), showed promising cytotoxicity towards 
human leukaemia (HL60), breast (MCF-7), and lung (A549) cancer cells. However, it also 
displayed rather poor selectivity towards healthy lung fibroblast cells (MRC-5) which 
suggested that the selectivity of the complex needed to be improved. The 
[(C^Npz^C)Au(NHC)]+ complexes were also very stable under physiological conditions and 
were tolerant to increased levels of glutathione (GSH).39 As discussed previously in Section 
1.26, an increased intracellular concentration of GSH is often associated to high levels of 
cellular growth in cancer as well as being a major contributing factor towards drug resistance 
by deactivation.81, 82  
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Figure 38 – Structure of the benzimidazole-based NHC complex, 19 and its cytotoxicity 
towards human cell lines in comparison to cisplatin; a Leukaemia, b Breast carcinoma. c Lung 
carcinoma, c Normal lung fibroblasts. Data taken from ref 39. 
Some of the limitations of platinum based chemotherapeutics were outlined in Section 1.11. 
These include a limited spectrum of action, drug resistance and severe side effects.3, 4 
Improving the selectivity of potential new chemotherapeutic agents for cancer cells over 
healthy cells helps to avoid the side effects that limit the effectiveness of platinum based 
anticancer agents.5  
Recently, the coupling of organometallics to peptides has been shown to increase their 
selectivity for cancer cells.93, 94 This concept has been applied predominantly to goldI 
complexes using mono- or polypeptide vectors.95 Several examples of goldIII complexes 
conjugated to amino acid and peptide derivatives have already been discussed in Section 
1.19. These have also shown an increased selectivity towards cancer cells over healthy cells. 
For example, Glisic et al. synthesised two goldIII complexes with L-Histidine containing 
peptides (Figure 39); a tridentate Gly-L-His dipeptide derivative, [Au(Gly-L-His)Cl]NO3, 31a 
and a tetradentate Gly-Gly-L-His tripeptide derivative, [Au(Gly-Gly-L-His]Cl, 31b. The 
cytotoxic activity of both complexes was assessed towards cancer cell lines as well as healthy 
MRC-5 cells and although their activity was strongly cell line dependent, both complexes 
were nontoxic towards the healthy cells with IC50 values of more than 100 µM.50 
Amino acid and peptide derivatives have also been conjugated to goldIII centres using other 
methods. As mentioned previously, Lemke et al. synthesised a phenylalanine-NHC goldIII 
conjugate; 32,51 and Ortego et al. conjugated amino ester derivatives to a goldIII centre via a 
pyridine nitrogen; 33 (Figure 39).52 Other authors have used dithiocarbamate ligands to 
conjugate cancer targeting oligopeptides to goldIII centres (Section 1.16). One dipeptide 
derivative [AuBr2(DTC-Sar-AA-OtBu)], 26 synthesised by Nardon et al. showed high levels of 
  IC50 ± SD (µM) 
Complex HL60a MCF-7b A549c MRC-5d 
19 0.31 ± 0.15 0.56 ± 0.02 7.8 ± 1.3 1.4 ± 0.4 
Cisplatin 3.7 ± 0.25 21.2 ± 3.9 33.7 ± 3.7 10.7 ± 3.0 
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cytotoxicity towards MDA-MB-231, breast cancer cells both in vitro and in an in vivo nude 
mice model (Figure 39).47  
 
Figure 39 – Structures of previously reported goldIII derivatives with amino acid and peptide 
conjugates.47, 50-52 
Discussed above are several examples of goldIII complexes conjugated to amino acid 
derivatives but there are no examples of cyclometalated complexes. We therefore decided 
to explore the synthesis and anticancer activity of cyclometalated (C^Npz^C) goldIII acyclic 
carbene complexes bearing amino ester substituents. 
The first synthetic pathway to the cyclometalated acyclic carbene complexes was initially 
explored by our group using a three-step synthesis; the formation of the goldIII amino 
complex, followed by an insertion of an isocyanide into the Au-N bond to afford the 
corresponding insertion product, and protonation to form the acyclic carbene, (Scheme 5).  
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Scheme 5 – the first synthetic pathway to the goldIII acyclic carbene complex.  
This was initially explored using aniline and 2,6-diisopropylaniline, using a method previously 
reported by our group for other N-based ligands.96 Complexes 38a and 38b were obtained 
after activation of the (C^Npz^C)Au-Cl, 37 with tert-butoxide in toluene at room temperature, 
followed by the addition of the aniline derivative, as depicted in Scheme 6.  
 
Scheme 6 – synthesis of (C^Npz^C)Au aniline complexes. 
Complex 38a was then reacted successfully with 2,6-dimethylphenylisocyanide in toluene, at 
room temperature overnight to afford the corresponding insertion product, complex 39 
(Scheme 7). The reaction was also attempted with 38b but the sterically hindered 2,6-
diisopropylaniline ligand did not react and the starting material was isolated again. In an 
attempt to vary the isocyanide, an insertion into the Au-N bond of 38a was also attempted 
with both tert-butyl isocyanide and cyclohexyl isocyanide. Both reactions were unsuccessful; 
whereas tert-butyl isocyanide inserted successfully, the product would subsequently 
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rearrange to produce the corresponding cyanide complex. This was also previously observed 
during other reactions using the pyridine based pincer ligand undertaken by our group.97 
Cyclohexyl isocyanide also reacted but formed a mixture of products that could not be 
purified.  
 
Scheme 7 – synthesis of the insertion product from the corresponding aniline complex. 
The protonation of complex 39 with HBF4·OEt2 produced the air-stable goldIII acyclic diamino 
carbene, complex 40 (Scheme 8).  
 
Scheme 8 – protonation of complex 39 to produce the acyclic carbene complex, 40. 
The first synthetic pathway offered a succesful route to the goldIII acyclic diamino carbene 
complexes but offered little versitility as neither the amine nor the isocyanide functional 
groups could be easily changed and consequently biologically relevant functionality could not 
be introduced into the system. We therefore developed the second synthetic pathway with 
the aim to incorporate a wider range of primary amines and amino esters to the (C^Npz^C)AuIII 
backbone. This allowed the synthesis of a library of [(C^Npz^C)Au(ACC)]SbF6 complexes which 
were subsequently screened for their cytotoxicity against human lung cancer cells (A549). 
The four most promising were then further tested against a panel of human cancer cell lines 
including lung adenocarcinoma (A549), leukaemia (HL60), colon cancer (HCT-116), breast 
cancer (MCF-7 and MDA-MB-231) as well as healthy fibroblasts (MRC-5) for comparison. 
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2.3 Results and Discussion 
2.31 Synthesis and structural characterisation 
The cyclometalated (C^Npz^C)AuCl starting material, 37 was synthesised using previous 
methods; via a Suzuki cross-coupling reaction to generate the (HC^Npz^CH) ligand and a 
mercuration reaction, followed by a transmetalation to obtain the cyclometalated product, 
as depicted in Scheme 9.96 
 
Scheme 9 – synthesis of (C^Npz^C)AuIIICl, 37.96 
Following reported procedures,87-89 the (C^Npz^C)AuIII isocyanide complex was chosen as the 
starting point for this pathway because the isocyanide triple bond could be attacked by a 
wide range of primary amine nucleophiles. 2,6-dimethylphenyl isocyanide was chosen 
because it would not rearrange to form the corresponding cyanide complex. Complex 41 was 
synthesised in high yield, (84%) under strictly inert conditions (Scheme 10) and its formation 
was confirmed by both NMR and IR spectroscopy as well as elemental analysis. An upfield 
shift of the signal for H2 from 8.71 to 8.93 ppm in the 1H NMR and the appearance of a C≡N 
vibration at 2267 cm-1 in the IR spectrum also confirmed the presence of the coordinated 
isocyanide. 
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Scheme 10 – synthesis of complex 41. 
Slow diffusion of petroleum ether through a saturated solution of dichloromethane under a 
nitrogen atmosphere gave crystals of complex 41 as long orange needles. These were 
characterised in the solid state by single crystal X-ray diffraction by Dr Julio Fernandez-Cestau 
(Figure 40). 
 
Figure 40 – a. Crystal structure of complex 41. Ellipsoids set at 50% probability. Selected bond 
distances (Å) and angles (°): Au1-N1 1.975(4), Au1-C4 2.113(4), Au1-C13 1.992(6), C13-N3 
1.124(7), C4-Au1-N3 80.31(11), C4-Au1-C13 99.69(11), Au1-C13-N3 180. b. Crystal packing of 
complex 41. 
The crystals display the expected slightly distorted square planar structure to the goldIII 
centre that is usually observed due to the accommodation of the (C^Npz^C) pincer ligand. 
Crystal packing showed the presence of dimers, stabilised by of π···π and F···H interactions. 
Complex 41 was very hydrolytically sensitive and reacted readily with water to form the 
formamide, complex 42, as depicted in Scheme 11. The amide bond in this structure was 
confirmed by the presence of both an NH vibration at 3296 cm-1 and a C=O vibration at 1643 
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cm-1 in the IR spectrum and a singlet at 168.8 ppm for the C=O carbon in the 13C[1H] NMR 
spectrum.  
 
Scheme 11 – nucleophilic attack of water to form the formamide by-product, 42. 
Slow evaporation of a saturated dichloromethane solution of 42 gave crystals suitable for X-
ray diffraction. These were characterised in the solid state by single crystal X-ray diffraction 
by Dr Julio Fernandez-Cestau (Figure 41). 
 
Figure 41 – a. Crystal structure of complex 42. Ellipsoids set at 50% probability. Selected bond 
distances (Å) and angles (°): Au1-N1 2.0396(15), Au1-C7 2.0251(18), Au1-C22 2.0957(19), 
Au1-C62 2.0756(19), C7-N70 1.365(2), C7-Au1-N1 176.18(7), C7-Au-C62 97.15(7), N1-Au1-
C62 80.21(7), C7-Au1-C22 102.83(7), N1-Au1-C22 79.86(7), C62-Au-C22 160.01(7). b. Crystal 
packing of complex 42. 
The goldIII centre once again displayed the typical distorted square planar geometry. The 
crystals formed a rod structure with the molecules packed in antiparallel columns stabilised 
by π-π stacking and weak intermolecular N70-H70···N4 hydrogen bonds. 
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The (C^Npz^C)AuIII isocyanide complex, 41 was then reacted with an array of amines and 
amino ester substrates under strictly anhydrous conditions, at room temperature for 16 
hours (Scheme 12) to form our library of complexes. 
 
Scheme 12 – synthesis of complexes 43a-43g. 
Complex 41 was reacted with distilled aniline strictly anhydrous conditions to produce the 
air-stable goldIII acyclic diamino carbene, complex 43a in good yield, (58%) (Figure 42). Two 
inequivalent NH peaks appeared in the 1H spectrum at 9.68 and 9.40 ppm, and the movement 
of other diagnostic peaks such as the upfield shift of H2 to 8.96 ppm and the downfield shift 
of H8 to form a multiplet with H5, all suggested carbene formation. The C=N vibration at 1586 
cm-1 in the IR spectrum also confirmed the successful formation of the acyclic diamino 
carbene complex. Elemental analysis also confirmed the predicted percentage of carbon, 
hydrogen and nitrogen in the expected monomeric unit of the complex. 
 
Figure 42 – structure of complex 43a. 
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A reaction of complex 41 with adamantylamine lead to the isolation of 43b in reasonable 
yield, (53%) (Figure 43). 
 
 
Figure 43 – structure of complex 43b. 
 
The formation of complex 43b was confirmed by NMR and IR spectroscopy. Both the up-field 
shift to 8.92 ppm in the H2 peak and the appearance of two broad NH singlets at 8.42 and 
6.64 ppm in the 1H NMR spectrum indicated the formation of a carbene. The IR spectrum 
also showed a carbene vibration at 1586 cm-1 and two distinct NH vibrations at 3312 cm-1 and 
3210 cm-1, giving further evidence to the differing chemical character of the aryl and alkyl 
amines. Light yellow square plate crystals were successfully grown by the slow evaporation 
of a dichloromethane/toluene (50:1) solution and characterised in the solid state by single 
crystal X-ray diffraction by Dr Julio Fernandez-Cestau (Figure 44). 
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Figure 44 – a. Crystal structure of complex 43b. Ellipsoids set at 50% probability. Toluene 
molecules are omitted for clarity. Selected bond distances (Å) and angles (°): Au-N1 2.01(1), 
Au-C7 2.03(1), Au-C22 2.10(1), Au-C62 2.09(1), N1-Au-C7 175.8(4), N1-Au-C22 80.4(4), N1-
Au-C62 80.5(4), C22-Au-C7 101.6(5), C62-Au-C7 97.4(4), C22-Au-C62 160.9(4). b. Crystal 
packing of complex 43b. 
The expected distorted square planar geometry was observed around the goldIII centre and 
the molecules were packed in antiparallel columns stabilised by π-π stacking, weak 
intermolecular N8-H8···N4 hydrogen bonds and F···H interactions with the SbF6 anions. 
The same synthesis pathway was then used to synthesise five acyclic diamino carbene 
complexes with amino ester decorated functional groups (43c-43g) (Figure 45). The amino 
esters were bought as their commercially available hydrochloride salts, (Gly-OEt.HCl, Ala-
OMe.HCl, Val-OMe.HCl, PhGly-OMe.HCl, and Met-OMe.HCl), and were neutralised with 
K2CO3 before the resulting amines were reacted with complex 41 under strictly anhydrous 
conditions. Complexes 43c-43g were all obtained in moderate to good yields, (59%, 67%, 
75%, 53% and 74% respectively). 
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Figure 45 – structures 43c-43g, the acyclic carbene complexes decorated with amino ester 
functional groups. 
The formation of the carbene complexes was confirmed using both 1H and 13C[1H] NMR 
spectroscopy as well as IR spectroscopy. For complex 43c, which contained the non-chiral 
glycine ethyl ester derived acyclic carbene, both the 1H and 13C[1H] NMR spectra showed 
equivalent signals for the (C^Npz^C) pincer ligand. However, in the case of 43d-43g, when a 
chiral amino ester was introduced, we saw a loss of symmetry in the (C^Npz^C) pincer ligand, 
and many of the diagnostic peaks such as the tert-butyl, H5 and H8 were doubled. This loss of 
equivalency is due to the square planar geometry of the goldIII centre which permits the chiral 
alkyl side chain of the amino ester to interact with the (C^Npz^C) pincer ligand. The effect is 
most prominent in complexes 43e and 43f due to the steric bulk of the isopropyl and phenyl 
side chains interacting to a greater extent with the pincer ligand. All the complexes also 
displayed a prominent carbene vibration at around 1585 cm-1 and a tight C=O vibration at 
around 1740 cm -1 in their IR spectra. 
Suitable crystals for X-ray diffraction of the glycine amino ester derivative, 43c, were 
successfully grown by the slow diffusion of petroleum ether through a saturated 
dichloromethane solution. These were characterised in the solid state by single crystal X-ray 
diffraction by Dr Julio Fernandez-Cestau (Figure 46). 
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Figure 46 – a. Crystal structure of complex 43c. Ellipsoids set at 50% probability. Selected bond 
distances (Å) and angles (°): Au1-N1 2.012(2), Au1-C25 2.010(3), Au1-C6 2.098(3), Au1-C16 
2.102(3), N1-Au1-C25 177.0(1), C6-Au1-C16 160.8(1), N1-Au1-C6 80.6(1), N1-Au1-C16 
80.3(1), C6-Au1-C25 98.8(1), C16-Au1-C25 100.4(4), N3-C25-N4 118.5(3). b. Crystal packing 
of complex 43c. 
Once again, the typical, slightly distorted square planar geometry around the goldIII centre 
was observed, with the crystals packed in anti-parallel columns, stabilised NH···Npz hydrogen 
bonds and F···H interactions with the SbF6 anions. 
2.32 In vitro antiproliferative activity 
Although poorly soluble in aqueous medium by themselves, all the complexes appeared 
soluble enough in DMSO not to precipitate when diluted up to 100 µM in aqueous cell 
medium with 1% of DMSO. A preliminary cytotoxicity screening for all the air stable 
complexes was carried out on human lung adenocarcinoma cells (A549). This cell line was 
chosen for its ability to discriminate between structurally similar (C^Npz^C)AuIII carbene 
complexes.39 
Complexes 42 and 43a-43g, as well as the starting gold chloride, complex 37, were tested at 
concentrations of 100 µM and 10 µM in comparison to the clinically available drug cisplatin. 
The preliminary cytotoxicity assay for complexes 43b and 43g was carried out by Dr Benoît 
Bertrand. The inhibition of cellular proliferation was determined using an MTS assay after 72 
hours of incubation. This is a colorimetric assay for the quantification of viable cells based on 
the reduction of MTS tetrazolium compound by viable cells to generate a coloured formazan 
product. The results are summarised in Figure 47. 
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Figure 47 – Inhibition of A549 cellular proliferation by complexes 37, 42, and 43a-43g in DMSO 
in comparison to cisplatin. Data represents the average ± the standard deviation of three 
experiments. 
Both of the neutral complexes; the gold chloride starting material, 37 and the formamide 
hydrolysis product, 42 appeared to be non-toxic at both 10 and 100 µM concentrations. This 
is consistent with previous cytotoxicity results obtained by our group using neutral 
(C^N^C)Au complexes with phenylacetylide and thiophenolate ligands.39 It is possible that 
this reduced cytotoxicity is a product of reduced cellular uptake. 
The acyclic diamino carbene complex with the aniline substituent, 43a appeared poorly toxic 
at both concentrations, (cell viability of 38.0% at 100 µM and 69.5% at 10 µM). This is in good 
agreement with previous cytotoxicity data obtained by our group for the BF4 analogue of this 
complex, 40 synthesised by the first synthetic pathway, discussed in Section 2.2, (cell viability 
of 64.6% and 69.5% for 100 µM and 10 µM respectively) (Figure 48). This indicates that the 
two different anions BF4 and SbF6 were only having a marginal effect on the toxicity of the 
complexes at low concentrations. 
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Figure 48 – structure of the aniline acyclic carbene complexes, 40 and 43a synthesised by the 
first and second synthetic pathways respectively and their cytotoxicity towards A549 Lung 
cancer cells, portrayed as % of cell viability.  
Complexes 43b-43g all appeared to inhibit cancer cellular proliferation at 100 µM, (cell 
viability of 6.3%, 7.6%, 9.7%, 13.8%, 6.3% and 9.3% for complexes 43b-43g respectively). The 
two complexes with the most lipophilic side chains; 43e (isopropyl) and 43f (phenyl) showed 
reduced cytotoxicity at 10 µM, (51.1% and 69.0% respectively). Only four complexes showed 
less than 50% cell viability at 10 µM, 43b-43d and 43g, (9.6%, 38.4%, 14.9%, and 23.5% for 
complexes 43b-43d and 43g respectively). These four complexes were therefore selected for 
further testing. 
IC50 values for these four complexes, (the half maximal inhibitory concentration, i.e. the 
concentration required to inhibit 50% of cellular proliferation), were then determined on a 
panel of human cancer cell lines. These included solid tumour cell lines; lung adenocarcinoma 
cells (A549), breast adenocarcinoma (MCF-7 and MDA-MB-231) and human colon cancer 
(HCT-116) and suspension cells; promyelocytic leukaemia (HL60) and also healthy lung 
fibroblast cells (MRC-5). The results are reported in Table 1 in comparison to cisplatin and 
our previously reported benzimidazole-based NHC complex, 19 (Figure 49). 
 
Figure 49 – structures of cisplatin and complex 19. 
  Cell viability (% of controls) 
Complex 100 µM 10 µM 
40 64.6% 69.5% 
43a 38.0% 69.5% 
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Table 1 – IC50 values for complexes 43b-43d, 43g and 19 in comparison to cisplatin against 
different human cancer cell lines and healthy lung fibroblast cells after 72 h of incubation. 
 IC50 ± SD (µM)a 
Complex A549 MCF-7 HL60 HCT-116 MDA-MB-
231 
MRC-5 
43b 6.1 ± 1.1 5.2 ± 0.2 0.8 ± 0.1 0.6 ± 0.1 0.3 ± 0.1 0.37 ± 0.03 
43c 13.0 ± 3.6 6.4 ± 1.6 16.7 ± 2.5 8.4 ± 0.5 5.1 ± 2.0 8.8 ± 1.0 
43d 7.9 ± 1.5 3.9 ± 0.6 8.1 ± 0.9 8.1 ± 0.4 4.7 ± 0.7 6.9 ± 1.1 
43g 7.7 ± 1.6 3.4 ± 0.2 6.9 ± 0.6 7.3 ± 0.4 11.1 ± 2.8 6.4 ± 0.7 
19 7.8 ± 1.3b 0.56 ± 0.02b 0.3 ± 0.1b 11.2 ± 1.5 5.7 ± 0.4 1.4 ± 0.4b 
Cisplatin 33.7 ± 3.7b 21.2 ± 3.9b 3.7 ± 0.3b 5.3 ± 0.2 28.4 ± 0.1 10.7 ± 3.0b 
a Mean ± the standard error of at last three independent experiments. b Values from ref 39. 
All four of the selected acyclic diaminocarbene complexes were between 3-5 times more 
cytotoxic than cisplatin against the A549 and MCF-7 cell lines and the adamantyl derivative, 
43b was also more cytotoxic than cisplatin against the HL60, HCT-116, and MDA-MB-231 cell 
lines. However, all the new carbene complexes appeared slightly less active than our 
previously reported benzimidazole-based NHC complex, 19 against both MCF-7 and HL60 
although they showed comparable cytotoxicity against A549, HCT-116 and MDA-MB-231. 
Even so, the low micromolar activities of these complexes against the A549, MCF-7 and MDA-
MB-231 cell lines, which all show reduced sensitivity to cisplatin, make them promising for 
the development of new anticancer drugs. 
The adamantyl derivative, 43b was over ten times more active than 19 against HCT-116 and 
MDA-MB-231 cells. Among the amino ester derivatives 43c, 43d, and 43g, the glycine based 
complex, 43c was the least cytotoxic in the series while the alanine, 43d and methionine, 43g 
derivatives showed similar activities across the panel of cancer cell lines, (with the exception 
of MDA-MB-231). Complex 43b showed the highest overall activity with IC50 values in the low 
micromolar ranges for A549 and MCF-7 cells and values of under 1 µM for HL60, MDA-MB-
231 and HCT-116 cells. This complex, however, also showed very poor selectivity for the 
healthy MRC-5 cells. 
The amino ester derivatives, (43c, 43d and 43g) appeared to have reduced activity against 
the healthy MRC-5 cells, particularly in comparison to our previously reported heterocyclic 
complex, 19.39 All of the amino-ester containing complexes also showed an improved 
selectivity for MCF-7 cells versus healthy MRC-5 fibroblasts (selectivity factor SMCF-7/MRC5 = >1) 
and were also significantly more selective than cisplatin (SMCF-7/MRC-5 = 0.5). 
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2.33 Quantification of reactive oxygen species 
The induction of reactive oxygen species (ROS) is a recognised mechanism of action for metal-
based drugs, including AuI-NHC complexes.75 With this in mind, we tested the four most 
active acyclic diaminocarbene complexes, 43b-43d and 43g for the production of ROS. The 
amount of intracellular ROS was measured after treatment of A549 cells with 100 µM, 50 µM 
and 10 µM concentrations of these complexes and also the less cytotoxic aniline derivative, 
43a, to act as a negative control. The results are summarised in Figure 50. None of the 
complexes tested appeared to increase the production of ROS and therefore this mode of 
action can be ruled out for these acyclic diamino carbene complexes. 
 
Figure 50 – ROS measurements in A549 cells after 24 h incubation with complexes 43a-43d 
and 43g. 
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2.34 Reaction with Glutathione 
GoldIII complexes are frequently unstable under physiological conditions and are easily 
reduced by GSH (Section 1.26), whereupon the GSH is oxidised to GSSG (Figure 51). 
Incorporating a cyclometalating ligand can help to improve the stability of the complexes 
towards this reduction.19, 28 Bis-cyclometalated goldIII NHC complexes, like 19 (Figure 49) 
generally show a higher tolerance towards reduction and substitution by GSH.39 With this in 
mind we tested the stability of two of the new acyclic carbene complexes, 43c and 43d 
towards reduction by GSH using 1H NMR spectroscopy to follow the course of the reaction. 
 
Figure 51 – structures of reduced glutathione (GSH) and oxidised glutathione (GSSG). 
Each complex was mixed at room temperature with reduced glutathione in a 1:1 mixture of 
DMSO-d6 and D2O and monitored by 1H NMR over a 24 h period. Although no reaction was 
observed for either complex over the first hour, over 24 hours the formation of oxidised 
glutathione (GSSG) was observed as well as the disappearance of signals for the 
[(C^Npz^C)AuIII(ACC)]+ cations and the formation of a pale yellow product (Figure 52a and 
52b). This was attributed to the reduction product, (C^Npz^CH)AuI(ACC). This leads to the 
conclusion that acyclic carbene complexes are more sensitive towards reduction by GSH than 
benzimidazole-type goldIII carbene complexes.39 
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Figure 52a – 1H NMR spectra of a 1:1 mixture of 43c with GSH at different reaction times at 
room temperature, in comparison with the starting materials 43c, GSH and GSSG (DMSO-
d6/D2O 1:1). 
 
Figure 52b – 1H NMR spectra of a 1:1 mixture of 43d with GSH at different reaction times at 
room temperature, in comparison with the starting materials 43d, GSH and GSSG (DMSO-
d6/D2O 1:1). 
2.4 Conclusion 
This chapter has described the synthesis and characterization of nine new pyrazine-based 
cyclometalated (C^Npz^C)AuIII complexes along with the first examples of cyclometalated 
goldIII complexes decorated with amino acid derivatives. The two-step synthesis started with 
the formation of a cationic (C^Npz^C)AuIII isocyanide complex followed by the nucleophilic 
attack onto the highly electrophilic isocyanide carbon by a broad range of nucleophiles, 
leading to the synthesis of two amine derivatives and five amino ester decorated 
[(C^Npz^C)AuIII(ACC)]X complexes. 
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A preliminary cytotoxicity assay against human lung adenocarcinoma cells, (A549) showed 
that complexes 43b (adamantyl), 43c (glycine), 44d (alanine) and 44g (methionine) were the 
most promising candidates. These were further tested on a panel of human cancer cell lines 
and one healthy cell line for comparison. The amino ester derivatives displayed some 
promising selectivity profiles for MCF-7 breast cancer cells over healthy MRC-5 cells. 
The antiproliferative mode of action of these complexes is unknown although certain 
methods can be ruled out; in this case, we established that these complexes did not increase 
the formation of reactive oxygen species. However, two of the amino ester derivatives, 43c 
and 43d showed reduction in the presence of GSH which could indicate that they are reduced 
to a goldI active species within a cellular environment. Further work could investigate the 
possible modes of action of these acyclic carbene complexes and also continue to work on 
improving the cell selectivity. 
2.5 Experimental 
When required, manipulations were performed using standard Schlenk techniques under dry 
nitrogen or in an MBraun glove box. Nitrogen was purified by passing through columns of 
supported P2O5 with moisture indicator and activated 4 Å molecular sieves. Anhydrous 
solvents were freshly distilled from appropriate drying agents. 1H and 13C[1H] spectra were 
recorded using a Bruker Avance DPX-300 spectrometer. 1H NMR spectra (300.13 MHz) were 
referenced to the residual protons of the deuterated solvent used. 13C[1H] NMR spectra 
(75.47 MHz) were referenced internally to the D-coupled 13C resonances of the NMR solvent. 
Elemental analyses were carried out at London Metropolitan University. Complex 37 was 
synthesized following reported procedures.96 
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2.51 Synthesis of [(C^Npz^C)Au(2,6-dimethylphenyl isocyanide)]SbF6 (41) 
 
A mixture of 37 (0.150 g, 0.261 mmol), 2,6-dimethylphenyl isocyanide (0.041 g, 0.313 mmol), 
AgSbF6 (0.107 g, 0.313 mmol) and a few pellets of 4 Å molecular sieves were combined in a 
flame-dried Schlenk flask under a nitrogen atmosphere with dry dichloromethane (15 mL). 
The mixture was left to stir at room temperature for 4 h. A white precipitate of AgCl was 
removed by filtration through celite, and the filtrate collected under an N2 atmosphere. The 
solvent was evaporated to a minimum and the product precipitated with an excess of light 
petroleum (bp. 40-60 °C). The supernatant was removed and the residue dried under vacuum 
to yield a yellow solid (0.198 g, 84%). Anal. Calcd. for C33H35AuN3SbF6 (906.4): C, 43.73; H, 
3.89; N, 4.64. Found: C, 43.84; H, 3.69; N, 4.75. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.93 (s, 
2H, H2), 7.89 (d, 4J = 1.80 Hz, 2H, H8), 7.77 (d, 3J = 8.25 Hz, 2H, H5), 7.59 (t, 3J = 7.47 Hz, 1H, 
H15), 7.53 (dd, 3J = 8.25 Hz, 4J = 1.8 Hz, 2H, H6), 7.42 (d, 3J = 7.47 Hz, 2H, H14), 2.73 (s, 6H, H16), 
1.36 (s, 18H, tBu). 13C[1H] NMR (CD2Cl2, 75 MHz): δ 168.1 (s, C9), 159.5 (s, C4), 158.4 (s, C7), 
143.8 (s, C3), 140.2 (s, C2), 137.4 (s, C13), 134.4 (s, C8), 133.6 (s, C14), 129.6 (s, C15), 127.6 (s, C5), 
126.7 (s, C6), 36.2 (s, C(CH3)3), 31.1 (s, C(CH3)3), 19.4 (s, C16). IR: νmax (neat)/cm-1: 2957 (CH), 
2267 (C≡N). 
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Figure 2.51a – H1 NMR of complex 41 in CD2Cl2. 
 
Figure 2.51b – C13[1H] NMR of complex 41 in CD2Cl2.  
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2.52 Synthesis of (C^Npz^C)Au(2,6-dimethylphenyl formamide) (42) 
 
A mixture of 41 (0.055 g, 0.061 mmol) and K2CO3 (0.025 g, 0.182 mmol), dissolved in a mixture 
of tetrahydrofuran (5 mL) and water (2 mL), was stirred at room temperature for 3 h. The 
THF was removed under vacuum and water (10 mL) was added. The product was extracted 
using dichloromethane (3 × 10 mL) and the organic layer washed with water (3 × 10 mL) and 
dried with anhydrous Na2SO4. The solution was evaporated and the solid residue washed 
twice with light petroleum (bp. 40-60 °C) and dried, to yield a bright yellow solid (0.038 g, 
68%). Anal. Calcd. for C33H36AuN3O (687.6): C, 57.64; H, 5.28; N, 6.11. Found: C, 57.42; H, 
5.18; N, 6.19. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.80 (s, 2H, H2), 8.00 (d, 4J = 2.01 Hz, 2H, 
H8), 7.60 (d, 3J = 8.16 Hz, 2H, H5), 7.33 (dd, 3J = 8.16 Hz, 4J = 2.01 Hz, 2H, H6), 7.16 (s, 3H, H14+15), 
7.07 (s, 1H, NH), 2.50 (s, 6H, H16), 1.34 (s, 18H, tBu). 13C[1H] NMR (CD2Cl2, 75 MHz): δ 168.8 (s, 
C10), 167.5 (s, C9), 156.6 (s, C7), 156.4 (s, C4), 144.8 (s, C3), 138.4 (s, C2), 136.7 (s, C12), 135.8 (s, 
C13), 134.9 (s, C8), 128.5 (s, C14), 127.2 (s, C15), 126.0 (s, C5), 124.3 (s, C6), 35.7 (s, C(CH3)3), 31.4 
(s, C(CH3)3), 19.7 (s, CH316). IR: νmax (neat)/cm-1: 3296 (NH), 2962 (CH), 1643 (C=O). 
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Figure 2.52a – H1 NMR of complex 42 in CD2Cl2. 
Figure 2.52b – C13[1H] NMR of complex 42 in CD2Cl2. 
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2.53 Synthesis of [(C^Npz^C)Au[C(NHPh)(NHC6H3Me2-2,6)]]SbF6 (43a) 
 
Complex 41 (0.066 g, 0.073 mmol) and aniline (0.014 g, 0.146 mmol) were combined in a 
flame-dried Schlenk flask, under N2 atmosphere, with molecular sieves and dry 
dichloromethane (5 mL). The solution was stirred at room temperature for 16 h. The product 
was precipitated by addition of a 2/1 mixture of light petroleum (bp. 40-60 °C) and diethyl 
ether, filtered off and dried under vacuum to yield a bright yellow solid (0.060 g, 0.050 mmol, 
58%). Calcd. for C39H42AuF6N4Sb·3H2O (1053.6): C, 44.46; H, 4.59; N, 5.32. Found: C, 44.02; H 
4.94; N 5.25. 1H NMR (CD3CN, 300 MHz, 298 K): δ 9.68 (s, 1H, NH), 9.40 (s, 1H, NH), 8.96 (s, 
2H, H2), 7.80-7.71 (m, 4H, HAr.), 7.46-7.32 (m, 7H, HAr.), 7.24-7.14 (m, 3H, HAr.), 2.53 (s, 6H, 
H16), 1.34 (s, 18H, tBu). 13C[1H] NMR (CD3CN, 75 MHz): 175.1 (s, C10), 164.9 (s, C9), 156.8 (s, 
C4), 156.5 (s, C3), 144.7 (s, C7), 139.6 (s, C2), 138.9 (s, C13), 135.6 (s, CAr.), 133.2 (s, C8), 132.5 (s, 
C12), 130.0 (s, C15), 129.6 (s, C14), 129.6 (s, CAr.), 127.9 (s, C18), 126.7 (s, C5), 125.1 (s, C6), 124.0 
(s, CAr.), 35.3 (s, C(CH3)3), 30.4 (s, C(CH3)3), 18.5 (s, C16). IR: νmax (neat)/cm-1: 3311 (NH) , 2958 
(CH), 1586 (carbene). 
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Figure 2.53a – H1 NMR of complex 43a in CD3CN. 
Figure 2.53b – C13[1H] NMR of complex 43a in CD3CN.  
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2.54 Synthesis of [(C^Npz^C)Au[C(NH-1-Ad)(NHC6H3Me2-2,6)]]SbF6 (43b) 
 
Complex 41 (0.050 g, 0.055 mmol) and 1-adamantylamine (0.017 g, 0.110 mmol) were 
combined in a flame-dried Schlenk flask, under N2 atmosphere with molecular sieves and dry 
dichloromethane (5 mL). The solution was stirred at room temperature for 16 h. The product 
was precipitated with an excess of light petroleum (bp. 40-60 °C), filtered off and dried under 
vacuum to yield a bright yellow solid (0.031 g, 53%). Anal. Cald. for C43H52AuN4SbF62H2O 
(1093.66): C, 47.22; H, 5.16; N, 5.12. Found: C, 47.16; H, 4.71; N, 5.30. 1H NMR (CD2Cl2, 300 
MHz, 298 K): δ 8.92 (s, 2H, H2), 8.42 (s, 1H, NH), 7.78 – 7.72 (m, 4H, H5/8), 7.49 (dd, 3J = 8.30 
Hz, 4J = 1.8 Hz, 2H, H6), 7.47 – 7.36 (m, 3H, H14+15), 6.64 (s, 1H, NH), 2.55 (s, 6H, H16), 2.04 (s, 
9H, CHAd. + CH2Ad.), 1.54 – 1.51 (m, 6H, CH2ad.), 1.36 (s, 18H, tBu). 13C[1H] NMR (CD2Cl2, 75 MHz): 
δ 172.4 (s, C10), 166.5 (s, C9), 157.9 (s, C7), 157.3 (s, C4), 144.5 (s, C3), 139.5 (s, C2), 135.9 (s, 
C13), 134.6 (s, C8), 130.8 (s, C15), 130.5 (s, C14), 127.0 (s, C5), 125.6 (s, C6), 57.5 (s, CAd.), 44.6 (s, 
CH2Ad.), 36.0 (s, C(CH3)3), 35.6 (s, CAd.), 31.2 (s, C(CH3)3), 29.8 (s, CH2Ad.), 19.5 (s, C16). IR: νmax 
(neat)/cm-1: 3311 (NH), 3210 (NH), 2958 (CH), 1586 (carbene). 
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Figure 2.54a – H1 NMR of complex 43b in CD2Cl2. 
 
Figure 2.54b – C13[1H] NMR of complex 43b in CD2Cl2. 
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2.55 Synthesis of [(C^Npz^C)Au[C(NHCH2CO2Et)(NHC6H3Me2-2,6)]]SbF6 (43c) 
 
Glycine ethyl ester HCl (0.020 g, 0.146 mmol) was added to a flame-dried Schlenk flask 
charged with K2CO3 (0.012 g, 0.088 mmol) and acetonitrile (10 mL). The solution was 
sonicated for 30 min and transferred to a separate flame-dried Schlenk flask containing 41 
(0.066 g, 0.073 mmol). The reaction was then stirred for 16 h at room temperature and the 
precipitate removed from solution via filtration through a celite plug. Next, the solvent was 
removed under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The 
product was precipitated using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether 
(5 mL) and after removing the solvent, dried under vacuum to yield a bright yellow solid 
(0.062 g, 0.061 mmol, 59%). Calcd. for C37H44AuF6N4O2Sb (1009.5): C, 44.02; H, 4.39; N, 5.55. 
Found: C, 43.91; H 4.45; N 5.48. 1H NMR (CD3CN, 300 MHz, 298 K): δ 9.66 (s, 1H, NH), 8.99 (s, 
2H, H2), 7.81 (d, 3JH-H = 8.3 Hz, 2H, H5), 7.70 (d, 4JH-H = 2.0 Hz, 2H, H8), 7.57 (s, 1H, NH), 7.45 
(dd, 3JH-H = 8.3 Hz, 4JH-H = 2.0 Hz, 2H, H6), 7.40 – 7.28 (m, 3H, H14+15), 4.25 (d, 3JH-H = 4.3 Hz, 2H, 
H18), 3.97 (q, 3JH-H = 7.2 Hz, 2H, H20) 2.50 (s, 6H, H16), 1.33 (s, 18H, tBu), 1.01 (t, 3JH-H =7.2 Hz, 
3H, H21). 13C[1H] NMR (CD3CN, 75 MHz): δ 177.7 (s, C10), 168.2 (s, C19), 165.2 (s, C9), 156.8 (s, 
C4), 156.4 (s, C3), 144.9 (s, C7), 139.6 (s, C2), 135.8 (s, C13), 133.3 (s, C8), 132.4 (s, C12), 129.8 (s, 
C15), 129.4 (s, C14), 126.8 (s, C5), 125.0 (s, C6), 61.6 (s, C20), 50.0 (s, C18), 35.3 (s, C(CH3)3), 30.4 
(s, C(CH3)3), 18.3 (s, C16), 13.3 (s, C21). IR: νmax (neat)/cm-1: 3317 (NH), 3171 (NH), 2963 (CH), 
1740 (C=O), 1585 (carbene). 
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Figure 2.55a – H1 NMR of complex 43c in CD3CN. 
 
Figure 2.55b – C13[1H] NMR of complex 43c in CD3CN.
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2.56 Synthesis of [(C^Npz^C)Au[C(NHCH(Me)CO2Me)(NHC6H3Me2-2,6)]]SbF6 (43d)  
 
L-alanine methyl ester HCl (0.020 g, 0.146 mmol) was added to a flame-dried Schlenk flask 
charged with K2CO3 (0.012 g, 0.088 mmol) and acetonitrile (5 mL). The solution was sonicated 
for 30 min and transferred to a separate flame-dried Schlenk flask containing 41 (0.066 g, 
0.073 mmol). The reaction was then stirred for 16 h at room temperature and the precipitate 
removed from solution via filtration through a celite plug. Next, the solvent was removed 
under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The product was 
precipitated using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether (5 mL), and 
after removing the solvent, dried under vacuum to yield a bright yellow solid (0.070 g, 0.069 
mmol, 67%). Calcd. for C37H44AuF6N4O2Sb (1009.50): C, 44.02; H, 4.39; N, 5.55. Found: C, 
43.92; H 4.37; N 5.46. 1H NMR (CD3CN, 300 MHz, 298 K): δ 9.40 (s, 1H, NH), 9.00 (s, 2H, H2/2’), 
7.85 (d, 3JH-H = 8.3 Hz, 1H, H5/5’), 7.81 (d, 3JH-H = 8.3 Hz, 1H, H5/5’), 7.74 (d, 4JH-H = 2.0 Hz, 1H, 
H8/8’), 7.70 (s, 1H, NH), 7.66 (d, 4JH-H= 2.0 Hz, 1H, H 8/8’), 7.49 (dd, 3JH-H = 8.3 Hz, 4JH-H = 2.0 Hz, 
1H, H6/6’), 7.45 (dd, 3JH-H = 8.3 Hz, 4JH-H = 2.0 Hz, 1H, H6/6’), 7.37-7.27 (m, 3H, H14+14’+15), 4.86 (m, 
1H, H18), 3.53 (s, 3H, H20), 2.58 (s, 3H, H16), 2.44, (s, 3H, H16’), 1.39 (d, 3JH-H = 7.2 Hz, 3H, CH3Ala.), 
1.32 (s, 9H, tBu), 1.32 (s, 9H, tBu). 13C[1H] NMR (CD3CN, 75 MHz): δ 176.2 (s, C10), 170.9 (s, C19), 
165.2 (s, C9), 164.9 (s, C9’), 157.0 (s, C7), 156.8 (s, C7’), 156.4 (s, C4), 156.3 (s, C4’), 145.0 (s, C3), 
144.9 (s, C3’), 139.8 (s, C2), 139.7 (s, C2’), 135.9 (s, C13), 135.7 (s, C13’), 133.9 (s, C8), 132.9 (s, 
C8’), 132.4 (s, C12), 129.9 (s, C15), 129.5 (s, C14), 129.4 (s, C14’), 127.1 (s, C5), 126.8 (s, C5’), 125.3 
(s, C6), 125.1 (s, C6’), 58.6 (s, C18), 52.6 (s, C20), 35.3 (s, C(CH3)3), 30.4 (s, C(CH3)3), 30.4 (s, 
C(CH3)3), 18.6 (s, H16), 18.5 (s, H16), 17.4 (s, CH3Ala.). IR: νmax (neat)/cm-1: 3319 (NH), 3062 (NH), 
2961 (CH), 1750 (C=O), 1582 (carbene). 
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Figure 2.56a – H1 NMR of complex 43d in CD3CN. 
Figure 2.56b – C13[1H] NMR of complex 43d in CD3CN.
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2.57 Synthesis of [(C^Npz^C)Au[C(NHCH(iPr)CO2Me)(NHC6H3Me2-2,6)]]SbF6 (43e)  
 
L-valine methyl ester HCl (0.029 g, 0.175 mmol) was added to a flame-dried Schlenk flask 
charged with K2CO3 (0.012 g, 0.088 mmol) and acetonitrile (5 mL). The solution was sonicated 
for 30 min and transferred to a separate flame-dried Schlenk flask containing 41 (0.079 g, 
0.087 mmol). The mixture was stirred for 16 h at room temperature and the precipitate 
removed by filtration through a celite plug. Next, the solvent was removed under vacuum 
and the solid residue re-dissolved in dichloromethane (2 mL). The product was precipitated 
using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether (5 mL), and after removing 
the solvent, dried under vacuum to yield a bright yellow solid (0.068 g, 75%). Anal. Calcd. for 
C39H48AuN4O2SbF6 (1037.56): C, 45.15; H, 4.66; N, 5.40. Found: C, 44.86; H, 4.52; N, 5.52. 1H 
NMR (CD3CN, 300 MHz, 298 K): δ 9.50 (s, 1H, NH), 9.03 (s, 1H, H2), 9.02 (s, 1H, H2’), 7.89-7.82 
(m, 2H, H5+5’), 7.77 (d, 4J = 1.9 Hz, 1H, H8), 7.54-7.46 (m, 4H, NH + H6+6’+8’), 7.42-7.32 (m, 3H, 
H14+14’+15), 4.50 (m, 1H, H18), 3.39 (s, 3H, H20), 2.56 (s, 3H, H16), 2.54 (s, 3H, H16’), 2.13 (m, 1H, 
HVal.), 1.33 (s, 9H, tBu), 1.32 (s, 9H, tBu), 0.84 (d, 3JH-H = 6.9 Hz, 6H, CH3Val.). 13C[1H] NMR (CD3CN, 
75 MHz): δ 177.7 (s, C10), 171.7 (s, C19), 166.5 (s, C9), 165.6 (s, C9’), 157.9 (s, C7), 157.8 (s, C7’), 
157.4 (s, C4), 157.4 (s, C4’), 145.9 (s, C3), 145.8 (s, C3’), 140.7 (s, C2), 136.7 (s, C13), 136.5 (s, C13’), 
134.6 (s, C8), 134.0 (s, C8’), 133.0 (s, C2’), 131.1 (s, C15), 130.7 (s, C14), 130.6 s, C14’), 127.9 (s, 
C5), 127.8 (s, C5’), 126.5 (s, C6), 126.2 (s, C6’), 69.4 (s, C18), 53.2 (s, C20), 36.3 (s, C(CH3)3), 36.3 (s 
C(CH3)3), 32.2 (s, CVal.), 31.4 (s, C(CH3)3), 31.4 (s, C(CH3)3), 19.9 (s, C16), 19.7 (s, C16’), 19.5 (s, 
CVal.), 19.3 (s, CVal.). IR: νmax (neat)/cm-1: 3300 (NH), 3189 (NH), 2965 (CH), 1742 (C=O), 1582 
(carbene). 
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Figure 2.57a – H1 NMR of complex 43e in CD3CN. 
 
Figure 2.57b – C13[1H] NMR of complex 43e in CD3CN.
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2.58 Synthesis of [(C^Npz^C)Au[C(NHCH(Ph)CO2Me)(NHC6H3Me2-2,6)]]SbF6 (43f)  
 
D-phenylglycine methyl ester HCl (0.030 g, 0.146 mmol) was added to a flame-dried Schlenk 
flask charged with K2CO3 (0.012 g, 0.087 mmol) and acetonitrile (5 mL). The solution was 
sonicated for 30 min and transferred to a separate flame-dried Schlenk flask containing 41 
(0.066 g, 0.073 mmol). The reaction was stirred for 16 h at room temperature and the 
precipitate removed from solution via filtration through a celite plug. The solvent was 
removed under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The 
product was precipitated using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether 
(5 mL), and after removing the solvent, dried under vacuum to yield an orange solid (0.059 
g, 0.055 mmol, 53%). Calcd. for C42H46AuF6N4O2Sb.2CH2Cl2 (1241.4): C, 42.57; H, 4.06; N, 4.51. 
Found: C, 42.55; H 4.03; N 4.15. 1H NMR (CD3CN, 300 MHz, 298 K): δ 9.51 (s, 1H, NH), 9.02 (s, 
1H, H2), 8.97 (s, 1H, H2’), 8.11 (d, 3JH-H = 6.0 Hz, 1H, NH), 7.87 (d, 3JH-H = 8.2 Hz, 1H, H5), 7.74 (d, 
3JH-H = 8.2 Hz, 1H, H5’), 7.68 (d, 4JH-H = 1.6 Hz, 1H, H8), 7.51 (dd, 3JH-H = 8.2 Hz, 4JH-H = 1.6 Hz, 1H, 
H6), 7.41-7.30 (m, 4H, H6’+14+14’+15), 7.28 (d, 4JH-H = 1.6 Hz, 1H, H8’), 7.21-7.06 (m, 5H, HPhGly.), 
5.68 (d, 3JH-H = 6.0 Hz, 1H, H18), 3.54 (s, 3H, H20), 2.51 (s, 3H, H16), 2.43 (s, 3H, H16’), 1.35 (s, 9H, 
tBu), 1.17 (s, 9H, tBu). 13C[1H] NMR (CD3CN, 75 MHz): δ 176.5 (s, C10), 169.4 (s, C19), 165.3 (s, 
C9), 164.3 (s, C9’), 157.1 (s, C7), 156.5 (s, C7’), 156.4 (s, C4), 156.4 (s, C4’), 145.0 (s, C3), 144.4 (s, 
C3’), 139.6 (s, C2), 139.6 (s, C2’), 135.7 (s, C13), 135.6 (s, C13’), 134.7 (s, C12), 133.4 (s, C8), 133.0 
(s, C8’), 132.1 (s, CPhGly.), 130.0 (s, C15), 129.6 (s, C14), 129.6 (s, C14’), 129.4 (s, CPhGly.), 129.0 (s, 
CPhGly.), 128.3, (s, CPhGly.), 127.1 (s, C5), 126.5 (s, C5’), 125.3 (s, C6), 125.0 (s, C6’), 65.5 (s, C18), 
53.2 (s, C20), 35.3 (s, C(CH3)3), 35.1 (s, C(CH3)3), 30.4 (s, C(CH3)3), 30.4 (s, C(CH3)3), 18.6 (s, C16), 
18.5 (s, C16’). IR: νmax (neat)/cm-1: 3295 (NH), 3173 (NH), 2963 (CH), 1744 (C=O), 1586 
(carbene).  
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Figure 2.58a – H1 NMR of complex 43f in CD3CN. 
 
Figure 2.58b – C13[1H] NMR of complex 43f in CD3CN.
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2.59 Synthesis of [(C^Npz^C)Au[C(NHCH(CH2CH2SMe)CO2Me)(NHC6H3Me2-2,6)]]SbF6 (43g) 
 
L-methionine methyl ester HCl (0.035 g, 0.175 mmol) was added to a flame-dried Schlenk 
flask charged with K2CO3 (0.012 g, 0.087 mmol and acetonitrile (5 mL). The solution was 
sonicated for 30 min and transferred to a separate flame-dried Schlenk flask containing 41 
(0.079 g, 0.087 mmol). The reaction was then stirred for 16 h at room temperature and the 
precipitate removed from solution via filtration through a celite plug. Next, the solvent was 
removed under vacuum and the solid residue re-dissolved in dichloromethane (2 mL). The 
product was precipitated using a 2:1 mixture of light petroleum (bp. 40-60 °C) / diethyl ether 
(5 mL), and after removing the solvent, dried under vacuum to yield an orange solid (0.069 
g, 74%). Anal. Calcd. for C39H48AuN4O2SSbF6 (1069.6): C, 43.79; H, 4.52; N, 5.24. Found: C, 
43.58; H, 4.37; N, 5.08. 1H NMR (CD2Cl2, 300 MHz, 298 K): δ 8.88 (s, 2H, H2), 8.71 (s, 1H, NH), 
8.29 (d, 3JH-H = 9.0 Hz, 1H, NH), 7.76 – 7.60 (m, 4H, H5/8), 7.50 – 7.30 (m, 5H, H6+14+15), 5.00 (m, 
1H, H18), 3.60 (s, 3H, H20), 2.63 (s, 3H, H16), 2.52 (s, 3H, H16’), 2.14 (m, 2H, HMet.), 1.66 (s, 3H, 
HMet.), 1.36 (s, 9H, tBu), 1.33 (s, 9H, tBu), 1.14 (s, 2H, HMet.). 13C[1H] NMR (CD2Cl2, 75 MHz): δ 
178.2 (s, C10), 170.6 (s, C19), 165.8 (s, C9), 165.1 (s, C9’), 158.1 (s, C7), 158.0 (s, C7’), 157.0 (s, C4), 
156.9 (s, C4’), 144.7 (s, C3), 144.6 (s, C3’), 139.5 (s, C2), 139.4 (s, C2’), 136.3 (s, C13), 135.7 (s, 
C13’), 133.9 (s, C8), 132.9 (s, C8’), 131.7 (s, C15), 130.9 (s, C14), 130.5 (s, C14’), 130.2 (s, C12), 127.3 
(s, C5), 127.1 (s, C5’), 125.9 (s, C6), 125.8 (s, C6’), 61.5 (s, C20), 36.0 (s, C18), 36.0 (s, CMet.), 31.3 
(s, C(CH3)3), 31.2 (s, C(CH3)3), 30.4 (s, C(CH3)3), 30.0 (s, C(CH3)3), 19.4 (s, C16), 19.2 (s, C16’), 18.9 
(s, CMet.), 14.8 (s, CMet.). IR: νmax (neat)/cm-1: 3304 (NH), 3169 (NH), 2960 (CH), 1744 (C=O), 
1585 (carbene). 
69 
 
 
Figure 2.59a – H1 NMR of complex 43g in CD2Cl2. 
 
Figure 2.59b – C13[1H] NMR of complex 43g in CD2Cl2.
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2.510 X-ray crystallography 
Crystal structures were solved by Dr Julio Fernandez-Cestau. 
2.511 Antiproliferation assay 
The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 
medium with 10% foetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg 
mL−1 streptomycin (Invitrogen). The cells were maintained under a humidified atmosphere 
at 37 °C and 5% CO2. The human MCF-7, HCT116 and MDA-MB-231 cancer cell lines (from 
ECACC) and the healthy fibroblast MRC-5 cells were cultured in DMEM medium with 10% 
foetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg mL−1 streptomycin 
(Invitrogen). The cells were maintained under a humidified atmosphere at 37 °C and 5% CO2. 
Inhibition of cancer cell proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay using the CellTiter 96 
Aqueous One Solution Cell Proliferation Assay (Promega) and following the manufacturer’s 
instructions. Briefly, the cells (3 × 104 per 100 µL for HL60, 8 × 103 per 100 µL for A549, MCF-
7, HCT116, MDA-MB-231 and 2 × 103 per 100 µL for MRC-5) were seeded in 96-well plates 
and left untreated or treated with 1 µL of DMSO (vehicle control) or 1 µL of complexes diluted 
in DMSO at diﬀerent concentrations, in triplicate for 72 h at 37 °C with 5% CO2. Following 
this, MTS assay reagent was added for 4 h and absorbance measured at 490 nm using a 
Polarstar Optima microplate reader (BMG Labtech). IC50 values were calculated using 
GraphPad Prism Version 5.0 software. 
2.512 ROS assay 
100 μL of A549 cells were seeded at a density of 1 × 105 cells per mL in a 96-well black plate 
with a transparent bottom. The cells were incubated at 37 °C for 24 h. The medium was 
removed and replaced with 50 μM H2DCFDA (from Life Technologies) solution in PBS for 40 
min. H2DCFDA was removed and replaced with fresh medium. The cells were left for recovery 
for 20 min at 37 °C. Basal fluorescence was measured at 485/520 nm on a POLARstar Optima. 
The cells were incubated with 10 μM, 50 μM, or 100 μM of compounds, 1% DMSO (negative 
control) and 100 μM of H2O2 (positive control) for 24 h. Fluorescence was read at 485/520 
nm. Basal fluorescence was subtracted from the fluorescence in the treated cells to calculate 
the amount of fluorescence caused by the compounds. 
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Chapter 3 
 
The synthesis and anticancer activity of cyclometalated goldIII 
complexes with acridine decorated functional groups. 
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3.1 Abstract 
A series of novel goldIII complexes containing a cyclometalating (C^N) or (C^Npz^C) ligand and 
an acridine functional group have been synthesised and characterised as prospective 
anticancer drug candidates. Two types of complexes were synthesised. Firstly, a series of 
neutral mono-cyclometalated (C^N)-(N^X)AuIII complexes with acridine-decorated (N^O) and 
(N^N) chelating ligands (51-56) Secondly, two cationic bis-cyclometalated (C^Npz^C)AuIII 
complexes where the acridine moiety was connected to an acyclic diamino carbene ligand, 
(57) or to an N-heterocyclic carbene ligand, (58). The complexes have been screened for their 
cytotoxic activity against a panel of human cancer cell lines and show greater or comparable 
activity to cisplatin under the conditions used in this assay. Cell uptake studies demonstrated 
a clear correlation between cellular uptake and the in vitro cytotoxicity of the complexes. 
DNA binding studies showed that two of the derivatives achieve high levels of DNA 
stabilisation suggestive of DNA intercalation. 
3.2 Introduction 
Chapter 1 has already discussed the anticancer activity of a diverse number of structurally 
different goldIII complexes with chemotherapeutic properties. In particular, cyclometalated 
goldIII complexes have been attracting significant interest, (Section 1.13). Both bidentate, 
(C^N) or tridentate, (C^N^C), (C^N^N) or (N^C^N) cyclometalating ligands can be used to 
improve the physiological stability of the goldIII centre within the cellular environment.5, 6, 25, 
28, 31 
Some of the first cytotoxic (C^N) cyclometalated goldIII derivatives were synthesised in the 
1990s by Parish et al. These derivatives of ((dimethylamino)methyl)phenyl, 8 (Figure 53) 
displayed a similar cytotoxicity profile to cisplatin in both in vitro and in vivo experiments.20 
Numerous other cyclometalated goldIII complexes with a variety of different ligand systems 
have since been synthesised and tested for their cytotoxicity against human cancer cell 
lines.14, 37, 45, 46  
  
73 
 
 
Figure 53 – Au(damp)Cl2.20 
Kilpin et al. introduced a series of neutral cyclometalated (C^N)Au(N^N) chelated complexes 
containing phenylenediamine and ethylenediamine moieties, with the nitrogen atoms 
bearing electron withdrawing SO2Tol and COMe moieties, 12a-12d (Figure 54), (Tol = p-tolyl). 
The derivatives were tested for their in vitro cytotoxicity against mouse leukaemia cells 
(P388) and some showed very promising results in comparison to cisplatin. Several different 
(C^N) cyclometalating ligands were used, including the 6-membered ring, 2-benzyl pyridine 
cyclometalating ligand (12a and 12c) and the more rigid 5-membered ring, 2-phenyl pyridine 
cyclometalating ligand (12b and 12d). Derivatives 12a and 12c, containing the less rigid 6-
membered ring appeared to show increased cytotoxicity towards P388 cells with IC50 values 
falling to <1 µM.26 
 
Figure 54 – structures of (C^N)-(N^N) derivatives 12a-12d and their cytotoxicity towards 
cancer cells in comparison to cisplatin; a Mouse leukaemia. Data taken from ref 26. 
Other (C^N)-(N^N) derivatives, by Zhang et al. also used the more rigid five membered ring 
cyclometalating (butyl-C^N) ligand to stabilise a cationic water soluble goldIII complex, 
[Au(butyl-C^N)biguanidine]Cl, 10 (Figure 55) which combined the lipophilic, cyclometalated 
(C^N) ligand and the hydrophilic, H-bonding NH2 groups of the biguanidine ligand. The 
complex showed high levels of cytotoxicity towards cancer cell lines, with IC50 values in the 
 IC50 (µM) 
Complex P388a 
12a (Ph) 0.30 
12a (Et 0.33 
12b (Ph) 52.89 
12b (Et) 4.35 
12c 0.80 
12d 4.38 
Cisplatin 8.15 
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low micromolar ranges as well as a high selectivity profile towards cancer cells over healthy 
CCD-19-Lu cells.24 
 
Figure 55 – structure of the cyclometalated [Au(butyl-C^N)biguanidine]Cl complex.24 
Goss et al. also reported on the reactions of cyclometalated LAuIIICl2 complexes with catechol 
and phenol derivatives, using both the more flexible 6-membered ring and the more rigid 
five-membered ring cyclometalating ligands (Figure 56). Reactions with catechol gave stable 
complexes containing five-membered Au-O-C-C-O rings, 44a and 44b. Reactions with 2-
acetamidophenol also gave the corresponding (C^N)-(N^O) complexes with Au-N-C-C-O 
rings, 44c. The catechol derivatives 44a and 44b showed the highest antitumor activity 
towards p388 cells with IC50 values of 0.66 and 0.46 µM respectively (in comparison to 
cisplatin with an IC50 of 8.15 µM). However, the (C^N)-(N^O) derivatives also displayed 
significant levels of activity in comparison to cisplatin, (IC50 of 2.5 µM).98 
 
Figure 56 – structures of (C^N)-(O^O) and (C^N)-(N^N) derivatives 44a-44c and their 
cytotoxicity towards cancer cells in comparison to cisplatin; a Mouse leukaemia. Data taken 
from ref 98. 
 IC50 (µM) 
Complex P388a 
44a  0.66 
44b  0.46 
44c 2.50 
Cisplatin 8.15 
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Chapter 2 has described the synthesis and anticancer activity of novel cyclometalated 
(C^Npz^C) goldIII complexes with acyclic carbene ligands decorated with amine and amino 
ester derivatives, 43a-g (Figure 57).86 Although the antiproliferative screening of these 
complexes identified them as promising potential chemotherapeutic agents, they were also 
reduced to a goldI species in the presence of glutathione (GSH). Section 1.26 has already 
discussed the overexpression of GSH by cancer cells and the role it plays in the deactivation 
of platinum based chemotherapeutic agents.81, 82 GoldIII N-heterocyclic carbene (NHC) 
complexes appear to be more stable towards reducing agents like GSH and are also highly 
cytotoxic towards cancer cell lines (Section 1.14). Our group recently published a paper on 
the synthesis and anticancer activity of a pyrazine-based (C^Npz^C) pincer complex with a 
benzimidazole-based NHC ligand, 19 (Figure 57). This derivative showed high levels of in vitro 
cytotoxicity with IC50 values in the micromolar and sub-micromolar range against a panel of 
cancer cell lines.39  
 
Figure 57 – examples of cytotoxic goldIII complexes with cyclometalating (C^Npz^C) ligands 
and acyclic/ heterocyclic carbene ligands.39, 86 
Section 1.21 discusses the mechanism of cisplatin; the formation of covalent adducts 
between purine base pairs which results in the distortion of the DNA helix and the inhibition 
of DNA replication and transcription processes.53 In spite of the structural and electronic 
similarity between goldIII and platinumII compounds, they appear to have very different 
molecular targets within the cell and the binding of goldIII complexes to DNA is often weak 
and reversible in nature.49, 59 
Acridines, however, are known to bind to DNA by intercalation; by the direct insertion of the 
three planar aromatic rings in between the base pairs of DNA which causes unwinding of the 
double helix.99, 100 For example, Janočková et al. synthesised a series of acridine analogues, 
45 (Figure 58) and demonstrated their ability to inhibit cancer cell growth in acute 
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promyelocytic leukaemia cells (HL60); (IC50 of 1.6 µM). DNA binding studies towards calf 
thymus DNA showed a strong interaction through DNA intercalation resulting in the 
inhibition of certain enzymes such as topoisomerase 1 and 2.99 These enzymes unwind 
chromosomal DNA and represent an important target for anti-cancer agents.60 Howell et al. 
also studied the DNA binding and in vitro cytotoxicity of 9-aminoacridine carboxamides, 46 
towards various types of tertiary DNA structures. The derivatives were shown to target G-
quadruplex structures with some selectivity.101  
 
Figure 58 – two acridine derivatives with cytotoxic properties towards human cancer cells; a 
Leukaemia. Data taken from ref 99, 101. 
There are also examples of acridine motifs being used to enhance the cytotoxicity of metal 
based chemotherapeutic agents.102, 103 Smyre et al. made the platinum-acridine hybrid, 47 
(Figure 59) which showed extremely high levels of cytotoxicity towards non-small cell lung 
cancers, including in a very aggressive NCI-H460 xenograft model. The complex showed 
pronounced cytotoxic enhancement of 40-200 fold compared to cisplatin with IC50 values in 
the low nanomolar range. DNA binding studies showed that the compound also produced 
permanent DNA adducts more readily than cisplatin (half-lives of 20 min and 2 h 
respectively), suggesting that it was able to inhibit DNA replication to a greater extent.102 
 
Figure 59 – structure of the platinum-acridine hybrid, 47 and its cytotoxicity towards cancer 
cell lines in comparison to cisplatin; a Non-small cell lung cancer. Data taken from ref 102. 
  
 IC50 
(µM) 
Complex HL60a 
45 1.6 
46 0.33 
 
 IC50 ± SD (µM) 
Complex NCI-H460a NCI-H522a NCI-H1435a 
47 0.008 ± 0.002 0.018 ± 0.002 2.1 ± 0.3 
Cisplatin 1.2 ± 0.2 3.7 ± 0.8 85 ± 20 
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Other cytotoxic metal-acridine hybrids were synthesised by Matsheku et al., this time using 
iron, rhodium, iridium, ruthenium and osmium. All the derivatives displayed good in vitro 
cytotoxicity towards HL60 cells although the rhodium derivative, 48 (Figure 60) showed the 
highest activity as well as a good selectivity profile for this cell line over healthy skin fibroblast 
cells (FG0). NMR studies also suggested that DNA was the molecular target of this 
compound.103 
 
Figure 60 – the rhodium-acridine hybrid with cytotoxic properties.103  
Although there are examples of cytotoxic goldI-acridine hybrids, there do not appear to be 
any examples of cytotoxic goldIII-acridine hybrids.104, 105 This chapter introduces the synthesis 
and anticancer activity of some of the first cyclometalated goldIII complexes with acridine 
decorated functional groups. Firstly, a series of neutral (C^N)-(N^O) and (C^N)-(N^N) 
derivatives, (51-56), both with and without acridine functional groups, and secondly two 
pincer (C^Npz^C) complexes where the acridine functionality is joined by either an acyclic 
carbene (57) or an NHC ligand (58). The complexes were tested for their cytotoxicity towards 
three cancer cell lines; lung adenocarcinoma (A549), breast cancer (MCF-7) and leukaemia 
(HL60). The DNA binding abilities of the complexes towards dsDNA was also assessed using 
both UV-Vis spectroscopy and FRET DNA melting assays. 
3.3 Results and Discussion 
3.31 Synthesis and structural characterisation 
The cyclometalated 2-phenyl pyridine gold dichloride precursor was synthesised by a similar 
method to that described by Constable et al.; by refluxing potassium tetrachloroaurate with 
4-tert-butyl-2-phenyl pyridine in a 4:1 mixture of water and acetonitrile for 16 hours to form 
the N-coordinated gold trichloride, followed by a further reflux in water to form the 
cyclometalated gold dichloride, complex 49, in good yield (72%) as depicted in Scheme 13.106 
Similarly, the 2-benzyl pyridine gold dichloride precursor, complex 50, was synthesised in 
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high yield (81%) by the method described by Cinellu et al.; by refluxing 2-benzyl pyridine and 
potassium tetrachloroaurate in water (Scheme 13).107 
 
Scheme 13 – synthesis of the two (C^N) cyclometalated goldIII dichloride starting materials, 
49 and 50.106, 107 
When the cycloaurated goldIII dichloride starting materials were reacted with 2-
acetamidophenol in refluxing methanol with excess trimethylamine, the mono-
cyclometalated (C^N)-(N^O) complexes, 51 and 52, were isolated in good yields, (78% and 
65% respectively), by precipitation with water (Scheme 14). 
 
Scheme 14 – synthesis of the mono-cyclometalated (C^N)-(N^O) complexes 51 and 52. 
Complex 53 was synthesised in high yield, (89%), by reacting the gold dichloride starting 
material with 1,2-diacetamidobenzene and silver oxide in refluxing dichloromethane 
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(Scheme 15). The reaction was also attempted with the 2-benzyl pyridine gold dichloride 
starting material, 50 but caused decomplexation to the less rigid 6-membered ring. 
 
Scheme 15 – synthesis of the mono-cyclometalated (C^N)-(N^N) complex, 53. 
1H and 13C[1H] NMR were used to fully characterise complexes 49-53. The purity of the 
complexes was also assessed by elemental analysis. Upon reaction of complex 49 with 2-
acetamidophenol, the characteristic doublet observed for H2 shifted downfield from 9.71 
ppm to 8.97 ppm showing that the mono-cyclometalated (C^N)-(N^O) complex, 51, had been 
obtained. The singularity of each of the signals in the 1H NMR spectrum confirmed that only 
one isomer of complex 51 had been obtained. 
A slight downfield shift of H2, from 9.26 ppm to 9.24 ppm was also seen when complex 50 
was reacted with 2-acetamidophenol, confirming the coordination of the pyridine ring to the 
goldIII centre. The H7 methylene protons for complex 52 were also seen as a singlet at 4.29 
ppm, suggesting a loss of chemical inequivalence for the methylene protons and therefore 
the disruption of the characteristic AB system, indicating ring opening of the cyclometalating 
(C^N) 2-benzylpyridine ligand, possibly through loss of N-coordination. This feature was 
expected as this compound was previously synthesised by Goss et al.98  
Complex 53 was poorly soluble in the deuterated NMR solvents and therefore signals in both 
the 1H and particularly the 13C[1H] NMR were poorly resolved. This complex also showed a 
downfield shift of the H2 signal to 9.30 ppm, as a poorly resolved broad singlet. Two separate 
signals at 2.27 and 2.15 ppm for the two methyls of the acetate groups confirmed the 
formation of the bis-chelated (C^N)-(N^N) complex. These signals were not observed in the 
13C[1H] NMR spectrum although an HMQC carbon proton correlation spectrum confirmed 
their presence around 25 ppm (Section 3.52). 
Following the success, forming (N^O) and (N^N) chelate complexes with simpler ligands, an 
acridine moiety was attached to 2-amino phenol by a CDI assisted coupling with 4-(acridin-
9-ylamino)-benzoic acid. Instead of reacting at the carboxylic acid functional group as was 
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expected the compound instead reacted at the 9-amino group of the acridine moiety, joining 
the substituted phenol directly to the acridine by displacing the 4-aminobenzoic acid and 
forming L1. The same reaction also occurred when o-phenylenediamine was used, forming 
L2, as depicted in Scheme 16. 
 
Scheme 16 – synthesis of the substituted acridine ligands L1 and L2. 
Complex 54 was obtained in high yield, (94%), by reacting one equivalent of complex 49 with 
L1 in refluxing methanol with an excess of trimethylamine, followed by precipitation with 
water (Scheme 17). A reaction between complex 50 and L1 under the same conditions was 
also successful and complex 55 was obtained in moderate yield, (67%). 
 
Scheme 17 – synthesis of the acridine-decorated (C^N)-(N^O) complexes, 54 and 55. 
The corresponding (C^N)-(N^N) complex, 56 was obtained in good yield, (74%) by the 
reaction of complex 49 with L2 under the same reaction conditions (Scheme 18). Once again, 
the reaction was also attempted with 50 but this caused ring opening to the less rigid 6-
membered cyclometalating ring. 
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Scheme 18 – synthesis of the acridine-decorated (C^N)-(N^N) derivative, 56 
Diagnostic signals in the NMR spectra for the acridine substituted complexes, 54-56 were 
harder to determine due to the complexity of signals in the aromatic region. Complex 54 
showed a slight downfield shift to 9.61 ppm of the H2 signal in the 1H NMR spectrum which 
was seen as a doublet of doublets, due to coupling between both H3 and H4. Signals for the 
acridine substituent were clearly seen by a doublet of doublets at 8.49 ppm and a doublet at 
8.30 ppm, for H21+24.  
The 1H NMR spectrum of complex 55 was harder to resolve due to the steric bulk of the 
acridine moiety interacting with the phenyl ring of the cyclometalating (C^N) ligand, 
preventing free rotation and thus causing broad and poorly resolved signals. By lowering the 
temperature to -10 °C it was possible to slow the movement enough to obtain a well-resolved 
spectrum (Figure 61). Due to the lack of free rotation, all of the acridine protons, H22-25 were 
chemically inequivalent and seen as separate signals. Unlike complex 52, the characteristic 
AB system of two doublets at 4.43 ppm and 3.91 ppm was observed for the methylene bridge 
indicating the chemical inequivalence of these protons, confirming that ring opening had not 
occurred. 
Figure 61 – a. aromatic region of the 1H NMR spectrum of 55 at room temperature and b. 
aromatic region of the 1H NMR spectrum of 55 at -10 °C. 
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Complex 56 presented further problems with a large downfield shift in the H2 signal to around 
7.73 ppm in the 1H NMR spectrum, where it overlapped with other aromatic signals. For all 
of the three acridine-based complexes, 54-56, only one set of signals were observed for each 
proton, demonstrating the formation of only one isomer in each case, as seen previously with 
the simpler (N^O) and (N^N) complexes, 51-53. 
Slow diffusion of light petroleum ether through a dilute dichloromethane solution of complex 
54 yielded crystals suitable for X-ray diffraction. The crystals were characterised in the solid 
state by Dr Julio Fernandez-Cestau (Figure 62). 
 
Figure 62 – crystal structure of complex 54·CH2Cl2 (dichloromethane and hydrogen atoms 
omitted for clarity). Selected bond distances (Å) and angles (º). Au1-N1 2.028(3), Au1-C11 
2.034(4), Au1-O1 2.049(3), Au1-N2 1.990(3), C11-Au1-N1 81.1(1), C11-Au1-N2 103.8(1), N2-
Au1-O1 82.5(1), O1-Au1-N1 92.7(1), N1-Au1-N2 174.3(1), C11-Au1-O1 173.1(1), torsion Au1-
N2-C22-C23 110.4(3). 
The crystals display the typical, slightly distorted square planar geometry to the goldIII centre 
that occurs due to the accommodation of a cyclometalating ligand, with a C11-Au-N1 bond 
angle of 81.1 °. The acridine substituted nitrogen is in trans position to the nitrogen of the 
cyclometalated ligand, as this is the most electronically favoured orientation. The most 
electron donating atom is in trans position to the carbon of the cyclometalating ligand, 
despite the steric hindrance of the tert-butyl group. The acridine moiety is twisted with a 
Au1-N2-C22-C23 torsion angle of 110 °, presumably to avoid steric hindrance with the 
hydrogens of the tert-butyl group. As suggested by the NMR spectra, the crystal structure 
confirmed that only one isomer of the complex was obtained. 
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Crystals were also obtained of complex 56 using the same method of slow diffusion of light 
petroleum ether into a dilute dichloromethane solution of the complex. The crystals were 
characterised in the solid state by Dr Julio Fernandez-Cestau (Figure 63). 
 
Figure 63 – crystal structure of complex 56·CH2Cl2 (dichloromethane and hydrogen atoms 
omitted for clarity). Selected bond distances (Å) and angles (º). Au1-N1 2.063(7), Au1-C11 
2.015(6), Au1-N2 1.956(8), Au1-N3 2.081(6), N1-Au1-C11 80.9(3), C11-Au1-N2 95.2(3), N2-
Au1-N3 80.3(3), N3-Au1-N1 103.9(3), Au1-N2-H100 119(6), N1-Au1-N2 175.4(3), C11-Au1-N3 
173.0(3), torsion Au1-N3-C22-C23 67.3(9). 
Once again, the crystals display the typical, slightly distorted square planar geometry to the 
goldIII centre with a C11-Au1-N1 bond angle of 80.9 ° to the cyclometalating ligand. Whereas 
for the (N^O) chelate, complex 54, the acridine substituted nitrogen is in trans position to 
the nitrogen of the cyclometalating ligand, in the case of the (N^N) chelate, complex 56, the 
acridine substituent is instead in trans position to the carbon, presumably to avoid the steric 
hindrance of the tert-butyl group as both of the coordination sites of the (N^N) chelate are 
equivalent. Consequently, the torsion angle of the Au1-N3-C22-C23 is smaller (67.3 °).  
As described previously in Section 2.31 (Scheme 9), the cyclometalated (C^Npz^C)AuCl 
starting material, complex 37, was synthesised using previous methods; via a Suzuki cross-
coupling reaction to generate the HC^Npz^CH ligand, an activation reaction with Hg(O2CCF3)2 
and a transmetalation reaction to obtain the cyclometalated product.96 This was used as a 
starting material for the pincer complexes 57 and 58. 
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Chapter 2 describes the synthesis and anticancer activity of (C^Npz^C)AuIII complexes with 
acyclic carbene ligands.86 Complex 57, the acridine functionalised acyclic carbene, was 
synthesised using the same method; via the formation of a cationic [(C^Npz^C)AuIII]+ 
isocyanide complex, 41 followed by the nucleophilic attack of 9-amino acridine onto the 
highly electrophilic isocyanide carbon (Scheme 19). This allowed the comparison between 
goldIII complexes stabilised by a (C^N) or a (C^Npz^C) cyclometalated ligand. This complex was 
obtained in moderate yield, (46%), due to the presence of the formamide hydrolysis product, 
42 which was formed after the reaction of the isocyanide intermediate with water. 
 
Scheme 19 – synthesis of the acridine functionalised (C^N^C)AuIII open diaminocarbene, 57. 
Upon formation of complex 57, a broad NH singlet appears in the 1H spectrum at 10.34 ppm 
and the upfield H2 shift to 9.13 ppm confirms that a reaction has occurred and suggests that 
the acyclic carbene has been formed. The signal for H8 at 7.96 ppm is also in good agreement 
with H8 signals observed for the acyclic carbene complexes synthesised in Chapter 2. The IR 
spectrum of complex 57 shows a carbene vibration at 1586 cm-1 and two NH vibrations at 
3388 cm-1 and 3270 cm-1, again confirming the successful formation of 57. 
Complex 58 was synthesised in high yield, (78%), by reacting an acridine functionalised 
imidazolium salt with silver oxide, followed by the addition of the cyclometalated 
(C^Npz^C)AuCl starting material and potassium hexafluorophosphate, as depicted in Scheme 
20. The slight downfield shift in the signal for H2 and a larger downfield shift in H8 from 7.88 
to 7.21 ppm in the 1H NMR spectrum and also the appearance of a signal at 154.9 ppm for 
the Au bound NHC in the 13C NMR spectrum both suggest carbene formation, as previously 
reported by our group for cyclometalated pyrazine-based (C^Npz^C) pincer complex with a 
benzimidazole-based NHC ligands.39 
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Scheme 20 – synthesis of acridine functionalised (C^Npz^C)AuIII NHC, 58. 
 
3.32 In vitro antiproliferative activity 
Although insoluble in aqueous cell culture medium, all of the complexes and their ligand 
precursors were soluble enough in DMSO not to precipitate when diluted up to 100 µM in 
aqueous cell medium with 1% of DMSO. Complexes 49-58 and both of the acridine ligand 
precursors, L1 and L2 were screened for their antiproliferative properties in vitro on a panel 
of human cancer cell lines, including lung adenocarcinoma cells (A549), breast 
adenocarcinoma (MCF-7), and promyelocytic leukaemia (HL60). The IC50, (the half maximal 
inhibitory concentration), was then determined using a colorimetric MTS assay after 72 hours 
of incubation in comparison to cisplatin (as previously described in Section 2.32). The results 
are summarised in Table 2.  
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Table 2 – cytotoxic effects of complexes 49-58 and ligands L1 and L2 in comparison to cisplatin 
towards different human cancer cell lines after 72 h of incubation. 
 IC50 ± SD (µM)a 
Complex A549 MCF-7 HL60 
49 43.6 ± 4.1 10.8 ± 3.5 6.0 ± 0.5 
50 >100 38.7 ± 4.7 12.8 ± 0.3 
51 12.7 ± 2.5 5.2 ± 1.0 2.9 ± 0.7 
52 10.8 ± 2.7 3.6 ± 1.4 2.7 ± 0.4 
53 22.7 ± 2.5 9.9 ± 2.1 2.5 ± 0.1 
54 16.6 ± 2.8 2.7 ± 0.9 1.4 ± 0.4 
55 19.9 ± 3.9 4.3 ± 0.4 1.5 ± 0.1 
56 17.2 ± 4.4 6.7 ± 1.6 6.3 ± 0.1 
57 15.0 ± 2.0 7.5 ± 0.6 20.7 ± 0.4 
58 7.6 ± 0.6 1.5 ± 0.1 1.1 ± 0.1 
L1 >100 >100 >100 
L2 23.9 ± 3.5 14.4 ± 0.9 16.9 ± 0.9 
Cisplatin 33.7 ± 3.7b 21.2 ± 3.9b 3.7 ± 0.3b 
a Mean ± the standard error of at least three independent experiments. b Values from ref 39. 
Complexes 51-58 showed greater or comparable activity to cisplatin under the conditions 
used in this assay and were overall more cytotoxic than the gold dichloride precursors, 
complexes 49 and 50. The free ligands, L1 and L2, showed reduced cytotoxicity particularly 
L1 which was inactive against all of the cell lines tested, with an IC50 value of >100 µM against 
all three. L2 also showed reduced cytotoxicity in comparison to the gold complexes therefore 
indicating the significance of the goldIII centre to the cytotoxicity of these particular acridine 
derivatives. However, it is not clear why L1 was far more inactive than L2 (IC50 values of >100 
µM and 14-24 µM respectively). 
Overall, all of the mono-cyclometalated (C^N)-(N^X) complexes, 51-56 showed greater 
activity than cisplatin against both the MCF-7 and the A549 human cancer cell lines and 
comparable activity against the HL60 cell line. Complexes 51-56 all showed similar activities 
against the MCF-7 cell lines with IC50 values in the 2-10 µM range. Complexes 52, 54 and 55 
showed particularly high cytotoxicity with values between 2-4 µM. IC50 values for the A549 
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cell line were slightly higher, between 10-20 µM for all of the complexes. Here, the simpler 
structures, complexes 51 and 52 showed the greatest cytotoxicity. 
Changing the (C^N) cyclometalating ligand between the more rigid phenyl pyridine and the 
more flexible 2-benzyl pyridine derivatives appeared not to significantly alter the cytotoxicity 
of the complexes which suggests that rigidity of the ligand was not important in this respect. 
For example, for the HL60 leukaemia cell line, complexes 51 and 52 have IC50 values of 2.9 
and 2.7 µM respectively and complexes 54 and 55 have IC50 values of 1.4 and 1.5 µM 
respectively. This differs from results obtained by Kilpin et al., where complexes containing a 
six-membered cyclometalating ring displayed higher cytotoxicity than those with a five-
membered cyclometalating ring (discussed in Section 3.2).26  
In contrast, the two different types of chelating ligands, (N^O) and (N^N), appeared to have 
an effect on the cytotoxicity of the complexes. For all three cell lines, the (N^O) chelates 
appeared to be slightly more cytotoxic than the corresponding (N^N) chelates which is in 
contrast to the values obtained for the free acridine ligands, L1 and L2. For example, for the 
A549 lung cancer cell line the (N^O) chelate, complex 51 has an IC50 of 12.7 µM and the 
corresponding (N^N) chelate, 53 has an IC50 of 22.7 µM. The same pattern can be seen for 
the acridine functionalised derivatives. Complex 54, the (N^O) chelate is more cytotoxic than 
its (N^N) analogue, complex 56 against the all three cancer cell lines. Here the effect is most 
notable against the leukaemia HL60 cell line, (an IC50 of 1.4 and 6.3 µM respectively). 
Adding an acridine functionality appeared not to increase the overall cytotoxicity of the 
mono-cyclometalated (C^N)-(N^X) complexes. Complexes 54 and 55 were extremely 
cytotoxic against the MCF-7 breast cancer and the HL60 leukaemia cell lines with IC50 values 
of between 1 and 4 µM. In comparison, complex 56 showed a slightly reduced cytotoxicity 
with IC50 values of 6.7 and 6.3 µM for MCF-7 and HL60, respectively. Against the A549 lung 
cancer cells the simpler (N^O) chelates appeared to be more cytotoxic than their 
corresponding acridine functionalised complexes, e.g. complex 52 has the highest 
cytotoxicity here with an IC50 of 10.8 µM. The acridine functionality appeared to reduce the 
cytotoxicity towards this cell line, with complexes 54-56 all displaying IC50 values between 17 
and 20 µM. 
The (C^Npz^C)AuIII acyclic carbene, complex 57, showed a higher cytotoxicity than cisplatin 
against both the MCF-7 and the A549 cancer cell lines, (IC50 values of 7.5 and 15.0 µM for 
each respectively), although it showed reduced activity against the HL60 cell line, (20.7 µM). 
These values are in good agreement with other acyclic carbene complexes discussed in 
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Chapter 2, particularly when considering the amino ester derivatives (e.g. GlyOEt (44c) – IC50 
values of 6.4, 13.0 and 16.7 µM for MCF-7, A549 and HL60 respectively).86 
The other (C^Npz^C) pincer complex, 58 with the acridine functionality bound by an NHC 
ligand, showed the highest overall cytotoxicity with values in the low µM regions for all three 
cell lines. It was more than ten times more cytotoxic than cisplatin against MCF-7 cells and 3-
4 times more cytotoxic against the A549 and HL60 cell lines. The higher cytotoxicity of the 
[(C^N^C)Au(NHC)]+ complexes with respect to the [(C^N^C)Au(ACC)]+ complexes is in line 
with previous results already discussed in Chapter 2.39, 86 
3.33 Cellular uptake in MCF-7 cells 
The cellular uptake and the accumulation of drugs inside the cell are both major factors that 
influence the cytotoxicity of prospective anticancer agents.108 Inductively coupled plasma-
mass spectrometry, (ICP-MS) was used to quantify the amount of intracellular gold and thus 
measure the amount of compound taken up by the cell. ICP-MS measurements were 
completed by Dr Graham Chilvers.  
In order to see whether the cytotoxicity of the complexes was influenced by their ability to 
be taken up by the cell, complexes 50, 53, 54 and 58 were chosen. Complexes 50 and 53 were 
selected because 50 showed extremely poor activity, (IC50 of 38.7 µM) and 53 showed only 
average activity, (IC50 of 9.9 µM). Complex 54 was selected as it was the best of the acridine 
derivatised (N^X) chelate complexes and complex 58 as it showed the best overall 
cytotoxicity, (IC50 values of 2.7 and 1.5 µM respectively). 
MCF-7 cells were incubated for 6 hours with 10 µM concentrations of each of the complexes 
in 1% DMSO. The results of three independent experiments are depicted in Figure 64. 
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Figure 64 – cellular uptake of complexes 50, 53, 54 and 58 and a DMSO control in MCF-7 cells 
after 6 h of treatment at 10 µM in 1% DMSO. The results were analysed by t-test, P=0.05, 
50:53**, 54:58**.  
There was a clear correlation between cellular uptake and the in vitro cytotoxicity of the 
complexes with the most cytotoxic complexes showing the highest levels of cell uptake 
(Figure 65). This suggests that the primary limitation for the poorly toxic complexes is their 
very low uptake into the cell. 
Figure 65 – the correlation between cellular uptake (pmol Au/106 cells) and cytotoxicity (IC50). 
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3.34 Quantification of reactive oxygen species 
As mentioned previously (Section 2.33), the induction of reactive oxygen species (ROS) is a 
recognised mechanism of action for metal-based drugs.75 The acridine derivatised 
complexes, 54-58, were therefore tested for the production of ROS. The amount of 
intracellular ROS was measured after treatment of MCF-7 cells with 100 µM, 50 µM and 10 
µM concentrations of these complexes. However, no data could be obtained due to the 
fluorescent properties of the acridine groups interfering with the emission spectra of the 
fluorescent stain used in this assay. 
3.35 DNA binding assays 
Acridine derivatives are known to interact with duplex DNA as well as higher order DNA 
structures and this can influence the cytotoxic properties of the compounds.100, 101, 109 DNA 
intercalators are of interest as probes in the study of ligand-DNA interactions and also as 
potential therapeutic agents.110 DNA intercalation is a reversible mode of DNA-ligand binding 
which consists of the direct insertion of planar aromatic moieties in between the base pairs 
of DNA which causes unwinding to the double helix. There are several examples of goldIII 
complexes acting as DNA intercalators that have already been discussed in Section 1.21. For 
example, both terpyridine, (5)17 and aminoquinoline, (6)18 goldIII derivatives have been shown 
to bind to intracellular DNA by intercalation of the planar goldIII coordination plane between 
the DNA base pairs. 
In the presence of DNA, acridines have previously been shown to experience changes in their 
UV/visible absorption spectra with distinctive bathochromic shifts towards the longer 
wavelengths as well as hypochromic shifts indicating the decrease in absorption.111 While this 
does not prove that DNA intercalation has occurred, it does indicate some sort of DNA 
interaction. With this in mind, the acridine derivatives complexes 54-58, as well as their 
corresponding free ligand precursors, L1 and L2 were tested with a simple spectroscopic 
study for their ability to interact with duplex DNA. 
No change in absorption was observed for any of the complexes when 1 mM solutions of 54-
58 and L1/L2 (in a 50:50 PBS/DMSO mix) were combined with a 1 mM solution of calf-thymus 
DNA (50:50, PBS/DMSO) (Figure 66). This suggests that no DNA interaction was occurring, 
suggesting that DNA is not the primary target for the cytotoxic effects of these complexes, 
possibly due to steric hindrance between the cyclometalating (C^N) or (C^Npz^C) ligands and 
the acridine substituent. A longer linker between the acridine functionality and the goldIII 
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centre could help to overcome this. However, the negative result in this simple study could 
also be due to lack of solubility in the PBS/DMSO solvents and consequently the precipitation 
of the complexes. 
 
Figure 66 – UV/Vis absorbance spectra of a 1 mM solution of complex 58 in DMSO/PBS, with 
and without 1 mM of DNA. 
Further tests were also done to determine whether or not the acridine-functionalised 
complexes were interacting with DNA. The Fӧrester resonance energy transfer (FRET) DNA 
melting assay was used to measure the ability of complexes 51-58 and L1 and L2 to stabilise 
double stranded DNA. FRET is used as a tool for detecting spatial relationships between two 
fluorophores and involves measuring the changes in fluorescence as FRET donor and 
acceptor moieties are brought closer together or moved further apart as a result of DNA 
stabilisation or denaturation. As a result of the large differences in fluorescence between 
these folded and unfolded DNA structures it is possible to measure the interaction of a 
particular drug molecule with the DNA.112, 113 Results are expressed as the changes in DNA 
melting temperature (ΔTm) when double stranded DNA (0.2 µM) was dosed with 50 µM 
concentrations of each drug (Figure 67). 
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Figure 67 – stabilisation of ds DNA (0.2 µM base pairs) by complexes 51-58 and L1/L2 at 50 
µM concentrations measured by FRET DNA melting assay. Data represents the average and 
standard deviation of two separate experiments. 
Only two complexes showed the ability to stabilise double-stranded DNA at high 
temperatures. Indeed, complexes 51-53 and 56 actually appeared to destabilise ds DNA. 
While this can be explained for complexes 51-53, which do not contain an acridine 
functionality, the result for the (N^N) chelated acridine functionalised derivative, complex 56 
is less easy to explain. Complex 55, the acridine functionalised 2-benzylpyridine derivative 
and the [(C^Npz^C)Au(NHC)]+ derivative, 58 both showed high levels of DNA stabilisation 
which suggests that they are interacting with the DNA in some manner, possibly by 
intercalation of the planar aromatic rings of the acridine moiety between the base pairs of 
the DNA.  
Our group recently discussed the DNA binding ability of another cyclometalated pyrazine-
based (C^Npz^C) goldIII complex with a benzimidazole-based NHC ligand, 19 (Figure 57). This 
complex was shown to interact with higher order DNA structures in a dose dependent 
manner but showed a reduced affinity towards dsDNA.39 However, the acridine functionality 
on complex 58 appears to improve the interaction with dsDNA. 
It is difficult to explain why the acridine functionalised 2-benzyl pyridine derivative, 55 should 
be notably better than the corresponding 2-phenyl pyridine derivatives, 54 and 56. 
Hypothetically, the positive result for this complex could be due to the absence of the bulky 
tert-butyl group which is present in both of the other acridine derivatised (C^N)-(N^X) 
complexes which could hinder their interaction with DNA. It could also be a function of the 
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more flexible, 2-benzyl pyridine 6-membered cyclometalating ring enabling the release of 
some steric hindrance in the structure and thus allowing DNA interaction. 
3.36 Reaction with Glutathione 
The reduction of goldIII complexes by glutathione (GSH) to goldI and gold0 species has been 
discussed in Section 1.26. The stability of complex 58 and complex 54 towards reduction by 
GSH was therefore explored by proton NMR. Each complex was mixed at room temperature 
with reduced glutathione in a 1:1 mixture of DMSO-d6 and D2O and monitored by proton 
NMR over time. Our group recently demonstrated the stability of a cyclometalated pyrazine-
based (C^Npz^C) goldIII complex with a benzimidazole-based NHC ligand, 19 (Figure 57) 
towards reduction by GSH.39 However, complex 58, the acridine substituted 
[(C^Npz^C)AuNHC]+ complex appeared less stable and over a 24 hour period the gradual 
formation of oxidised glutathione (GSSG) was observed, along with the disappearance of 
signals for reduced GSH (Figure 68a). Although signals for the complex were extremely poorly 
resolved due to its poor solubility in the solvents this suggests that the complex was being 
gradually reduced to a goldI active species. The same pattern was seen for the acridine 
substituted (C^N)-(N^O) chelate complex, 54 (Figure 68b). 
 
Figure 68a – 1H NMR spectra of a 1:1 mixture of 58 with GSH at room temperature, in 
comparison with the starting materials, 58, GSH and GSSG (DMSO-d6/D2O 1:1).  
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Figure 68b – 1H NMR spectra of a 1:1 mixture of 54 with GSH at room temperature, in 
comparison with the starting materials, 54, GSH and GSSG (DMSO-d6/D2O 1:1). 
3.4 Conclusion 
This chapter has described the synthesis and anticancer activity of a series of new 
cyclometalated goldIII complexes. These complexes included a series of neutral mono-
cyclometalated (C^N)-(N^X)AuIII complexes with both simple and acridine-decorated (N^O) 
and (N^N) chelating ligands and two bis-cyclometalated (C^Npz^C)AuIII pincer complexes 
where the acridine functionality is attached by either an acyclic or N-heterocyclic carbene 
ligand. 
The complexes were tested for their cytotoxicity towards three cancer cell lines and these 
studies identified complex 58, the NHC derivative as the most promising candidate, with IC50 
values in the low µM range for all three cell lines. However, having an acridine functionality 
did not appear to increase the cytotoxicity of the complexes towards the cancer cell lines. 
Cell uptake studies demonstrated a clear correlation between cellular uptake and the in vitro 
cytotoxicity of the complexes with the most cytotoxic complexes showing the highest levels 
of cell uptake, thus indicating that cellular uptake is the primary limitation for the non-toxic 
complexes. Finally, DNA binding studies showed that two of the derivatives; complex 55, the 
acridine functionalised 2-benzylpyridine derivative and the N-heterocyclic carbene 
derivative, complex 58 both showed high levels of DNA stabilisation suggestive of DNA 
intercalation. 
However, both the bis-cyclometalated [(C^Npz^C)Au(NHC)]+ derivative, 58 and also one of the 
mono-cyclometalated (C^N)Au(N^X) derivatives, 54 showed reduction in the presence of 
glutathione which could suggest that it is reduced to a goldI active species within a cellular 
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environment. Further work is required to investigate other the possible modes of action of 
these complexes. 
3.5 Experimental 
When required, manipulations were performed using standard Schlenk techniques under dry 
nitrogen or in a MBraun glove box. Nitrogen was purified by passing through columns of 
supported P2O5 with moisture indicator and activated 4 Å molecular sieves. Anhydrous 
solvents were freshly distilled from appropriate drying agents. 1H and 13C[1H] spectra were 
recorded using a Bruker Avance DPX-300 spectrometer. 1H NMR spectra (300.13 MHz) were 
referenced to the residual protons of the deuterated solvent used. 13C[1H] NMR spectra 
(75.47 MHz) were referenced internally to the D-coupled 13C resonances of the NMR solvent. 
Elemental analyses were carried out at London Metropolitan University. Complexes 49, 50 
and 52 and the (C^Npz^C)Au-Cl starting material, 37, were synthesized following reported 
procedures.98, 106, 107 
3.51 Synthesis of complex 51 
 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (49), (0.200 g, 0.418 mmol), 2-
acetamidophenol (0.100 g, 0.661 mmol) and aqueous trimethylamine (2 mL) was refluxed in 
methanol (30 mL) for 30 min. The reaction was then cooled and water (40 mL) was added 
causing an immediate orange precipitation. The flask was then placed in the freezer for two 
days. The orange solid was filtered and purified by dissolving in minimal dichloromethane (2 
mL) and precipitating the product with an excess of light petroleum (bp. 40-60 °C) (20 mL). 
This was filtered and dried under vacuum (0.181 g, 0.325 mmol, 78%). Anal. Calcd. for 
C23H23AuN4O2.2H2O (592.45): C, 46.63; H, 4.59; N, 4.73. Found: C, 46.23; H 4.21; N 4.76. 1H 
NMR (CD2Cl2, 300 MHz, 298 K): 8.97 (d, 3JH-H = 5.1 Hz, 1H, H2), 8.07 (t, 3JH-H = 8.1 Hz, 1H, H4), 
7.83 (d, 3JH-H = 8.1 Hz, 1H, H5), 7.75 (d, 4JH-H = 1.5 Hz, 1H, H11), 7.51-7.40 (m, 2H, H3+8), 7.37 (dd, 
3JH-H = 8.3 Hz, 4JH-H = 1.5 Hz, 1H, H9), 7.22 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.3 Hz, 1H, H14/17), 6.84 (m, 
1H, H15/16), 6.66 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.3 Hz, 1H, H14/17), 6.49 (m, 1H, H15/16), 2.32 (s, 3H, 
H20), 1.35 (s, 9H, tBu). 13C[H1] NMR (CD2Cl2, 75 MHz): 173.7 (s, C19), 164.2 (s, C12), 161.3 (s, 
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C6/7), 155.5 (s, C6/7), 147.0 (s, C2), 144.7 (s, C10), 144.3 (s, C13/18), 142.7 (s, C4), 139.4 (s, C13/18), 
133.0 (s, C11), 125.4 (s, C3), 124.8 (s, C8), 124.2 (s, C9), 123.8 (s, C14/17), 123.4 (s, C14/17), 120.2 
(s, C5), 115.6 (s, C15/16), 115.3 (s, C15/16), 35.3 (s, C(CH3)3), 30.8 (s, C(CH3)3), 25.2 (s, C20). 
Figure 3.51a – H1 NMR of complex 51 in CD2Cl2. 
Figure 3.51b – C13[1H] NMR of complex 51 in CD2Cl2.
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3.52 Synthesis of complex 53 
 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (50) (0.200 g, 0.418 mmol), 1,2-
diacetamidobenzene (0.081 g, 0.421 mmol) and silverI oxide (200 mg, 0.863 mmol) was 
added to dichloromethane (30 mL) and refluxed for 24 h. The mixture was then cooled, 
filtered through celite and the filtrate was concentrated under vacuum. A large excess of 
diethyl ether (20 mL) was added to precipitate the product as a pale-yellow, fluffy, solid. This 
was filtered and dried under vacuum (0.224 g, 0.375 mmol, 89%). Anal. Calcd. for 
C25H26AuN3O2 (597.47): C, 50.26; H, 4.39; N, 7.03. Found: C, 50.12; H 4.38; N 6.97. 1H NMR 
(CD2Cl2, 300 MHz, 298 K): 9.30 (s, 1H, H2), 8.02 (t, 3JH-H = 7.8 Hz, 1H, H4), 7.79 (d, 3JH-H = 7.8 Hz, 
1H, H5), 7.55 (d, 4JH-H = 1.4 Hz, 1H, H11), 7.48 (d, 3JH-H = 8.0 Hz, 1H, H8), 7.41-7.28 (m, 3H, 
H9+3+14/17), 7.09 (m, 1H, H14/17), 6.99 (dt, 3JH-H = 7.3 Hz, 4JH-H = 1.4 Hz, 1H, H15/16), 6.91 (dt, 3JH-H 
= 7.3 Hz, 4JH-H = 1.4 Hz, 1H, H15/16), 2.27 (s, 3H, H20/22), 2.15 (s, 3H, H20/22), 1.34 (s, 9H, tBu). 
13C[1H] NMR (CD2Cl2, 75 MHz): 174.1 (s, C19/21), 173.1 (s, C19/21), 164.6 (s, C12), 154.8 (s, C2), 
153.3 (s, C6/7), 145.5 (s, C10), 142.2 (s, C4), 140.5 (s, C13/18), 130.8 (s, C11), 125.2 (s, C3/9), 124.6 
(s, C15/16), 124.2 (s, C8), 124.0 (s, C14/17), 123.0 (s, C3/9), 122.7 (s, C15/16), 119.7 (s, C5), 35.3 (s, 
C(CH3)3), 30.8 (s, C(CH3)3).  
98 
 
Figure 3.52a – H1 NMR of complex 53 in CD2Cl2. 
Figure 3.52b – C13[1H] NMR of complex 53 in CD2Cl2. 
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Figure 3.52c – HMQC spectrum of complex 53 in CD2Cl2 showing C20+22. 
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3.53 Synthesis of complex 54 
 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (49), (0.235 g, 0.491 mmol), ligand 
L1 (0.300 g, 1.048 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 
mL) for 30 min. The reaction was then cooled and water (40 mL) was added causing an 
immediate dark brown precipitation. The flask was placed in the freezer for two days. The 
brown solid was filtered off and purified by dissolving in dichloromethane (2 mL), followed 
by precipitation with an excess of light petroleum (bp. 40-60 °C) (20 mL). This product was 
filtered off and dried under vacuum (0.273 g, 0.394 mmol, 80%). Anal. Calcd. for C34H28AuN3O 
(691.19): C, 59.05; H, 4.08; N, 6.08. Found: C, 58.84; H 4.13; N 6.02. 1H NMR (CD2Cl2, 300 MHz, 
298 K): 9.61 (dd, 3JH-H = 5.9 Hz, 4JH-H = 1.0 Hz, 1H, H2), 8.49 (dd, 3JH-H = 8.7 Hz, 4JH-H = 0.7 Hz, 2H, 
H21/24), 8.30 (d, 3JH-H = 8.7 Hz, 2H, H21/24), 8.08 (dt, 3JH-H = 8.1 Hz, 4JH-H = 1.0 Hz, 1H, H4), 7.82 (d, 
3JH-H = 8.1 Hz, 1H, H5), 7.75 (m, 2H, H22/23), 7.54 (m, 1H, H3), 7.48-7.36 (m, 3H, H8+22/23), 7.01 
(dd, 3JH-H = 8.2 Hz, 4JH-H = 1.7 Hz, 1H, H9), 6.85 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H14/17), 6.48 
(dt, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H15/16), 6.12 (dt, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H15/16), 
5.39 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.2 Hz, 1H, H14/17), 5.23 (d, 4JH-H = 1.7 Hz, 1H, H11), 0.35 (s, 9H, 
tBu). 13C[1H] NMR (CD2Cl2, 75 MHz): 163.3 (s, C2), 156.1 (s, C12), 155.2 (s, C6/7), 153.3 (s, C6/7), 
151.0 (s, C19), 150.9 (s, C20), 147.5 (s, C10), 142.5 (s, C13/18), 141.9 (s, C4), 140.2 (s, C13/18), 130.3 
(s, C21), 130.2 (s, C22), 127.4 (s, C9), 126.2 (s, C23), 125.4 (s, C8), 124.5 (s, C25), 124.3 (s, C24), 
124.0 (s, C11), 123.5 (s, C3), 120.2 (s, C5), 118.4 (s, C15/16), 117.0 (s, C15/16), 115.1 (s, C14/17), 113.7 
(s, C14/17), 34.4 (s, C(CH3)3), 29.9 (s, C(CH3)3). 
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Figure 3.53a – H1 NMR of complex 54 in CD2Cl2 (tert-Bu singlet at 0.35 ppm not shown). 
Figure 3.53b – C13[1H] NMR of complex 54 in CD2Cl2.  
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3.54 Synthesis of complex 55 
 
A mixture of 2-benzylpyridine gold dichloride, (50), (0.200 g, 0.459 mmol), ligand L1 (0.178 g, 
0.622 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 mL) for 30 
min. The reaction was then cooled and water (40 mL) was added causing an immediate dark 
brown precipitation. The flask was then placed in the freezer for two days. The brown solid 
was then filtered and purified by dissolving in minimal dichloromethane and acetone (3 mL). 
the product was precipitated with an excess of light petroleum (bp. 40-60 °C) (20 mL), filtered 
off and dried under vacuum (0.201 g, 0.309 mmol, 67%). Anal. Calcd. for C31H22AuN3O.5H2O 
(739.58): C, 50.35; H, 4.36; N, 5.68. Found: C, 50.63; H 3.36; N 7.45. 1H NMR (CD2Cl2, 300 MHz, 
263 K): 9.23 (d, 3JH-H = 5.6 Hz, 1H, H2), 8.51 (d, 3JH-H = 8.6 Hz, 1H, H22/25), 8.46 (d, 3JH-H = 8.6 Hz, 
1H, H22/25), 8.21 (d, 3JH-H = 8.6 Hz, 1H, H22/25), 8.03 (dt, 3JH-H = 7.7 Hz, 4JH-H = 1.4 Hz, 1H, H4), 7.95 
(d, 3JH-H = 8.6 Hz, 1H, H22/25), 7.80 (m, 1H, H23/24), 7.67 (d, 3JH-H = 7.7 Hz, 1H, H5), 7.62-7.46 (m, 
3H, H3+23/24), 7.25 (t, 3JH-H = 8.6 Hz, 1H, H23/24), 6.78-6.71 (m, 2H, H15/18+9/12), 6.55 (t, 3JH-H = 7.4 
Hz, 1H, H16/17), 6.47 (t, 3JH-H = 7.4 Hz, 1H, H10/11), 6.16 (t, 3JH-H = 7.4 Hz, 1H, H16/17), 5.99-5.84 
(m, 2H, H9/12+10/11), 5.69 (dd, 3JH-H = 7.4 Hz, 4JH-H = 1.0 Hz, 1H, H15/18), 4.43 (d, 2JH-H = 15.3 Hz, 1H, 
H7/7’), 3.91 (d, 2JH-H = 15.3 Hz, 1H, H7/7’). 13C[1H] NMR (CD2Cl2, 75 MHz): 157.2 (s, C13), 157.1 (s, 
C6/8), 151.7 (s, C6/8), 151.5 (s, C14/19), 150.7 (s, C2), 141.7 (s, C4), 138.5 (s, C14/19), 132.3 (s, 
C20/21/26), 130.2 (s, C22/25), 130.1 (s, C9/12), 129.8 (s, C22/25), 129.5 (s, C23/24), 126.4 (s, C9/12), 126.4 
(s, C10/11), 126.4 (s, C10/11), 126.1 (s, C5), 125.6 (s, C23/24), 124.7 (s, C3), 118.3 (s, C16/17), 116.7 (s, 
C16/17), 115.4 (s, C15/18), 113.4 (s, C15/18), 47.8 (s, C7/7’).  
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Figure 3.54a – H1 NMR of complex 55 in CD2Cl2. 
Figure 3.54b – C13[1H] NMR of complex 55 in CD2Cl2.  
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3.55 Synthesis of complex 56 
 
A mixture of 2-(4-t-butyl)phenyl pyridine gold dichloride, (49), (0.200 g, 0.418 mmol), ligand 
L2 (0.177 g, 0.620 mmol) and aqueous trimethylamine (2 mL) was refluxed in methanol (30 
mL) for 30 min. The reaction was then cooled and water (40 mL) was added causing an 
immediate light brown precipitation. The flask was then placed in the freezer for two days. 
The brown solid was then filtered and purified by dissolving in minimal dichloromethane (2 
mL). The product was precipitated with an excess of light petroleum (bp. 40-60 °C) (20 mL), 
filtered off and dried under vacuum (0.214 g, 0.310 mmol, 74%). Anal. Calcd. for 
C34H29AuN4.3H2O (744.65): C, 54.84; H, 4.74; N, 7.52. Found: C, 54.25; H; 4.20 N; 7.41. 1H NMR 
(CD2Cl2, 300 MHz, 298 K): 8.40 (dd, 3JH-H = 8.7 Hz, 4JH-H = 0.7 Hz, 2H, H21/24), 8.24 (d, 3JH-H = 8.7 
Hz, 2H, H21/24), 7.78-7.68 (m, 4H, H22/23+2+4/5), 7.64-7.55 (m, 2H, H3+4/5), 7.41 (dd, 3JH-H = 8.2 Hz, 
4JH-H = 1.7 Hz, 1H, H9), 7.35 (m, 2H, H22/23), 6.97 (dd, 3JH-H = 7.7 Hz, 4JH-H = 1.1 Hz, 1H, H14/17), 
6.44 (t, 3JH-H = 7.7 Hz, 1H, H15/16), 6.36-6.18 (m, 3H, H8+11+15/16), 5.62 (dd, 3JH-H = 7.7 Hz, 4JH-H = 
1.1 Hz, 1H, H14/17), 1.46 (s, 9H, tBu). 13C[1H] NMR (CD2Cl2, 75 MHz): 164.6 (s, C2), 155.3 (s, C12), 
154.5 (s, C6/7), 150.5 (s, C6/7), 149.6 (s, C19), 148.0 (s, C20), 145.6 (s, C10), 145.0 (s, C13/18), 140.4 
(s, C4), 139.7 (s, C13/18), 130.2 (s, C21/24), 130.0 (s, C21/24), 126.5 (s, C25), 126.0 (s, C9), 125.5 (s, 
C22/23), 124.9 (s, C8), 124.8 (s, C22/23), 124.6 (s, C11), 122.3 (s, C3), 120.1 (s, C5), 118.2 (s, C15/16), 
116.3 (s, C15/16), 113.3 (s, C14/17), 112.6 (s, C14/17), 35.6 (s, C(CH3)3), 31.0 (s, C(CH3)3). 
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Figure 3.55a – H1 NMR of complex 56 in CD2Cl2 (tert-Bu singlet at 1.46 ppm not shown). 
 
Figure 3.55b – C13[1H] NMR of complex 56 in CD2Cl2.  
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3.56 Synthesis of complex 57 
 
A mixture of (C^Npz^C)AuCl, (37), (0.060 g, 0.104 mmol), 2,6-dimethylphenyl isocyanide 
(0.016 g, 0.125 mmol), AgSbF6 (0.043 g, 0.125 mmol) and a few pellets of 4 Å molecular sieves 
were combined in a flame-dried Schlenk flask under a nitrogen atmosphere with dry 
dichloromethane (15 mL). The mixture was left to stir at room temperature for 4 h. A white 
precipitate of AgCl was removed by filtration through celite, and the filtrate collected under 
an N2 atmosphere. The solvent was evaporated to a minimum and the product was 
precipitated with an excess of light petroleum (bp. 40-60 °C). The supernatant was removed 
and the residue dried under vacuum to yield a yellow solid. 9-amino acridine (0.028 g, 0.146 
mmol) was added to a flame-dried Schlenk flask. The solution was sonicated for 30 min and 
transferred to a separate flame-dried Schlenk flask containing the [(C^Npz^C)Au(2,6-
dimethylphenyl isocyanide)]SbF6. The reaction was then stirred for 16 h at room temperature 
and the precipitate removed from solution via filtration through a celite plug. Next, the 
solvent was removed under vacuum and the solid residue re-dissolved in dichloromethane 
(2 mL). The product was precipitated using a 2:1 mixture of light petroleum (bp. 40-60 °C) / 
diethyl ether (5 mL), and after removing the solvent, dried under vacuum to yield a dark 
yellow solid. Proton NMR showed a mixture of the desired product and the formamide 
hydrolysis product. The solid was washed twice with dry dichloromethane (40 mL) followed 
by petroleum ether (10 mL) and dried under vacuum (0.053 g, 0.048 mmol, 46%). Anal. Calcd. 
for C46H45AuF6N5Sb (1100.62): C, 50.20; H, 4.12; N, 6.36. Found: C, 49.97; H 4.03; N 6.35. 1H 
NMR ((CD3)2SO, 300 MHz, 298 K): 10.34 (s, 1H, NH), 9.14 (s, 2H, H2), 8.26 (d, 3JH-H = 8.2 Hz, 2H, 
H20/23), 7.96 (d, 4JH-H = 1.5 Hz, 2H, H8), 7.85 (d, 3JH-H = 8.4 Hz, 2H, H5), 7.74-7.57 (m, 4H, 
H20/23+21/22), 7.30 (dd, 3JH-H = 8.4 Hz, 4JH-H = 1.5 Hz, 2H, H6), 7.25-7.14 (m, 3H, H14+15), 6.96 (t, 2H, 
3JH-H = 7.5 Hz, 2H, H21/22), 2.56 (s, 6H, H16), 1.20 (s, 18H, tBu). 13C[1H] NMR (CD3CN, 75 MHz): 
167.6 (s, C9), 156.0 (s, C4), 155.6 (s, C3), 144.7 (s, C7), 139.9 (s, C2), 139.6 (s, C13), 135.1 (s, C8), 
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134.0 (s, C20/23), 128.6 (s, C15), 127.7 (s, C14), 127.6 (s, C20/23), 127.6 (s, C12), 127.0 (s, C5), 124.5 
(s, C6), 123.6 (s, C21/22), 123.5 (s, C21/22), 117.8 (s, C18), 117.8 (s, C19), 117.8 (s, C24), 35.7 (s, 
C(CH3)3), 31.4 (s, C(CH3)3), 19.3 (s, C16). υmax (neat)/cm-1: 3388 (NH), 3270 (NH) 2957 (tBu), 
2867 (Ar), 1586 (carbene). 
Figure 3.56a – H1 NMR of complex 57 in (CD3)2SO. 
 
Figure 3.56b – C13[1H] NMR of complex 57 in (CD3)2SO.  
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3.57 Synthesis of complex 58 
 
[(MeImAcr)H]Cl (0.070 g, 0.232 mmol) and silver oxide (0.043 g, 0.186 mmol) and acetonitrile 
(15 mL) were combined in a Schlenk and stirred for 56 h. (C^Npz^C)AuCl, (37), (0.133 g, 0.232 
mmol) and KPF6 (0.128 g, 0.695 mmol) were then added to the flask and the reaction was 
stirred for a further 16 h before being filtered through a celite plug. The filtrate was 
concentrated under vacuum and the product was precipitated using a 2:1 mixture of light 
petroleum (bp. 40-60 °C) / diethyl ether (5 mL), and after removing the solvent, dried under 
vacuum to yield a dark yellow solid (0.170 g, 0.180 mmol, 78%). Anal. Calcd. for 
C41H39AuF6N5P.5MeCN (1148.99): C, 53.31; H, 4.74; N, 12.19. Found: C, 52.92; H, 5.10; N, 
11.80. 1H NMR (CD3CN, 300 MHz, 298 K): 8.68 (s, 2H, H2), 8.12-8.02 (m, 3H, H11+19), 7.96 (d, 
1H, 3JH-H = 1.9 Hz, H12), 7.88-7.77 (m, 4H, H16+18), 7.55 (d, 2H, 3JH-H = 8.3 Hz, H5), 7.45 (t, 2H, 3JH-
H = 7.8 Hz, H17), 7.33 (dd, 2H, 3JH-H = 8.3 Hz, 4JH-H = 1.7 Hz, H6), 7.21 (d, 2H, 4JH-H = 1.7 Hz, H8), 
4.15 (s, 3H, H13), 1.30 (s, 18H, tBu). 13C[1H] NMR (CD3CN, 75 MHz): 166.1 (s, C9), 156.8 (s, C4), 
156.3 (s, C3), 154.9 (s, C10), 146.6 (s, C20), 144.6 (s, C7), 140.5 (s, C14), 139.3 (s, C2), 133.3 (s, 
C18), 133.0 (s, C8), 128.9 (s, C17), 127.0 (s, C12), 126.9 (s, C19), 126.7 (s, C5), 126.3 (s, C11), 125.2 
(s, C6), 123.5 (s, C16), 122.2 (s, C15), 39.1 (s, C13), 35.1 (s, C(CH3)3), 30.3 (s, C(CH3)3). 
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Figure 3.57a – H1 NMR of complex 58 in CD3CN. 
 
Figure 3.57b – C13[1H] NMR of complex 58 in CD3CN.  
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3.58 Synthesis of L1 
 
4-(Acridin-9-ylamino)-benzoic acid (0.600 g, 2.100 mmol) and carbonyldiimidazol (0.341 g, 
2.103 mmol) were placed in a flame dried flask, fitted with a condenser and stirred in dry 
tetrahydrofuran (20 mL) under a nitrogen atmosphere, for 15 min. 2-amino phenol (0.301 g, 
2.758 mmol) was then added and the reaction was stirred for a further 15 min before being 
heated to reflux overnight. After cooling to room temperature, the orange solid was filtered 
and washed twice with light petroleum (bp. 40-60 °C) before being dried under vacuum 
(0.551 g, 1.925 mmol, 92%). 1H NMR ((CD2)SO, 300 MHz, 298 K): 10.18 (s, 1H, H8), 8.26 (d, 3JH-
H = 8.8 Hz, 1H, H3/6), 8.18 (d, 3JH-H = 7.9 Hz, 1H, H3/6), 8.08-7.88 (m, 5H, H4/5+11+14) 8.28-7.50 (m, 
4H, H12+13), 7.03 (t, 3JH-H = 7.9 Hz, 1H, H4/5). 13C[1H] NMR ((CD2)SO, 75 MHz): 156.8 (s, C2/7/9), 
152.9 (s, C2/7/9), 140.5 (s, C2/7/9), 136.1 (s, C11/14), 131.9 (s, C4/5), 130.5 (s, C10/15), 128.1 (s, C3/6), 
128.0 (s, C12/13), 125.9 (s, C3/6), 124.6 (s, C12/13), 121.0 (s, C10/15), 119.9 (s, C11/14), 117.8 (s, C4/5), 
114.1 (s, Cq). 
3.59 Synthesis of L2 
 
4-(Acridin-9-ylamino)-benzoic acid (1.500 g, 4.772 mmol) and carbonyldiimidazol (0.774 g, 
4.773 mmol) were placed in a flame dried flask, fitted with a condenser, and stirred in dry 
tetrahydrofuran (50 mL) under a nitrogen atmosphere for 15 min. O-phenylenediamine 
(0.675 g, 6.242 mmol) was then added and the reaction was stirred for a further 15 min 
before being heated to reflux overnight. After cooling to room temperature, the orange solid 
was filtered and washed twice with light petroleum (bp. 40-60 °C) before being dried under 
vacuum (1.102 g, 3.862 mmol, 81%). 1H NMR ((CD2)SO, 300 MHz, 298 K): 8.24 (d, 3JH-H = 8.1 
Hz, 2H, H11/14), 8.02 (d, 3JH-H = 8.1 Hz, 2H, H11/14), 7.90 (t, 3JH-H = 8.1 Hz, 2H, H12/13), 7.33 (t, 3JH-H 
= 8.1 Hz, 2H, H12/13), 7.18 (t, 3JH-H = 7.7 Hz, 1H, H4/5), 7.05 (d, 3JH-H = 7.7 Hz, 1H, H3/6), 6.89 (d, 
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3JH-H = 7.6 Hz, 1H, H3/6), 6.60 (t, 3JH-H = 7.6 Hz, 1H, H4/5). 13C[1H] NMR ((CD2)SO, 75 MHz): 156.5 
(s, C2/7/9), 145.1 (s, C2/7/9), 140.3 (s, C2/7/9), 135.3 (s, C12/13), 129.9 (s, C4/5), 127.2 (s, C3/6), 126.2 
(s, C11/14), 125.0 (s, C10/15), 123.7 (s, C12/13), 119.2 (s, C11/14), 116.9 (s, C4/5), 116.3 (s, C3/6), 113.6 
(s, C10/15). 
3.510 X-ray crystallography 
Crystal structures were solved by Dr Julio Fernandez-Cestau. 
3.511 Antiproliferation assay 
The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 
medium with 10% foetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg 
mL−1 streptomycin (Invitrogen). The cells were maintained under a humidified atmosphere 
at 37 °C and 5% CO2. The human MCF-7 cancer cell line (from ECACC) was cultured in DMEM 
medium with 10% foetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg 
mL−1 streptomycin (Invitrogen). The cells were maintained under a humidified atmosphere 
at 37 °C and 5% CO2. Inhibition of cancer cell proliferation was measured by the 3-(4,5-
dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) 
assay using the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega) and 
following the manufacturer’s instructions. Briefly, the cells (3 × 104 per 100 µL for HL60, 8 × 
103 per 100 µL for A549 and MCF-7) were seeded in 96-well plates and left untreated or 
treated with 1 µL of DMSO (vehicle control) or 1 µL of complexes diluted in DMSO at diﬀerent 
concentrations, in triplicate for 72 h at 37 °C with 5% CO2. Following this, MTS assay reagent 
was added for 4 h and absorbance measured at 490 nm using a Polarstar Optima microplate 
reader (BMG Labtech). IC50 values were calculated using GraphPad Prism Version 5.0 
software. 
3.512 Uptake study 
MCF-7 cells were grown in 75 cm2 flasks up to 70% of confluence in 10 mL of culture medium. 
Compounds 50, 53, 54 and 58 were added to the flasks (100 µL of 1 mM solution in DMSO) 
and incubated for 6 h at 37 °C with 5% CO2. Negative controls were used by incubating cells 
with DMSO alone under the same conditions. After removal of the medium and washing of 
the cells with PBS pH 7.4, the cells were detached using a trypsin solution. After quenching 
of trypsin with fresh medium, centrifugation and removal of the supernatant, the cell pellet 
was resuspended into 1 mL of PBS pH 7.4 and split into twice 500 µL for metal and protein 
quantification. The number of cells (expressed per million cells) of each sample was 
determined by measuring the protein content of the treated samples using a BCA assay 
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(ThermoFischer Scientific) corrected by the amount of protein/106 cells determined for each 
cell type by measuring the protein content of an untreated sample and dividing by the 
corresponding number of cells measured with a hematocytometer following a reported 
procedure. Microwave digestion was used to solvate the samples to liquid form. Nitric acid 
and hydrogen peroxide were used in a Milestone Ethos 1 microwave system using SK-10 10 
place carousel. The digest was ramped to 200 °C in 15 minutes holding at 200 °C for 15 min. 
The sample was weighed into a microwave vessel before digestion, and decanted and rinsed 
into a pre- weighed PFA bottle after digestion. ICP-MS samples were spiked with rhodium 
internal standard and run on a Thermo X series 1 ICP-MS. The isotopes selected were 63Cu, 
65Cu, 107Ag, 109Ag and 197Au. Certified standards and independent reference were used for 
accuracy. Acid blanks were run through the system and subtracted from sample 
measurements before corrections for dilution. 
3.513 ROS assay 
100 μL of MCF-7 cells were seeded at a density of 1 × 105 cells per mL in a 96-well black plate 
with a transparent bottom. The cells were incubated at 37 °C for 24 h. The medium was 
removed and replaced with 50 μM H2DCFDA (from Life Technologies) solution in PBS for 40 
min. H2DCFDA was removed and replaced with fresh medium. The cells were left for recovery 
for 20 min at 37 °C. Basal fluorescence was measured at 485/520 nm on a POLARstar Optima. 
The cells were incubated with 10 μM, 50 μM, or 100 μM of compounds, 1% DMSO (negative 
control) and 100 μM of H2O2 (positive control) for 24 h. Fluorescence was read at 485/520 
nm. Basal fluorescence was subtracted from the fluorescence in the treated cells to calculate 
the amount of fluorescence caused by the compounds. 
3.514 FRET assay. 
The initial FRET melting screen was performed using a fluorescence resonance energy 
transfer (FRET) DNA melting based assay. The sequence used was DSFRET FAM-d(TAT-AGC-
TAT-A-HEG(18)-TAT-AGC-TAT-A)-TAMRA-3′). The labelled oligonucleotide (donor 
fluorophore FAM is 6-carboxyfluorescein; acceptor fluorophore TAMRA is 6-
carboxytetramethyl-rhodamine) were prepared as a 220 nM solution in 10 mM sodium 
cacodylate buffer at the indicated pH with 100 mM sodium chloride and then thermally 
annealed. Strip-tubes (QIAgen) were prepared by aliquoting 20 μL of the annealed DNA, 
followed by 0.5 μL of the compound solutions. Control samples for each run were prepared 
with the same quantity of DMSO with the DNA in buffer. Fluorescence melting curves were 
determined in a QIAgen Rotor-Gene Q-series PCR machine, using a total reaction volume of 
20.5 μL. Measurements were made with excitation at 470 nm and detection at 510 nm. Final 
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analysis of the data was carried out using QIAgen Rotor-Gene Q-series software and Origin 
or Excel.  
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Chapter 4 
 
The synthesis and anticancer activity of cyclometalated goldIII 
dithiocarbamate complexes. 
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4.1 Abstract 
A series of cyclometalated goldIII dithiocarbamate complexes have been synthesised and 
characterised as prospective anticancer drug candidates. These included a series of cationic 
2-phenyl pyridine derivatives, [AuIII(C^N)(R2NCS2)]+, where R = methyl (61), ethyl (62), 
sarcosine ethyl ester (63), pyrrolidine (64) and butyl (65). The final complex was a neutral 
(C^C) cyclometalated diethyldithiocarbamate derivative, AuIII(C^C)(Et2NCS2), (66). The 
complexes have been screened for their cytotoxic activity against a panel of human cancer 
cell lines with several of the derivatives displaying high levels of cytotoxicity with IC50 values 
dropping to sub-micromolar levels. Cell uptake studies demonstrated a clear correlation 
between the cellular uptake and the in vitro cytotoxicity of the complexes. FRET DNA binding 
studies towards higher order DNA structures showed a correlation between the cytotoxicity 
of the complexes and their ability to stabilise i-motif and G-quadruplex structures indicating 
these structures as a possible target of these complexes. 
4.2 Introduction 
Chapter 1 (Section 1.1) has already introduced cisplatin and its clinically approved derivatives 
carboplatin and oxaliplatin.1 These are highly effective and successful chemotherapeutic 
agents and in the past forty years they have revolutionised the treatment of cancer.2 
However, despite their clinical success they do have some drawbacks. One of the most severe 
is that high dosage of platinum-based therapeutics, and the resulting accumulation of 
platinum within the body, causes severe side effects including severe nephrotoxicity (renal 
failure) and this limits the administrable dosage to patients.3 
Pabla et al. hypothesised that one of the causes of cisplatin induced nephrotoxicity is the 
platinum binding to, and the resulting inactivation of thiol-containing enzymes.114 The high 
affinity of platinum towards sulfur-containing biomolecules such as glutathione, albumin, 
cysteine and methionine is thought to play an important role in the metabolic processes of 
platinum based drugs. The strong and irreversible binding of platinum towards intercellular 
thiolato ligands contributes towards drug deactivation, and reactions with sulphur-
containing peptides and proteins can lead to conformational changes in the protein which 
causes changes to their biological activity.115 As a result, thiol and sulfur-based nucleophiles 
have been tested as chemoprotectants in combination with cisplatin to modulate cisplatin 
nephrotoxicity, and sodium diethyldithiocarbamate was shown to be particularly 
effective.116, 117 As a result of these findings, Ronconi et al. designed a series of metal-
dithiocarbamato complexes to combine the cytotoxic activity of the metal centres with the 
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nephroprotective benefits of the dithiocarbamate ligand. These included platinum, 59 and 
gold, 23a and 23b derivatives (Figure 69).118 
 
 
Figure 69 – structures of platinumII and goldIII dithiocarbamate derivatives and their 
cytotoxicity towards human cancer cell lines in comparison to cisplatin; a Cervical 
adenocarcinoma, b Leukaemia, c Lung carcinoma, d Cisplatin sensitive ovarian carcinoma, e 
Cisplatin resistant ovarian carcinoma. Data taken from ref 118. 
Despite the platinum dithiocarbamate variant, 59 showing very promising results both in in 
vitro and in vivo experiments, it was poorly soluble in aqueous medium and highly unstable 
under physiological conditions thus rendering it unsuitable as a drug candidate. The goldIII 
derivatives however showed better solubility properties as well as high cytotoxicities towards 
a panel of human cancer cell lines. The dimethyl variant, 23a was particularly effective, 
displaying higher cytotoxicities than both cisplatin and the platinum dithiocarbamate 
derivative, 59. The in vivo antitumor activity of 23a on Ehrlich solid-tumour bearing mice 
resulted in 74% inhibition of tumour growth after 11 days of treatment compared to the 
untreated control animals – a two-fold increase compared to the activity of cisplatin under 
the same conditions. Chemotherapy with the gold derivative was also better tolerated than 
with cisplatin particularly regarding the nephrotoxic effect which was considerably 
reduced.59, 118 
The mechanism of action of the AuIIICl2(DTC) complexes remains unclear although one thing 
remains undisputed; that the mechanism of action of these AuIII-dithiocarbamate derivatives 
differs from that of classical platinumII-based anticancer agents.59, 118 Section 1.21 introduces 
the mechanism of action of cisplatin; briefly, cisplatin forms covalent adducts between DNA 
  IC50 (µM) 
Complex HeLaa HL60b A549c 2008d C13e 
59 7.0 2.9 15.2 5.9 8.3 
23a (X = Cl) 2.1 0.8x10-2 0.4x10-2 0.2x10-2 0.1x10-2 
23b (X = Cl) 8.2 0.4 4.7 49.3 23.8 
Cisplatin 15.6 25.6 35 43.2 556 
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base pairs, causing distortion of the DNA double helix which inhibits DNA replication and 
transcription processes.53 Although the AuIIICl2(DTC) complexes were proved to bind to DNA 
to a greater extent than cisplatin, it was thought that this was a consequence of their higher 
reactivity towards isolated biological molecules and therefore DNA cannot be assigned as the 
only target of these complexes.118 Indeed, Tomasello et al. showed that 23b was able to 
suppress tumour growth by proteasome inhibition in MCF-7 cells,69 and Milacic et al. also 
demonstrated a similar result for 23a in MDA-MB-231 breast cancer cells.68 Other work also 
showed that the complexes were able to inhibit the enzyme thioredoxin reductase (TrxR) by 
irreversible covalent binding to its catalytic site, leading to an increase in intracellular reactive 
oxygen species (ROS) (Section 1.24).43, 44 
Dithiocarbamate ligands can also be used to conjugate cancer targeting oligopeptides to a 
goldIII centre; 26 and 60 (Figure 70/71) (Section 1.16).47 These ‘second generation’ goldIII 
compounds are able to maintain both high levels of anticancer activity together with an 
improved selectivity towards cancer cells. This is achieved by the targeting of peptide 
transporters which are upregulated in certain cancers, which improves the bioavailability of 
the complex as well as the tumour specificity.47, 119 One dipeptide derivative AuIIIBr2(DTC-Sar-
AA-OtBu), 26 (AA = Glycine) (Figure 70), synthesised by Nardon et al. showed high levels of 
cytotoxicity towards MDA-MB-231 breast cancer cell cultures in vitro (IC50 of 13 µM) and 
towards MDA-MB-231 xenographs in an in vivo nude mice model. Remarkably, tumour 
growth was inhibited by more than 57% in comparison to the negative control with no 
observed side effects from the treatment. The proteasome was identified as the major target 
of the complex, both in vitro in purified human 20S proteasome and also in intact MDA-MB-
231 cell extracts as well as in an in vivo nude mice model.47 
 
Figure 70 – goldIII dithiocarbamate peptide conjugate, 26.47 
Other tripeptide derivatives by Kouodom et al., AuIIICl2(DTC-Pro-(MeAla)2-OtBu, 60 (Figure 
71) also showed high levels of in vitro cytotoxic activity with IC50 values lower than cisplatin 
towards all of the tested cell lines. The complex was thought to act by inducing apoptosis and 
necrosis.119 
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Figure 71 – structure of 60 and its cytotoxicity towards human cancer cell lines in comparison 
to cisplatin; a Prostate cancer, b Cisplatin sensitive ovarian cancer, c Cisplatin resistant ovarian 
cancer, d Hodgkin’s lymphoma. Data taken from ref 119. 
There are very few examples of cyclometalated goldIII dithiocarbamate derivatives although 
one example has already been discussed in Section 1.15; derivatives of [AuIII(C^N)(R2NCS2)]+ 
were synthesised by Zhang et al. (C^N = 2-phenylpyridine), 25 (Figure 72). These derivatives 
were shown to act as potent deubiquitinase inhibitors as well as showing selective in vitro 
cytotoxicity towards MDA-MB-231 breast cancer cells over immortalised liver cells (MIHA). 
The cytotoxicity correlated to a high uptake of the gold complexes into the cell resulting in 
cell cycle arrest and apoptosis.46 
 
Figure 72 – structure of the cyclometalated goldIII dithiocarbamate derivative.46 
This chapter introduces the synthesis and anticancer activity of cyclometalated 
[AuIII(C^N)(R2NCS2)]+ complexes (C^N = 2-(4-t-butyl)phenyl pyridine). The complexes were 
tested for their cytotoxicity towards a panel of human cancer cells and Human Umbilical Vein 
Endothelial cells for comparison. Studies into the possible mode of action were also 
undertaken and the reactivity of the complexes towards GSH, N-acetyl cysteine, double-
stranded DNA and higher order DNA structures, (i-motifs and G-quadruplexes), was tested.  
  
  IC50 ± SD (µM) 
Complex PC3a 2008b C13c L540d 
60 3.0 ± 0.2 8.2 ± 0.7 7.8 ± 0.5 2.2 ± 0.2 
Cisplatin 3.3 ± 0.3 19.4 ± 1.2 117.2 ± 9.1 2.5 ± 0.1 
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4.3 Results and Discussion 
4.31 Synthesis and structural characterisation  
The 2-(4-t-butyl)phenyl pyridine) cyclometalated gold dichloride precursor was synthesised 
in good yield, (72%) by previously reported methods (Section 3.31, Scheme 13).106 An 
overnight reaction with sodium dimethyl-dithiocarbamate hydrate in methanol followed by 
the addition of aqueous potassium hexafluorophosphate gave the cyclometalated dimethyl-
dithiocarbamate complex, 61 in good yield (82%), as depicted in Scheme 21. 
1H NMR showed a significant downfield shift in the characteristic H2 doublet from 9.71 ppm 
to 8.74 ppm as well as a downfield shift in the signal for H11 from 8.03 to 7.03 ppm, confirming 
the successful formation of complex 61. The appearance of two inequivalent methyl groups 
at 3.49 and 3.44 ppm also confirmed the successful coordination of the dithiocarbamate 
ligand. The two methyl groups are inequivalent due to the rigidity of the delocalised double 
bond between the NCS2 ligand which prevents free rotation. A singlet at 193.3 ppm in the 
C13[1H] NMR for the NCS2 carbon was also present. The presence of the KPF6 anion was 
confirmed by both fluorine and phosphorus NMR. The IR spectrum also showed a clear 
vibration 1579 cm-1 which can be attributed to the delocalised NCS2 system of the 
dithiocarbamate ligand.  
 
Scheme 21 – synthesis of the [(C^N)Au(DMDTC]+, 61 (DMDTC = N,N-dimethyl 
dithiocarbamate). 
By replacing the sodium dimethyl-dithiocarbamate with the diethyl variant, complex 62 was 
obtained in high yield, (94%) (Figure 73). Once again, the significant downfield shift in the 
signals for both H2 and H11 in the 1H NMR spectrum to 8.78 and 7.06 ppm respectively as well 
as the distinctive vibration at 1559 cm-1 in the IR spectrum and a singlet at 193.3 ppm in the 
C13[1H] NMR for the NCS2 carbon confirmed the successful formation of complex 62. Two 
multiplets also appeared at 3.87 and 1.35 ppm in the 1H NMR for the two ethyl groups of the 
dithiocarbamate ligand.  
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Figure 73 – structure of complex 62, the (C^N) AuIII dithiocarbamate.  
Slow vapour diffusion of diethyl ether into a concentrated acetonitrile solution of complex 
62 gave crystals suitable for X-ray diffraction. These were characterised in the solid state by 
Dr David Hughes (Figure 74). 
 
Figure 74 – structure of 62 (hydrogen atoms omitted for clarity). Ellipsoids set at 50% 
probability. Selected bond distances (Å) and angles (°): Au1-N1 2.061 (3), Au1-C10 2.038 (3), 
Au1-S21 2.984 (8), Au1-S22 2.2821 (8), C10-Au1-N1 80.64 (11), C10-Au1-S22 98.36 (9), N1-
Au1-S21 105.30 (7), S22-Au1-S21 75.54 (3), N1-Au1-S22 177.22 (7), C10-Au1-S21 173.08 (9), 
S21-C23-S22 111.47 (19). 
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The crystals display the typical, slightly distorted square planar geometry to the goldIII centre 
due to the accommodation of the (C^N) cyclometalating ligand with a C10-Au1-N1 angle of 
80.64 ° in the cyclometalating ligand. The coordinated dithiocarbamate ligand also 
contributes to the distortion due to the restricted chelate angle of 75.54 ° of the S21-Au1-
S22 dithiocarbamate ligand. The Au1-S21 and Au1-S22 bond distances also differ from each 
other; Au1-S21 = 2.984 Å and Au1-S22 = 2.2821 Å. Both these bond distances and also the 
angle of the coordinated dithiocarbamate ligand are in good agreement with other crystal 
structures for AuIIICl2(DTC) complexes, synthesised by Altaf et al.45  
A reaction with sarcosine ethyl ester dithiocarbamate under the same conditions gave 
complex 63 in good yield (78%) (Figure 75). This time both isomers of the product were 
obtained in a 1:0.8 ratio and consequently all the proton signals for the cyclometalating (C^N) 
ligand were doubled. The presence of two doublets at 8.77 and 8.71 ppm and two singlets at 
7.15 and 7.01 ppm in the 1H NMR spectrum for H2 and H11 respectively confirmed the 
successful formation of complex 63 as two separate isomers. Two singlets also appeared at 
3.54 and 3.45 ppm for the NMe protons in the sarcosine ligand along with two singlets for 
the NCH2CO protons at 4.82 and 4.78 ppm and two multiplets for the ethyl group protons at 
4.21 and 1.23 ppm. 
The 13C[1H] NMR of this complex was of poor quality due to the poor solubility of the complex 
in the NMR solvent. However, the presence of a broad singlet at 198.7 ppm for the 
delocalised dithiocarbamate NCS2, and the presence of two separate signals at 166.3 and 
166.2 ppm for the C=O (one in each isomer), also confirmed the successful formation of 
complex 63. The IR spectrum for this complex also showed the distinctive NCS2 vibration 1558 
cm-1 as well as a sharp C=O vibration at 1736 cm-1.  
 
Figure 75 – isomers of complex 63. 
A reaction with sodium pyrrolidine dithiocarbamate also led to the successful formation of 
complex 64, (71%) (Figure 76). The formation of this complex was once again confirmed by 
122 
 
the downfield shift of the signals for H2 and H11 to 8.48 and 7.13 ppm respectively and the 
appearance of two multiplets at 3.98 and 2.24 ppm for the pyrrolidine protons in the 1H NMR 
spectrum. A singlet at 190.4 ppm for the delocalised dithiocarbamate NCS2 in the C13[1H] NMR 
and an NCS2 vibration at 1556 cm-1 in the IR spectrum also confirmed the successful 
formation of 64. 
 
Figure 76 – structure of 64. 
Complex 65 was more difficult to obtain as the product from the first reaction step, 
[(C^N)AuIII(DTC)]Cl, was too insoluble to react with the aqueous potassium 
hexafluorophosphate in the anion exchange step. Dissolving in dichloromethane and adding 
an excess of silver hexfluoroantimonate gave complex 65 in good yield (71%), (Scheme 22). 
Once again, the formation of 5 was confirmed by the downfield shift of the signals for H2 and 
H11 to 8.40 and 7.08 ppm respectively in the 1H NMR spectrum as well as the appearance of 
four multiplets at 3.77, 1.78, 1.42 and 0.98 ppm for the butyl protons. A singlet at 194.4 ppm 
for the delocalised dithiocarbamate NCS2 in the C13[1H] NMR and an NCS2 vibration at 1550 
cm-1 in the IR spectrum also confirmed the successful formation of 65. 
 
Scheme 22 – synthesis of dithiocarbamate 65. 
Complex 66 was synthesised by Dr Isabel Fernandez using previous methods published by 
David et al.; by the reaction of the oligomeric (AuCl(tBu2Bip))n with sodium diethyl-
dithiocarbamate to form the neutral (C^C)AuIII(DTC) complex (Figure 77).92 Complex 66 was 
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included to see whether the presence of the more lipophilic (C^C) cyclometalated ligand and 
the absence of a positive charge would significantly alter the cytotoxicity of the complex. 
 
Figure 77 – structure of complex 66.92 
4.32 In vitro antiproliferative activity 
Although the dithiocarbamate complexes 61-66 were poorly soluble in aqueous cell culture 
medium by themselves, they were soluble enough in DMSO not to precipitate when diluted 
up to 100 µM in the aqueous culture medium with 1% DMSO. IC50 values for the six complexes 
were then determined on a panel of human cancer cell lines. These included solid tumour 
cell lines; lung adenocarcinoma cells (A549), breast adenocarcinoma (MCF-7 and MDA-MB-
231) and human colon cancer (HCT-116) and suspension cells; promyelocytic leukaemia 
(HL60) as well as healthy Human Umbilical Vein Endothelial Cells (HUVEC) for comparison. 
Results were determined using a colorimetric MTS assay after 72 hours of incubation in 
comparison to cisplatin (as previously described in Section 2.32). The results are reported in 
Table 3. 
Table 3 – IC50 values for complexes 61-66 in comparison to cisplatin against different human 
cancer cell lines and healthy lung fibroblast cells after 72 h of incubation. 
 IC50 ± SD (µM)a 
Complex A549 MCF-7 HL60 HCT-116 MDA-MB-
231 
HUVEC 
61 4.6 ± 0.7 1.4 ± 0.3 0.2 ± 0.05 2.5 ± 0.3 8.6 ± 1.0 0.8 ± 0.04 
62 2.9 ± 0.6 1.2 ± 0.2 0.2 ± 0.03 2.4 ± 0.4 1.9 ± 0.1 0.7 ± 0.02 
63 >100 >100 17.8 ± 2.1 >100 >100 33.9 ± 5.4 
64 10.8 ± 0.3 1.1 ± 0.03 1.4 ± 0.07 6.0 ± 0.4 3.0 ± 0.2 0.7 ± 0.05 
65 5.3 ± 0.3 1.7 ± 0.04 0.8 ± 0.01 3.5 ± 0.3 3.1 ± 0.1 1.2 ± 0.2 
66 >100 8.8 ± 0.2 1.9 ± 0.3 >100 >100 3.3 ± 0.03 
Cisplatin 33.7 ± 3.7b 21.2 ± 3.9b 3.7 ± 0.3b 5.3 ± 0.2c 28.4 ± 0.1c >100 
a Mean ± the standard error of at least three independent experiments. b Values from ref 39. 
c Values from ref 86.  
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Complexes 61, 62, 64 and 65 all showed similar cytotoxicity profiles, with high levels of 
cytotoxicity towards all the tested cell lines. The dimethyl-dithiocarbamate, complex 61 
showed 7 times the activity of cisplatin towards the lung cancer cell line (A549) and more 
than 15 times the activity towards the MCF-7 breast cancer and the HL60 leukaemia cells. 
The complex also showed more than twice the activity of cisplatin towards the MDA-MB-231 
metastatic breast cancer and the HCT-116 colon cancer cell lines. 
Complex 62, the diethyl variant, showed even higher activity with more than fifteen times 
the activity of cisplatin towards the A549, MCF-7, HL60 and MDA-MB-231 cell lines and IC50 
values of between 2.9-0.2 µM. It was assumed that this was because the slight increase in 
lipophilicity of the complex increased its cellular uptake. However, the more lipophilic 
pyrrolidine and dibutyl variants, 64 and 65, showed slightly reduced levels of cytotoxicity in 
comparison to 61 and 62 although they still showed extremely promising levels in 
comparison to cisplatin. 
However, despite their promising anticancer activities, all four of the complexes showed poor 
selectivity towards the Human Umbilical Vein Endothelial Cells, HUVEC, although further 
tests on other healthy cell lines are needed for a more accurate conclusion as HUVEC are 
perhaps not the most reliable comparison as they typically show a reduced sensitivity 
towards cisplatin. 
The sarcosine ethyl ester dithiocarbamate, complex 63, showed extremely low cytotoxicity 
across the panel of cells with IC50 values of more than 100 µM for A549, MCF-7, MDA-MB-
231 and HCT-116. This could be due to poor cellular uptake as the complex is extremely 
hydrophilic and therefore might struggle to cross the cell membrane. The complex also 
showed poor activity towards HL60 leukaemia cells with an IC50 of 17.8 µM. However, this 
complex also showed the best selectivity profile of the new dithiocarbamates towards this 
cell line (selectivity factor SHL60/HUVEC = 1.9). 
The (C^C) variant, complex 66, also showed reduced cytotoxicity, particularly towards the 
HCT-116, MDA-MB-231 and A549 cells although it showed a reasonable activity towards 
MCF-7 breast cancer and HL60 leukaemia cells, (IC50 of 8.8 and 1.9 µM respectively). Once 
again, the reduced activity could be due to a reduced cellular uptake as the (C^C) 
cyclometalated ligand and the absence of the positive charge makes this complex extremely 
lipophilic and this could affect its ability to cross the cell membrane. 
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4.33 Cellular uptake in MCF-7 cells 
As mentioned previously (Section 3.33), the cellular uptake of drugs can have a significant 
influence on the cytotoxicity of prospective chemotherapeutic agents.108 ICP-MS was used to 
quantify the amount of intracellular gold and determine whether the cellular uptake of the 
dithiocarbamate complexes was affecting their cytotoxicity. ICP-MS measurements were 
completed by Dr Graham Chilvers. Complexes 61 and 65 (the dimethyl and dibutyl variants) 
were selected as these represented the smallest and largest alkyl group respectively in the 
[AuIII(C^N)(R2NCS2)]+ series of complexes. Complex 63, the sarcosine ethyl ester variant, was 
selected because it showed extremely poor cytotoxicity towards all the cell lines tested and 
66, the (C^C) diethyl dithiocarbamate, as it was the only complex with a (C^C) 
cyclometalating ligand and the absence of a positive charge. MCF-7 cells were incubated for 
6 hours with 10 µM concentrations of each of the complexes in 1% DMSO. The results of 
three independent experiments are depicted in Figure 78. 
Figure 78 – cellular uptake of complexes 61, 65, 66 and 63 and a DMSO control in MCF-7 cells 
after 6 h of treatment at 10 µM in 1% DMSO. The results were analysed by t-test, P=0.05, 
61:65*, 65:66*, 66:63*. 
There was a clear correlation between the cellular uptake and the in vitro cytotoxicity of the 
complexes. The most cytotoxic complexes, 61 and 65, which have IC50 values of 1.4 and 1.7 
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µM respectively both show high levels of uptake, particularly the dimethyl variant, 61 which 
displays more than three times the cellular uptake of complex 65. Complex 66, the neutral 
(C^C) dithiocarbamate, displays moderate cytotoxicity towards MCF-7 cells with an IC50 of 
8.8 µM and also displays moderate cellular uptake. Both 61 and 65 display significantly higher 
levels of cellular uptake than 66 (twenty-eight and eight times respectively). This could be a 
factor of the increased lipophilicity of this complex due to the lack of positive charge which 
makes it poorly soluble in aqueous medium. Complex 63, the most hydrophilic sarcosine 
ethyl ester variant, displays both extremely poor in vitro cytotoxicity (IC50 value of >100 µM) 
and also poor cellular uptake. This could be a factor of the increased hydrophilicity of the 
complex hindering its ability to cross the phospholipid bilayer. 
4.34 Quantification of reactive oxygen species 
As previously mentioned in Section 2.33, the induction of reactive oxygen species (ROS) is a 
recognised mechanism of action for metal-based drugs, including AuI-NHC complexes.75 All 
six of the cyclometalated dithiocarbamate complexes were therefore tested for the 
production of ROS. The amount of intracellular ROS was measured after treatment of MCF-7 
cells with 100 µM, 50 µM and 10 µM concentrations of each complex. The results are 
summarised in Figure 79. None of the complexes tested appeared to increase the production 
of ROS and therefore this mode of action can be ruled out for these cyclometalated 
dithiocarbamate complexes. 
 
Figure 79 – ROS measurements in MCF-7 cells after 24 h incubation with complexes 61-66. 
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4.35 Reaction with Glutathione and N-Acetyl Cysteine 
Cytotoxic gold compounds have shown high reactivity towards model proteins and 
consequently gold-protein interactions are generally thought to be responsible for the 
cytotoxic effects of these complexes and proteins are generally regarded as their primary 
targets.5, 6, 120 Metal-protein binding sites generally involve the side chain residues of amino 
acids such as the thioether and thiolate sulphur atoms in L-methionine and L-cysteine 
respectively.50 Complex 61 was selected to act as the representative [AuIII(C^N)(DTC)]+ and 
was reacted with glutathione and N-acetyl cysteine, which were selected to act as reliable 
models of target biomolecules (Figure 80). 
 
Figure 80 – structures of reduced glutathione (GSH), oxidised glutathione (GSSG), reduced N-
acetyl cysteine (NAC) and oxidised N-acetyl cysteine (NACy). 
When complex 61 was mixed at room temperature with reduced glutathione in a 1:1 mixture 
of DMSO-d6 and D2O, 1H NMR spectroscopy showed the immediate formation of oxidised 
glutathione (GSSG) (Figure 81). Although no signals for the complex could be seen due to its 
poor solubility in the solvents, the formation of a pale-yellow product was observed thus 
suggesting that an immediate reduction to a goldI species was occurring. The goldI species 
can be attributed to (CH^N)AuI(S2CNR2).  
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Figure 81 – 1H NMR spectra of a 1:1 mixture of 61 with GSH at room temperature, in 
comparison with the starting materials, GSH and GSSG (DMSO-d6/D2O 1:1).  
The reduction of complex 61 by GSH to a goldI species could be followed by UV/Vis 
spectroscopy. Upon mixing a 1 mM solution of the complex in DMSO with 1 mM of reduced 
glutathione in H2O, the characteristic ligand-to-metal-charge-transfer (LMCT) band at 350 nm 
completely disappeared, confirming that an immediate reduction was occurring. The 
presence of a pale-yellow product also suggested that a goldI species was being formed. 
Casini et al. demonstrated a very similar result using goldIII complexes with bipyridyl 
ligands.121 The appearance of a low but broad band at 400-450 nm could also be tentatively 
attributed to a goldI species.59 The same features could be seen when all of the 
dithiocarbamate derivatives were reacted with GSH. The UV-Vis spectra of 61 are depicted 
in Figure 82. 
 
Figure 82 – UV/Vis spectrum of complex 61 (1 mM), GSH (1 mM) and a mixture of complex 61 
and GSH (1mM), (DMSO-H2O 1:1). 
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The interaction of 61 and 62 with N-acetyl cysteine (NAC) was also investigated, using NAC 
as a model for thiol containing biomolecules. Boscutti et al. showed that AuIIIBr2(DTC) 
complexes underwent a rapid multi-step reduction in the presence of NAC during which the 
NAC was oxidised to NACy and the goldIII was reduced to a goldI species, possibly AuBr with 
the release of the dithiocarbamate ligand.122 Both 61 and 62 were mixed at room 
temperature with NAC in CD3CN and 1H NMR spectroscopy was used to follow the reaction 
over a 48 h period (Figure 83a and 83b). No reaction was observed for either complex during 
this time and it was concluded that the presence of the (C^N) cyclometalating ligand gave 
the system stability towards reduction by NAC. 
 
Figure 83a – 1H NMR spectra of a 1:1 mixture of 61 with NAC at different reaction times at 
room temperature, in comparison with the starting materials 61 and NAC (CD3CN). 
 
Figure 83b – 1H NMR spectra of a 1:1 mixture of 62 with NAC at different reaction times at 
room temperature, in comparison with the starting materials 62 and NAC (CD3CN). 
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4.36 DNA-binding properties  
As previously discussed in Section 1.22, higher order DNA structures like G-quadruplexes and 
i-motifs are emerging as promising targets for the development of new anticancer agents.61-
64 G-quadruplexes are four-stranded DNA secondary structures that form in guanine-rich 
DNA sequences. They are formed by the stacking of tetrads of guanine residues linked via 
hydrogen-bonding and stabilized by the presence of typically monovalent cations in the 
centre of the tetrad.123 The selective stabilization of G-quadruplex structures has been 
investigated as a method of controlling key cellular events such as telomerase activity or 
oncogene expression. These structures are gaining interest as potential anticancer targets, 
particularly because they are found both in the telomers and in the over-expressed gene 
protomer regions of cancer genes.61, 62 Recently, there have been several examples of 
potential chemotherapeutic goldIII and goldI complexes that target G-quadruplexes.33, 66 
Bazzicalupi et al. co-crystallised a caffeine-based goldI bis NHC cation with a G-quadruplex, 
showing that DNA-ligand interaction occurred via π-stacking on the accessible tetrads.124 
Gratteri et al. also showed that dioxobridged goldIII complexes and cyclometalated oxo-
compounds were able to bind strongly and selectively to DNA G-quadruplexes whereas 
double stranded DNA was not affected at all.66 
i-Motifs are also emerging as potential targets for anticancer agents. These are higher order 
DNA structures that form in cytosine-rich DNA sequences via hydrogen bonding between 
hemiprotonated pairs of cytosines. As i-motifs require cytosine-rich sequences, they are 
likely to form in the complementary strands opposing G-quadruplexes in the genome.63 
Stabilisation of i-motif structures has been shown to alter gene expression of the oncogene 
bcI-2 and disrupt telomerase activity and therefore compounds that stabilise these structures 
also have potential as anticancer drugs.64 Our group recently showed that a goldIII 
benzimidazole-based NHC complex could selectively stabilise both G-quadruplex and i-motif 
structures over double stranded DNA.39 
The established Fӧrester resonance energy transfer (FRET) DNA melting assay was used to 
give a broad indication of the DNA binding capabilities of the dithiocarbamate complexes 61-
66 towards different DNA targets.125 These included a G-quadruplex forming sequence from 
the human telomere (hTeloG), the human telomeric i-motif sequence (hTeloC), an i-motif 
forming sequence from the promoter region of the oncogene (hif-1-α), a promoter i-motif 
forming sequence (c-MycC), as well as double stranded DNA. The human telomeric i-motif 
forming sequence, TeloC is only stable up to pH 5.5. The binding capabilities of the complexes 
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were therefore assessed at a transitional pH of 6.0 (the pH where the structure is 50% 
folded).126 The c-MYC i-motif is also only stable up to pH 6.5 and has a transitional pH of 6.6.64 
The remaining sequences were all tested at the transitional pH of hif-1-alpha, pH 7.2.127 
As mentioned previously in Section 3.34, FRET measures the changes in fluorescence as the 
spatial distance between two fluorophores is changed as they are brought closer together or 
moved further apart as a result of DNA stabilisation or denaturation.112, 113 Results are 
expressed as the changes in DNA melting temperature (ΔTm) when double stranded DNA (0.2 
µM) was dosed with 50 µM concentrations of each drug. A higher ΔTm suggests an increased 
level of DNA stabilisation and thus a compound-DNA interaction (Figure 84). 
 
Figure 84 – stabilisation of different DNA structures (0.2 µM) when dosed with 50 µM 
concentrations of dithiocarbamate complexes 61-66. Data represents the average and 
standard deviations of two experiments. 
Complexes 61, 62, 64 and 65 appeared to show high levels of DNA stabilisation towards all 
of the DNA structures tested. These four complexes showed particularly high levels of 
stabilisation towards two of the i-motif forming sequences; the human telomeric i-motif 
sequence, (hTeloC) and the promoter i-motif forming sequence, (c-MycC). For these two 
sequences, ΔTm values were between 47-51 °C for complexes 61, 62 and 64 and >60 °C for 
complex 65. For the G-quadruplex forming sequence, (hTeloG), and the i-motif forming 
sequence, (hif-1-α), ΔTm values were somewhat lower, between 26-37 °C for all four 
complexes, indicating lower levels of complex-DNA stabilisation and thus weaker DNA 
binding. 
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In good agreement with the cytotoxicity data, both 63, the least cytotoxic of the 
[(C^N)Au(DTC)]+ complexes, and 66, the neutral (C^C)Au(DTC) showed extremely poor levels 
of DNA interaction towards all of the tested structures. For both of these complexes, ΔTm 
values were below 10 °C for all of the DNA structures tested. Indeed, complex 66 appeared 
to destabilise all three of the i-motif forming sequences; hTeloC, hif1-α and c-MycC, (ΔTm = 
<0 °C). These values could be a product of the lack of a cationic charge as this is consistent 
with our previous work which highlights the importance of a cationic charge on the ability of 
gold complexes to interact with higher order nucleic acid structures.39 However, the data is 
generally in good agreement with the cytotoxicity data, with the most cytotoxic complexes 
displaying the highest levels of stabilisation towards the higher order DNA structures. This 
suggests that the stabilisation of G-quadruplex and i-motif structures is a possible mechanism 
of action for these complexes. Higher order nucleic acid structures could therefore be a 
possible intracellular target of these goldIII dithiocarbamate complexes. 
4.4 Conclusion 
This chapter has introduced the synthesis and anticancer activity of a series of goldIII 
dithiocarbamate complexes. These included a series of cationic [AuIII(C^N)(R2NCS2)]+ 
complexes with methyl (61), ethyl (62), sarcosine ethyl ester (63), pyrrolidine (64) and butyl 
(65) groups and also one AuIII(C^C)(Et2NCS) complex, (66) to act as a comparison between the 
cationic and neutral complexes.  
The complexes were tested for their in vitro cytotoxicity towards a panel of human cancer 
cell lines including lung adenocarcinoma cells (A549), breast adenocarcinoma (MCF-7 and 
MDA-MB-231), human colon cancer (HCT-116) and promyelocytic leukaemia (HL60) as well 
as healthy Human Umbilical Vein Endothelial Cells (HUVEC) for comparison. Complexes 61, 
62, 64 and 65 showed the highest levels of cytotoxicity with IC50 values dropping to sub-
micromolar levels. The most hydrophilic complex, 63, the sarcosine ethyl ester derivative, 
was non-toxic across all of the cell lines, and the most lipophilic complex, the (C^C) derivative, 
66, also showed extremely poor cytotoxicity. 
Cellular uptake studies in MCF-7 breast cancer cells indicated that there was a clear 
correlation between the in vitro cytotoxicity of the complexes and their ability to enter the 
cell. Complex 61 and 65 both showed high levels of cellular uptake in comparison to 63 and 
66. This suggests that low cellular uptake is one of the limitations of the non-toxic complexes. 
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The antiproliferative mode of action of these complexes is so far unknown although FRET 
DNA binding studies towards higher order DNA structures suggested that there was a 
correlation between the cytotoxicity of the complexes and their ability to stabilise i-motif and 
G-quadruplex structures. Complex 61 was also rapidly reduced in the presence of GSH which 
could indicate that these particular dithiocarbamate complexes are reduced to a goldI active 
species under physiological conditions. However, neither 61 nor 62 showed any reaction with 
N-acetyl cysteine, which was used as a model for other thiol containing biomolecules. Other 
mechanisms of action have also been ruled out and we established that these complexes did 
not increase the formation of reactive oxygen species. Further studies are currently 
underway to see if any of these new dithiocarbamate complexes act as Thioredoxin 
reductase inhibitors.  
4.5 Experimental 
When required, manipulations were performed using standard Schlenk techniques under dry 
nitrogen or in a MBraun glove box. Nitrogen was purified by passing through columns of 
supported P2O5 with moisture indicator and activated 4 Å molecular sieves. Anhydrous 
solvents were freshly distilled from appropriate drying agents. 1H and 13C[1H] spectra were 
recorded using a Bruker Avance DPX-300 spectrometer. 1H NMR spectra (300.13 MHz) were 
referenced to the residual protons of the deuterated solvent used. 13C[1H] NMR spectra 
(75.47 MHz) were referenced internally to the D-coupled 13C resonances of the NMR solvent. 
Elemental analyses were carried out at London Metropolitan University. The (C^N)Au-Cl 
starting material, 49 and complex 66 were synthesized following reported procedures.92, 106 
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4.51 Synthesis of complex 61 
 
Sodium dimethyldithiocarbamate hydrate (0.020 g, 0.140 mmol) in methanol (10 mL) was 
added drop by drop to a suspension of 2-(4-t-butyl)phenyl pyridine gold dichloride (0.060 g, 
0.125 mmol) in methanol (15 mL) and stirred at room temperature overnight. A colour 
change from white to pale yellow was observed during the addition. Excess saturated KPF6 
(aqueous solution) was then added causing an immediate fluffy white precipitation. The solid 
was filtered and purified by dissolving in minimal acetonitrile (2 mL) and precipitating the 
product with an excess of diethyl ether (20 mL). This was filtered and dried under vacuum 
(0.069 g, 0.103 mmol, 82%). Anal. Calcd. For C18H22AuF6N2PS2.5H2O (762.51): C, 28.35; H, 
4.23; N, 3.67. Found C, 28.15; H, 3.98; N, 3.69. 1H NMR ((CD3)2SO, 300 MHz, 298 K): 8.74 (d, 
3JH-H = 6.0 Hz, 1H, H2), 8.43-8.30 (m, 2H, H4+5), 7.99 (d, 3JH-H = 8.2 Hz, 1H, H8), 7.60 (t, 3JH-H = 6.0 
Hz, 1H, H3), 7.53 (d, 3JH-H = 8.2 Hz, 1H, H9), 7.03 (s, 1H, H11), 3.49 (s, 3H, H14/14’), 3.44 (s, 3H, 
H14/14’), 1.28 (s, 9H, tBu). 13C[1H] NMR ((CD3)2SO, 75 MHz): 193.3 (s, C13), 163.7 (s, C12), 155.8 
(s, C6/7), 151.6 (s, C6/7), 150.1 (s, C2), 144.1 (s, C4), 141.8 (s, C10), 127.5 (s, C8), 126.7 (s, C9), 
126.2 (s, C3), 124.7 (s, C11), 122.6 (s, C5), 42.5 (s, C14), 41.2 (s, C14’), 35.9 (s, C(CH3)3), 31.2 (s, 
C(CH3)3). IR: νmax (neat)/cm-1: 2960 (tBu), 2868 (Ar), 1579 (Dithiocarbamate). 
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Figure 4.51a – 1H NMR of 61 in (CD3)2SO. 
Figure 4.51b – C13[1H] NMR of 61 in (CD3)2SO.  
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4.52 Synthesis of complex 62 
 
Sodium diethyldithiocarbamate hydrate (0.028 g, 0.125 mmol) in methanol (10 mL) was 
added drop by drop to a suspension of 2-(4-t-butyl)phenyl pyridine gold dichloride (0.060 g, 
0.125 mmol) in methanol (15 mL) and stirred at room temperature overnight. A colour 
change from white to pale yellow was observed during the addition. Excess saturated KPF6 
(aqueous solution) was then added causing an immediate fluffy white precipitation. The solid 
was filtered and purified by dissolving in minimal acetonitrile (2 mL) and precipitating the 
product with an excess of diethyl ether (20 mL). This was filtered and dried under vacuum 
(0.083 g, 0.118 mmol, 94%). Anal. Calcd. For C20H26AuF6N2PS2.6H2O (808.58): C, 29.71; H, 
4.74; N, 3.46. Found C, 29.46; H, 4.52; N, 3.55. 1H NMR ((CD3)2SO, 300 MHz, 298 K): 8.78 (d, 
3JH-H = 5.4 Hz, 1H, H2), 8.45-8.31 (m, 2H, H4+5), 8.00 (d, 3JH-H = 8.2 Hz, 1H, H8), 7.60 (t, 3JH-H = 5.4 
Hz, 1H, H3), 7.54 (dd, 3JH-H = 8.2 Hz, 4JH-H = 1.2 Hz, 1H, H9), 7.06 (d, 4JH-H = 1.2 Hz, 1H, H11), 3.87 
(m, 4H, H14+14’), 1.35 (m, 6H, H15+15’), 1.29 (s, 9H, tBu). 13C[1H] NMR ((CD3)2SO, 75 MHz): 193.3 
(s, C13), 163.6 (s, C12), 155.9 (s, C6/7), 151.7 (s, C6/7), 150.1 (s, C2), 144.2 (s, C4), 141.8 (s, C10), 
127.5 (s, C8), 126.6 (s, C9), 126.1 (s, C3), 124.8 (s, C11), 122.6 (s, C5), 48.8 (s, C14), 47.3 (s, C14’), 
35.9 (s, C(CH3)3), 31.2 (s, C(CH3)3), 13.0 (s, C15), 12.5 (s, C15’). IR: νmax (neat)/cm-1: 2948 (tBu), 
2866 (Ar), 1559 (Dithiocarbamate). 
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Figure 4.52a – 1H NMR of 62 in (CD3)2SO. 
Figure 4.52b – C13[1H] NMR of 62 in (CD3)2SO.  
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4.53 Synthesis of complex 63 
 
Sarcosine ethyl ester dithiocarbamate hydrate (0.100 g, 0517 mmol) in methanol (10 mL) was 
added drop by drop to a suspension of 2-(4-t-butyl)phenyl pyridine gold dichloride (0.060 g, 
0.125 mmol) in methanol (15 mL) and stirred at room temperature overnight. A colour 
change from white to pale yellow was observed during the addition. Excess saturated KPF6 
(aqueous solution) was then added causing an immediate fluffy white precipitation. The solid 
was filtered and purified by dissolving in minimal acetonitrile (2 mL) and precipitating the 
product with an excess of diethyl ether (20 mL). This was filtered and dried under vacuum 
(0.073 g, 0.098 mmol, 78%). Anal. Calcd. For C21H26AuF6N2PS2.8H2O (906.64): C, 27.82; H, 
4.89; N, 3.09. Found C, 27.34; H, 4.42; N, 3.29. 1H NMR ((CD3)2SO, 300 MHz, 298 K): 8.77 (d, 
3JH-H = 5.6 Hz, 0.8H, H2’), 8.71 (d, 3JH-H = 5.6 Hz, 1H, H2), 8.40-8.27 (m, 3.6H, H4+4’+5+5’), 7.94 (m, 
1.8H, H9+9’), 7.63-7.49 (m, 3.6H, H3+3’+8+8’), 7.15 (d, 4JH-H = 1.4 Hz, 1H, H11), 7.01 (d, 4JH-H = 1.4 
Hz, 0.8H, H11’), 4.82 (s, 1.6H, H15’), 4.78 (s, 2H, H15), 4.21 (m, 3.6H, H17+17’), 3.54 (s, 3H, H14), 
3.45 (s, 2.4H, H14’), 1.29 (s, 9H, tBu), 1.27 (s, 7.2H, tBu’), 1.23 (m, 5.4H, H18+18’). 13C[1H] NMR 
((CD3)2SO, 75 MHz): 198.7 (s, C13), 166.3 (s, C16’), 166.2 (s, C16), 163.5 (s, C12’), 163.3 (s, C12), 
156.0 (s, C6’/7’), 156.0 (s, C6/7), 151.5 (s, C6’/7’), 151.2 (s, C6/7), 150.1 (s, C2’), 150.0 (s, C2), 144.1 
(s, C4’), 144.1 (s, C4), 141.6 (s, C10’), 141.4 (s, C10), 127.4 (s, C8’), 127.4 (s, C8), 126.8 (s, C9’), 126.7 
(s, C9), 126.1 (s, C3), 126.0 (s, C3’), 124.8 (s, C11’), 124.7 (s, C11), 122.5 (s, C5’), 122.5 (s, C5), 62.6 
(s, C14’), 62.6 (s, C14), 55.3 (s, C15’), 54.1 (s, C15), 35.9 (s, C(CH3)3), 31.4 (s, C17’), 31.1 (s, C(CH3)3), 
31.0 (s, C17), 14.3 (s, C18), 14.3 (s, C18’). IR: νmax (neat)/cm-1: 2961 (tBu), 2867 (Ar), 1736 (C=O), 
1558 (Dithiocarbamate). 
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Figure 4.53a – 1H NMR of 63 in (CD3)2SO.  
Figure 4.53b – C13[1H] NMR of 63 in (CD3)2SO.  
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4.54 Synthesis of complex 64 
 
Sodium pyrrolidinedithiocarbamate hydrate (0.085 g, 0.502 mmol) in methanol (10 mL) was 
added drop by drop to a suspension of 2-(4-t-butyl)phenyl pyridine gold dichloride (0.060 g, 
0.125 mmol) in methanol (15 mL) and stirred at room temperature overnight. A colour 
change from white to pale yellow was observed during the addition. Excess saturated KPF6 
(aqueous solution) was then added causing an immediate fluffy white precipitation. The solid 
was filtered and purified by dissolving in minimal acetonitrile (2 mL) and precipitating the 
product with an excess of diethyl ether (20 mL). This was filtered and dried under vacuum 
(0.062 g, 0.089 mmol, 71%). Anal. Calcd. For C20H24AuF6N2PS2.4H2O (770.54): C, 31.18; H, 
4.19; N, 3.64. Found C, 30.85; H, 3.78; N, 3.25. 1H NMR (CD2Cl2, 300 MHz, 298 K): 8.48 (d, 3JH-
H = 5.6 Hz, 1H, H2), 8.26 (dt, 3JH-H = 8.1 Hz, 4JH-H = 1.5 Hz, 1H, H4), 8.07 (d, 3JH-H = 8.1 Hz, 1H, H5), 
7.72 (d, 3JH-H = 8.3 Hz, 1H, H8), 7.59-7.50 (m, 2H, H3+9), 7.13 (d, 4JH-H = 1.6 Hz, 1H, H11), 3.98 (t, 
3JH-H = 6.6 Hz, 4H, H14+14’), 2.24 (m, 4H, H15+15’), 1.36 (s, 9H, tBu). 13C[1H] NMR (CD2Cl2, 75 MHz): 
190.4 (s, C13), 164.4 (s, C12), 157.1 (s, C6/7), 151.8 (s, C6/7), 148.4 (s, C2), 143.6 (s, C4), 140.5 (s, 
C10), 126.6 (s, C8), 126.5 (s, C9), 125.3 (s, C3), 125.3 (s, C11), 122.0 (s, C5), 52.0 (s, C14/14’), 35.8 
(s, C(CH3)3), 30.7 (s, C(CH3)3), 24.6 (s, C15/15’), 24.2 (s, C15/15’). IR: νmax (neat)/cm-1: 2961 (tBu), 
2863 (Ar), 1556 (Dithiocarbamate). 
141 
 
Figure 4.54a – 1H NMR of 64 in CD2Cl2. 
Figure 4.54b – C13[1H] NMR of 64 in CD2Cl2.  
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4.55 Synthesis of complex 65 
 
Sodium dibutyldithiocarbamate (0.105 g, 0.379 mmol) in methanol (10 mL) was added drop 
by drop to a suspension of 2-(4-t-butyl)phenyl pyridine gold dichloride (0.060 g, 0.125 mmol) 
in methanol (15 mL) and stirred at room temperature overnight. A colour change from white 
to pale yellow was observed during the addition. The solvent was removed under vacuum 
and the dark yellow residue was dissolved in dichloromethane (15 mL). Excess AgSbF6 in 
dichloromethane (5 mL) was then added and the solvent was removed under vacuum. The 
solid was purified by dissolving in minimal acetonitrile (2 mL) and precipitating the product 
with an excess of diethyl ether (20 mL). This was filtered and dried under vacuum (0.073 g, 
0.086 mmol, 71%). Anal. Calcd. For C24H34AuF6N2S2Sb.2MeCN (929.49): C, 36.18; H, 4.34; N, 
6.03. Found C, 35.70; H, 3.96; N, 6.09. 1H NMR (CD3CN, 300 MHz, 298 K): 8.40 (d, 3JH-H = 5.6 
Hz, 1H, H2), 8.23 (dt, 3JH-H = 8.1 Hz, 4JH-H = 1.4 Hz, 1H, H4), 8.06 (d, 3JH-H = 8.1 Hz, 1H, H5), 7.71 
(d, 3JH-H = 8.1 Hz, 1H, H8), 7.55-7.44 (m, 2H, H3+9), 7.08 (d, 4JH-H = 1.7 Hz, 1H, H11), 3.77 (m, 4H, 
H14+14’), 1.78 (m, 4H, H15+15’), 1.42 (m, 4H, H16+16’), 1.33 (s, 9H, tBu), 0.98 (m, 6H, H17+17’). 13C[1H] 
NMR (CD3CN, 75 MHz): 194.4 (s, C13), 163.8 (s, C12), 156.4 (s, C6/7), 151.6 (s, C6/7), 148.9 (s, C2), 
143.6 (s, C4), 141.1 (s, C10), 126.7 (s, C8), 126.5 (s, C9), 125.5 (s, C3), 125.0 (s, C11), 122.1 (s, C5), 
53.6 (s, C14/14’), 52.0 (s, C14/14’), 35.5 (s, C(CH3)3), 30.2 (s, C(CH3)3), 28.9 (s, C15/15’), 28.6 (s, C15/15’), 
19.6 (s, C16/16’), 12.9 (s, C17/17’). IR: νmax (neat)/cm-1: 2962 (tBu), 2873 (Ar), 1550 
(Dithiocarbamate). 
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Figure 4.55a – 1H NMR of 65 in CD3CN. 
Figure 4.55b – C13[1H] NMR of 65 in CD3CN.
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4.56 X-ray crystallography 
Crystal structures were solved by Dr David Hughes. 
4.57 Antiproliferation assay 
The human A549 and HL60 cancer cell lines (from ECACC) were cultured in RPMI 1640 
medium with 10% foetal calf serum, 2 mM L-glutamine, 100 U mL−1 penicillin and 100 µg 
mL−1 streptomycin (Invitrogen). The cells were maintained under a humidified atmosphere 
at 37 °C and 5% CO2. The human MCF-7, HCT116 and MDA-MB-231 cancer cell lines (from 
ECACC) were cultured in DMEM medium with 10% foetal calf serum, 2 mM L-glutamine, 100 
U mL−1 penicillin and 100 µg mL−1 streptomycin (Invitrogen). The HUVEC cells were cultured 
In Endothelial Cell Growth Medium with growth and antibiotic supplement. The cells were 
maintained under a humidified atmosphere at 37 °C and 5% CO2. Inhibition of cancer cell 
proliferation was measured by the 3-(4,5-dimethylthiazol-2-yl)5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay using the CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (Promega) and following the manufacturer’s instructions. Briefly, the 
cells (3 × 104 per 100 µL for HL60, 8 × 103 per 100 µL for A549, MCF-7, HCT116, MDA-MB-231 
and HUVEC) were seeded in 96-well plates and left untreated or treated with 1 µL of DMSO 
(vehicle control) or 1 µL of complexes diluted in DMSO at diﬀerent concentrations, in 
triplicate for 72 h at 37 °C with 5% CO2. Following this, MTS assay reagent was added for 4 h 
and absorbance measured at 490 nm using a Polarstar Optima microplate reader (BMG 
Labtech). IC50 values were calculated using GraphPad Prism Version 5.0 software. 
4.58 Uptake study 
MCF-7 cells were grown in 75 cm2 flasks up to 70% of confluence in 10 mL of culture medium. 
Compounds 61, 63, 65 and 66 were added to the flasks (100 µL of 1 mM solution in DMSO) 
and incubated for 6 h at 37 °C with 5% CO2. Negative controls were used by incubating cells 
with DMSO alone under the same conditions. After removal of the medium and washing of 
the cells with PBS pH 7.4, the cells were detached using a trypsin solution. After quenching 
of trypsin with fresh medium, centrifugation and removal of the supernatant, the cell pellet 
was resuspended into 1 mL of PBS pH 7.4 and split into twice 500 µL for metal and protein 
quantification. The number of cells (expressed per million cells) of each sample was 
determined by measuring the protein content of the treated samples using a BCA assay 
(ThermoFischer Scientific) corrected by the amount of protein/106 cells determined for each 
cell type by measuring the protein content of an untreated sample and dividing by the 
corresponding number of cells measured with a hematocytometer following a reported 
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procedure. Microwave digestion was used to solvate the samples to liquid form. Nitric acid 
and hydrogen peroxide were used in a Milestone Ethos 1 microwave system using SK-10 10 
place carousel. The digest was ramped to 200 °C in 15 minutes holding at 200 °C for 15 min. 
The sample was weighed into a microwave vessel before digestion, and decanted and rinsed 
into a pre- weighed PFA bottle after digestion. ICP-MS samples were spiked with rhodium 
internal standard and run on a Thermo X series 1 ICP-MS. The isotopes selected were 63Cu, 
65Cu, 107Ag, 109Ag and 197Au. Certified standards and independent reference were used for 
accuracy. Acid blanks were run through the system and subtracted from sample 
measurements before corrections for dilution. 
4.59 ROS assay 
100 μL of MCF-7 cells were seeded at a density of 1 × 105 cells per mL in a 96-well black plate 
with a transparent bottom. The cells were incubated at 37 °C for 24 h. The medium was 
removed, and replaced with 50 μM H2DCFDA (from Life Technologies) solution in PBS for 40 
min. H2DCFDA was removed and replaced with fresh medium. The cells were left for recovery 
for 20 min at 37 °C. Basal fluorescence was measured at 485/520 nm on a POLARstar Optima. 
The cells were incubated with 10 μM, 50 μM, or 100 μM of compounds, 1% DMSO (negative 
control) and 100 μM of H2O2 (positive control) for 24 h. Fluorescence was read at 485/520 
nm. Basal fluorescence was subtracted from the fluorescence in the treated cells to calculate 
the amount of fluorescence caused by the compounds. 
4.510 FRET assay. 
The initial FRET melting screen was performed using a fluorescence resonance energy 
transfer (FRET) DNA melting based assay. The sequences used were hTeloCFRET (5′-FAM-
d[TAA-CCC-TAA-CCC-TAA-CCC-TAA-CCC]-TAMRA-3′); hif-1-αFRET (5′-d[CGC-GCT-CCC-GCC-
CCC-TCT-CCC-CTC-CCC-GCG-C]-TAMRA-3′), hTeloGFRET (5′-FAM-d[GGG-TTA-GGG-TTA-GGG-
TTA-GGG]-TAMRA-3′), cMycCFRET (5’-FAM-d[CCC-CAC-CTT-CCC-CAC-CCT-CCC-CAC-CCT-CCC-
C]-TAMRA-3’) and DSFRET FAM-d(TAT-AGC-TAT-A-HEG(18)-TAT-AGC-TAT-A)-TAMRA-3′). The 
labelled oligonucleotides (donor fluorophore FAM is 6-carboxyfluorescein; acceptor 
fluorophore TAMRA is 6-carboxytetramethyl-rhodamine) were prepared as a 220 nM 
solution in 10 mM sodium cacodylate buffer at the indicated pH with 100 mM sodium 
chloride and then thermally annealed. Strip-tubes (QIAgen) were prepared by aliquoting 20 
μL of the annealed DNA, followed by 0.5 μL of the compound solutions. Control samples for 
each run were prepared with the same quantity of DMSO with the DNA in buffer. 
Fluorescence melting curves were determined in a QIAgen Rotor-Gene Q-series PCR 
machine, using a total reaction volume of 20 μL. Measurements were made with excitation 
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at 470 nm and detection at 510 nm. Final analysis of the data was carried out using QIAgen 
Rotor-Gene Q-series software and Origin or Excel.  
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